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1
General introduction
Introduction in chronic pancreatitis
Pancreatitis is an inflammation of the pancreas and often also of the peri-pancreatic 
tissue and/or remote organ systems. Clinically, it can present as a sudden onset of 
acute pancreatitis (AP), it can progress to more recurrent acute pancreatitis (RAP) 
episodes and eventually to a chronic pancreatitis (CP).1, 2 A clinical flare-up of an 
acute pancreatitis can present as a mild inflammation that resolves on its own but in 
approximately 20% the clinical course can be very severe and life-threatening leading 
to a high morbidity and mortality.3 The difference in the definition between AP and CP 
is based on the irreversible morphological and functional changes that develop after 
a long-lasting inflammation. In CP, the chronic inflammation causes progressive and 
irreversible destruction of exocrine and endocrine tissue and the normal tissue is 
substituted by fibrotic tissue.
Though not every patient with AP or RAP develops a chronic inflammation of the 
pancreas and not every patient with CP has a similar clinical presentation. These clinical 
differences make CP an interesting research model. Several etiological factors can 
be found, from environmental to genetic and sometimes with an interaction between 
both.  
Epidemiology
Each year approximately 2-12 new CP patients per 100.000 people are diagnosed 
although the incidence depends on the geographic region, the culture but also on 
the study design and diagnostic criteria.4-8 Incidence rates seem to be increasing 
over the last decades in still developing countries like China, India and Japan ascribed to 
the increasing use of alcohol.7, 9 Also the United States shows an increasing incidence 
while in Europe it seems to be more stable.4, 6 The prevalence is about 10-20 patients 
per 100.000 persons for females and around 50 per 100.000 persons for males.5, 7, 8 
Males present more often with alcoholic CP (~ 60%),6, 8 but there is no difference in 
the male-female ratio for non-alcoholic CP.6 The median age of onset differs according 
to the studied population and the aetiology, but in overall the mean age of onset is set 
in the 4-5th decade for alcoholic CP and in the 3-4th decade for non-alcoholic CP.6, 10 
Hereditary pancreatitis however is of a complete different clinical entity with a much 
younger age of onset of 10-20 years.11 
Of clinical importance is the fact that patients with CP have more comorbidities than 
the normal population and have a higher risk for developing cancer, especially 
pancreatic cancer.1, 4, 12 Mortality rates are approximately 1-4 persons per 1.000.000 
people per year and remain mainly stable.4 
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Aetiology and pathophysiology
CP is a complex disease were several factors play a role and interact with each other. 
These factors are i.e. summarized in the widely used M-ANNHEIM classification 
system that is build-up of the following categories; Multiple risk factors, Alcohol 
consumption, Nicotine consumption, Nutritional factors, Hereditary factors, Efferent 
pancreatic duct factors, Immunological factors and various rare and Miscellaneous 
and metabolic factors.13 (Table 1) Next to this risk classification, the M-ANNHEIM 
classification also includes a clinical staging system and diagnostic criteria for CP. 
(Table 2 and 3)
Independent of the cause of CP, the progressive fibrotic destruction of the pancreatic 
parenchyma by processes as necrosis, apoptosis and inflammation lead to morpho - 
logical and structural changes of the pancreas. Acinar and ductal cells disappear 
and are replaced by extracellular matrix. 
What is interesting is that each separate etiological factor shows a different site of 
injury; for alcoholic chronic pancreatitis there is more a interlobular fibrosis, in 
hereditary pancreatitis a more peri-ductal fibrosis, a peri-ductal and interlobular 
fibrosis for auto-immune pancreatitis and a diffuse inter- and intra-lobular fibrosis in 
obstructive chronic pancreatitis.14 These changes are irreversible and cause functional 
impairments of the ductal drainage system but also of the endocrine and exocrine 
function of pancreatic islet cells. 
The main etiological factor is alcoholic CP (ACP) and is like hereditary CP (HCP) 
more frequently found in males.11, 15, 16 Alcohol consumption accounts for approximately 
60-90% of all CP cases and the chronic inflammation seems to develop proportional 
to the dose and duration of alcohol consumption (minimum 6-12 years, approximately 
80 gram of alcohol per day).17 What is highly interesting is that less than 10% of 
chronic alcoholics develop ACP. This would suggest that there are other factors 
involved that together with the alcohol intake lead to inflammation of the pancreas. 
Both environmental factors as nicotine, a high fat and protein diet but also genetic 
factors seem to play role here.18-22  
Mutations in genes involved in the trypsinogen pathway like the serine protease 
inhibitor kazal type 1(SPINK1) and chymotrypsin C (CTRC) but also mutations in the 
cystic fibrosis transmembrane conductance regulator gene (CFTR) and the recently 
discovered claudin-2 gene (CLDN2) are predisposing factors that together with 
alcohol intake might lead to higher risk for developing pancreatitis.23-26 
Genetic alterations are far more important in hereditary pancreatitis. In 1996 the first 
disease-causing mutations of this autosomal dominant disease were discovered in 
the cationic trypsinogen (PRSS1) gene.27  
Table 1  The M-ANNHEIM multiple risk factor classification of chronic pancreatitis
M Pancreatitis with Multiple risk factors
A Alcohol consumption
Excessive consumption (>80 g/day)
Increased consumption (20–80 g/day)
Moderate consumption (< 20 g/day)
N Nicotine consumption
(Description of nicotine consumption by pack-years)
N Nutritional factors
Nutrition (e.g., high caloric proportion of fat and protein)
Hyperlipidaemia
H Hereditary factors
Hereditary pancreatitis*
Familial pancreatitis*
Early-onset idiopathic pancreatitis***
Late-onset idiopathic pancreatitis***
Tropical pancreatitis (possible mutations in the PRSS1, CFTR 
or SPINK1 genes)
E Efferent duct factors
Pancreas divisum
Annular pancreas and other congenital abnormalities 
Pancreatic duct obstruction (for example tumours)
Posttraumatic pancreatic duct scars
Sphincter of Oddi dysfunction
I Immunological factors
Auto-immune pancreatitis; in association with Sjögrens syndrome 
or with inflammatory bowel disease
M Miscellaneous and rare metabolic factors
Hypocalcaemia and hyperparathyroidism
Chronic renal failure
Drugs
Toxins
 
The M-ANNHEIM classification is based on the assumption that in the majority of patients, chronic 
pancreatitis results from the interaction of multiple risk factors (M). The different risk factors are grouped 
into the major subcategories of alcohol consumption (A), nicotine consumption (N), nutritional factors 
(N), hereditary factors (H), efferent pancreatic duct factors (E), immunological factors (I) and various rare 
miscellaneous and metabolic factors (M).  
* Hereditary pancreatitis refers to otherwise unexplained pancreatitis in an individual from a family in 
which the pancreatitis phenotype appears to be inherited through a disease-causing gene mutation 
expressed in an autosomal dominant pattern. 
** Familial pancreatitis refers to pancreatitis due to any cause that occurs in a family with an incidence 
higher than would be expected by chance alone, given the size of the family and incidence of pancreatitis 
within a defined population. Thus, familial pancreatitis may or may not be caused by a genetic defect.
*** Idiopathic pancreatitis is defined as pancreatitis in isolated cases within a family, in which all other 
causes of the disease have been excluded.
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A very small amount of trypsin though gets already active in the pancreatic acinar 
cell. To prevent digestion of pancreatic cellular proteins there are two defence 
mechanisms; SPINK1 directly inhibits active trypsin were CTRC prevents further 
activation of trypsinogen by trypsin. (Figure 1) 
Next to PRSS1 also variants in the SPINK1 gene have been proven to be associated 
with hereditary pancreatitis but more as a modifying factor instead of a causing one. 29-32 
With these findings, new candidate-genes were tested and new approaches were 
applied (GWA’s studies) that largely increased our knowledge of genetics in chronic 
pancreatitis. Though for hereditary pancreatitis mutations in the PRSS1 gene are still 
the main etiological factor. Less frequent causes of CP are efferent ductal factors, 
autoimmune CP, tropical CP and metabolic factors. 
Disturbances in the drainage of the efferent duct of the pancreas can be caused 
by several problems that give obstruction; pancreas divisum, intraductal papillary- 
mucinous neoplasms, cystic and endocrine neoplasms, acquired fibrous strictures 
and papillary hyperplasia in the smaller pancreatic ducts.33 
Nowadays several variants are known of which the p.R122H and the p.N29I are the 
most frequently found.27, 28  
Trypsinogen is the inactive precursor of trypsin that gets activated in the duodenum 
by enteropeptidase were it is needed for the digestion of dietary proteins but also for 
the activation of other pancreatic digestive pro-enzymes. 
Table 2  M-ANNHEIM clinical staging of chronic pancreatitis
Asymptomatic chronic pancreatitis
0 Stage of subclinical chronic pancreatitis 
A Period without symptoms (determination by chance, e.g., autopsy)
B Acute pancreatitis—single episode (possible onset of chronic pancreatitis)*
C Acute pancreatitis with severe complications**
Symptomatic chronic pancreatitis
I Stage without pancreatic insufficiency
A (Recurrent) acute pancreatitis (no pain between episodes of acute pancreatitis)
B Recurrent or chronic abdominal pain (including pain between episodes of acute 
pancreatitis)
C I a/b with severe complications**
II Stage of partial pancreatic insufficiency
A Isolated exocrine (or endocrine) pancreatic insufficiency (without pain)
B Isolated exocrine (or endocrine) pancreatic insufficiency (with pain)
C II a/b with severe complications**
III Stage of painful complete pancreatic insufficiency
A Exocrine and endocrine insufficiency (with pain, e.g., requiring pain medication)
B III a with severe complications**
IV Stage of secondary painless disease (burnout)
A Exocrine and endocrine insufficiency without pain and without severe 
complications**
B Exocrine and endocrine insufficiency without pain and with severe 
complications**
* Patients with a single episode of acute pancreatitis (without other symptoms of chronic pancreatitis) 
and with risk factors for chronic pancreatitis (e.g., a history of increased alcohol consumption) would be 
classified as “0 b” without morphological or functional signs of chronic pancreatitis. In contrast, the 
patient would be categorized as “I a” in the presence of chronic pancreatitis features (e.g., calcifications).
** Severe complications are defined as severe organ complications not included in the Cambridge 
classification. Reversible severe complications include development of ascites, bleeding, pseudo- 
aneurysm, obstruction or stricture of the choledochal duct, pancreatic fistula, and duodenal stenosis. 
Irreversible severe complications are portal or splenic vein thrombosis with or without portal hypertension 
and pancreatic cancer.
Figure 1  Trypsinogen physiology
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This wide diversity of therapy strategies for pain treatment illustrates how complex 
and multifactorial the disease and treatment is. 
Endocrine insufficiency – diabetes mellitus type 3c
In a later stage, CP patients can develop endocrine and exocrine insufficiency when 
the pancreas already lost the gross part of its function by the structural fibrotic 
changes caused by the chronic inflammation. 
Diabetes mellitus type 3c (pancreatogenic diabetes) is found in approximately 
26-80% of CP patients, this wide range indicates that this depends on the cohort that 
is studied and the time of follow-up. It differs from other diabetes mellitus types 
because not only the insulin production from the islet ß-cells is impaired but also the 
production of glucagon and pancreatic polypeptide from the islet α-cells and the 
pancreatic polypeptide cells.41 Therapeutically insulin is the best choice for treating 
these patients.41 
Exocrine insufficiency
Another complication is exocrine insufficiency, better described as insufficient digestion 
caused by pancreatic pathology. Patients present with foul smelling loose stools, 
weight loss, muscle wasting and flatulence. 
The logical explanation for this is the loss of pancreatic digestive enzymes in the 
intestinal lumen leading to maldigestion and deficiencies in micro-nutrients like 
Apo-lipoproteins, total cholesterol, magnesium, lipid-soluble vitamins, retinol-binding 
protein, calcium, zinc and selenium. Important to know is that pancreatic exocrine 
secretion can be largely reduced without causing exocrine insufficiency. Steatorrhea 
for example, is not found in patients until pancreatic lipase output is reduced to 5-10% 
of the normal production.42 The main therapeutic strategy is pancreatic enzyme 
replacement.
Pancreatic cancer
Another major concern for CP patients is the risk of developing pancreatic cancer. 
Several studies have shown that this risk is especially found when pancreatitis develops 
at an early age and the pancreas is exposed to a chronic inflammation during a long 
time. The cumulative risk is estimated at 1.8% after 10 years and 1.5-4.0% after 20 years. 
This risk is even more increased in case of smoking.43-45 
Diagnosis
There is no worldwide consensus about the diagnostic criteria of CP but there are a 
few diagnostic algorithms available.13, 46, 47 (Table 3) Important in each of these 
algorithms is the combination of clinical symptoms, imaging and pancreatic function 
tests. Setting up diagnostic criteria for CP is difficult because there is no “gold 
Autoimmune CP (AIP) should be considered in patients that present with obstructive 
jaundice and a pancreatic mass. Clinically but also with imaging techniques it resembles 
pancreatic cancer what makes the diagnosis difficult.34 Less often it presents with 
acute pancreatitis or with pancreatic insufficiency. AIP can be divided in 2 different 
subtypes; type 1 AIP were the pancreas is part of a systemic positive IgG4 disease 
and other organ systems can be involved like the hepatobiliary tract, or in type 2 AIP 
without any IgG4 positive cells or systemic involvement. 35, 36 The best treatment 
for these patients are corticosteroids although it is highly important to make the 
 differentiation with pancreatic cancer.
Tropical CP (TCP) was for years defined as an idiopathic, juvenile, non-alcoholic form 
of chronic pancreatitis that was found in tropical developing countries. There were 2 
subtypes; Tropical calcific pancreatitis in young patients with abdominal pain and 
early diabetes, and fibro-calculous pancreatic diabetes in older patients but with 
diabetes as a first clinical sign. Etiological factors were not completely clear but 
attributed to nutritional factors like cassava and malnutrition. Recent insights though 
make clear that TCP is probably a misnomer and that the aetiology and clinical char-
acteristics don’t differ from idiopathic chronic pancreatitis in the rest of the world.37
Other rare causes of CP are metabolic changes like primary hypercalcemia, hyper-
parathyroidism and hyperlipidaemia.13 
Clinical symptoms
Pain
The most important clinical symptom is the severe abdominal pain that leads to the 
use of substantial amounts of pain-relief medication and frequent hospitalizations. 
The variability in the intensity of these pain attacks can be extensive. The pain can be 
mild and of short duration or severe and continues. When the disease progresses, 
the frequency of pain attacks seem to increase with shorter pain-free intervals. It is not 
completely understood what exactly causes the pain but it seems to be multifactorial. 
Factors that are described are; an increased intra-pancreatic pressure, the 
inflammation itself but also the altered pain perception at peripheral level and the 
central processing of the nociceptive pain information.38 Treatment is based on 
avoiding pancreatitis-inducing factors as alcohol and smoking, endoscopic and 
surgical treatments and pharmacological options. Analgesics like acetaminophen 
and non-steroidal anti-inflammatory drugs (NSAID’s) are especially used as a first-line 
treatment, followed by opioid receptor antagonists, tricyclic antidepressants (TCA’s), 
selective serotonin re-uptake inhibitors (SSRI’s) and pregabalin. Other strategies are 
nerve blocks, transcutaneous electronic nerve stimulation (TENS) and intrathecal 
pumps for infusion of opioids and anaesthetic agents.39, 40 
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Up to now, genetic testing is most commonly limited to the PRSS1, CFTR and SPINK1 
genes because they clearly have proven to be disease causing or associated, but with 
newer techniques becoming available in the daily clinic like genome wide sequencing, 
it might also be possible to find more low penetrant genes in individual cases.
standard” and there are several imaging modalities that can be used but not all 
techniques are always available in every clinic or are expensive or invasive. When CP is 
suspected based on the clinical symptoms, imaging techniques like trans-abdominal 
ultrasound, CT-scanning, MRI, MRCP or endoscopic ultrasound can be used. The 
most sensitive options are the MRCP and the endoscopic ultrasound although these 
techniques are not always available and maybe not the first choice for screening.48, 49 
Radiological diagnostic criteria are set up in the Cambridge classification of pancreatic 
morphology in chronic pancreatitis. Typical radiological features of CP are calcifications 
and ductal irregularities like widening or obstruction.50
Another part of the diagnosis is testing the exocrine functionality of the pancreas. The 
golden standard is a three-day faecal fat quantification and determination of the 
coefficient of fat absorption, though this test is unpleasant for the patient and for 
laboratory personnel that have to handle large amounts of faeces.51 The faecal 
elastase 1 test is an easier and more widely used test that with a small faecal sample 
looks for the amount of pancreatic faecal elastase 1 with a simple enzyme-linked 
immunosorbent assay.52, 53 
The reason why pancreatic faecal elastase 1 is used instead of other pancreatic 
enzymes is because the enzyme remains stable during the passage through the 
intestine.54 A more practical approach is a trial of pancreatic enzyme replacement 
therapy but this can lead to over- or underdiagnoses. 
Genetic testing
The first guidelines for genetic testing were established in 2001.55, 56 Patients should 
fulfil to some criteria mentioned below before genetic testing is considered because 
the results can have a high impact on their daily lives.
It has consequences for coping, potential future health problems, discrimination in 
health insurance, recurrence risks and family planning. Patients should therefore 
have genetic counselling prior to and after testing.
Criteria for considering genetic testing pancreatitis susceptibility genes are as next:
•	 An unexplained documented episode of pancreatitis as a child
•	 Idiopathic chronic pancreatitis, particularly when the onset of pancreatitis occurs 
before age 25
•	 A family history of recurrent acute pancreatitis, idiopathic chronic pancreatitis, or 
childhood pancreatitis without a known cause
•	 Relatives known to carry mutations associated with hereditary pancreatitis (i.e., 
PRSS1 mutations)
•	 Recurrent acute attacks of pancreatitis for which there is no identifiable cause
•	 Patients eligible for approved research protocols
Table 3  M-ANNHEIM diagnostic criteria of chronic pancreatitis
The diagnosis of chronic pancreatitis requires a typical clinical history of chronic 
pancreatitis (such as recurrent pancreatitis or abdominal pain, except for primary painless 
pancreatitis). Based on these features, there are three forms of chronic pancreatitis that 
are established by one or more of the following additional criteria:
Definite chronic pancreatitis 
1 Pancreatic calcifications
2 Moderate or marked ductal lesions (according to the Cambridge classification)
3 Marked and persistent exocrine insufficiency defined as pancreatic steatorrhea 
markedly reduced by enzyme supplementation
4 Typical histology of an adequate histological specimen
Probable chronic pancreatitis
1 Mild ductal alterations (according to the Cambridge classification)
2 Recurrent or persistent pseudocysts
3 Pathological test of pancreatic exocrine function (such as faecal elastase-1 test, 
secretin test, secretin–pancreozymin test)
4 Endocrine insufficiency (i.e., abnormal glucose tolerance test)
Borderline chronic pancreatitis
Defined by a typical clinical history of the disease but without any of the additional 
criteria required for definite or probable chronic pancreatitis. This form is also 
established as a first episode of acute pancreatitis with or without (1) a family history 
of pancreatic disease (i.e., other family members with acute pancreatitis or 
pancreatic cancer) or (2) the presence of M-ANNHEIM risk factors
Pancreatitis associated with alcohol consumption; Requires in addition to the above 
mentioned criteria for definite, probable, or borderline chronic pancreatitis one of the 
following features
1 History of excessive alcohol intake (>80 g/day for some years in men, smaller 
amounts in women)
2 History of increased alcohol intake (20–80 g/day for some years)
3 History of moderate alcohol intake (<20 g/day for some years) 
20 21
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Numerous amounts of genetic candidate studies are performed making it hard to get 
a clear overview of all the variants that are found in the different populations. We try 
to give a complete summary of the known genetic variants for each aetiology and we 
underscore the importance of these clinical variants in the daily clinical practice. 
For question 2, how do genetic variations influence the clinical course in CP patients?, 
an observational cohort study was done in a Dutch hereditary chronic pancreatitis 
cohort. 
We chose for this approach because both clinical data and blood samples were 
available thanks to the large and comprehensive database of CP patients that was 
built up in our outpatient clinic during the last decades. 
To complement the clinical characteristics we developed a questionnaire that was 
send to all the hereditary chronic pancreatitis patients. This questionnaire was derived 
from the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer 
(EUROPAC) (www.europac-org.eu), a study group that investigates the prevalence 
and clinical aspects of patients with hereditary pancreatitis in Europe and is especially 
interested in PRSS1 mutations and genotype-phenotype correlations. The questionnaire 
is not validated but gave us an extra possibility to complete missing data. The advantage 
of this is that all patients get the same questions and that they can complete the 
questionnaire when they prefer. The disadvantage is that not all patients will respond 
or they will not answer all the questions.  
For question 3, can we discover new candidate-genes and variants that are a causal, 
predisposing or modifying factor for CP in order to complete our missing knowledge?, 
we used different approaches. 
In chapter 4 were we studied tropical calcific pancreatitis and its association with CTRC 
and SPINK1 (p.N34S) variants and in chapter 5 were we investigated polymorphisms at 
PRSS1–PRSS2 and CLDN2–MORC4 loci in alcoholic and non-alcoholic chronic 
pancreatitis in Europe, a patient-control genetic association study was done. 
With this model the differences in allele frequencies or genotypes can be tested in a 
patient group compared with a control group that is unaffected or is randomly selected 
from the population. 
It is of big importance though that the patient group as well the control group is well 
defined so that ethnic or geographic differences cannot influence the final result 
giving a false positive association.57
Another approach we used in chapter 6 were we studied a new candidate gene, the 
IRF2 gene. Instead of performing an expensive genetic analysis in a control 
population, we used a whole genome sequencing database as a “control population” 
to see which variants can be found in the “normal” population compared to the tested 
patient group. 
Chronic pancreatitis as a research model
Chronic pancreatitis is an extremely interesting disease model because it is caused 
by a complex interaction of environmental and genetic factors. So many interacting 
factors are involved, not only in the development of chronic pancreatitis but also in 
the natural course. Why is someone more prone to develop chronic pancreatitis than 
someone else? Why can some people drink large amounts of alcohol without any 
problem while others only need a small amount to develop pancreatitis? For the 
clinical course similar questions can be raised; Are there factors that influence the 
amount of pancreatitis attacks, the severity of the pain or have they any influence on 
the development of complications like pancreatic cancer?
Individual human genetic variations are probably the answer to this question and 
although we already know several genes and genetic variants, there are still a lot of 
unresolved parts.
In this thesis we try to increase this understanding of the genetic factors that have an 
influence on the development and the clinical course of chronic pancreatitis. We 
searched for new candidate genes and new variants in already known genes that are 
related with CP in order to answer the above mentioned questions. 
In overall, the main question and hypothesis that we try to answer in this thesis is; 
Can we find new parts of the complex puzzle of genetic underlying factors of  
CP that have an influence on the development and clinical presentation of CP?
Research questions and disease model;
In order to answer the main question of this the thesis we composed the next research 
questions; 
1. What are the known genetic underlying mechanisms of chronic pancreatitis? 
(Chapter 2)
2. How do genetic variations influence the clinical course in CP patients? (Chapter 3)
3. Can we discover new candidate-genes and variants that are a causal, predisposing 
or modifying factor for CP in order to complete our missing knowledge? (Chapter 4, 
5 and 6)
4. What are the functional effects of variants found in CP related genes? (Chapter 4 
and 7)
Diverse study models are used to answer these research questions;
For question 1, what are the known genetic underlying mechanisms of chronic 
pancreatitis?, we performed a thorough systematic review of the literature. 
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With the possibilities of  whole exome sequencing, more and more is known of all the 
variants in the human genome. Using this data as a control group makes it possible 
to use large data sets and also decrease the costs of unnecessary analysing control 
patients. 
At last, for question 4, what are the functional effects of variants found in CP related 
genes and how do we translate that to the function of the human pancreas in situ?, 
we used cell models. 
With these cell models we hope to predict the clinical effects in situ for genetic 
variants in CP patients and find new pathophysiological mechanism that increase our 
understanding of this disease.
Cells are easily transfected with mutation containing plasmids so that functional tests 
can easily be performed. The disadvantage of cell models though is that each cell 
line has its own specific features and are not always comparable to the human 
pancreatic cell. 
 
Outline of this thesis
Chronic pancreatitis is a complex multifactorial disease with a high impact for the 
patient. Several genetic underlying factors were found during the last decades and 
largely increased our knowledge and understanding of this disease. In this thesis we 
try to increase that knowledge and we hope that finding more and more missing 
pieces of this highly interesting and difficult puzzle will not only lead to more 
understanding but ultimately also to therapeutic options. 
In Chapter 2, the known genetic factors in all types of CP are reviewed and summarized. 
As completely as possible all genetic underlying mechanisms for CP are described. 
In Chapter 3, the relation between clinical data and genetic analysis is investigated 
in a Dutch cohort of hereditary pancreatitis patients. The question at stake here is if 
genetic mutations in pancreatic risk-genes have influence on the clinical course of 
chronic pancreatitis. In Chapter 4, an Indian cohort of tropical chronic pancreatitis 
patients is investigated for mutations in the SPINK1 and the CTRC gene. 
In Chapter 5, a large European study leads to new insights and newly found 
polymorphisms in the PRSS1-PRSS2 and MORC4-CLDN2 genes in alcoholic and 
non-alcoholic CP patients. In Chapter 6, a new candidate gene, the IRF2 gene, is 
investigated for association with CP patients. IRF2 showed before to be a clear risk 
factor for the development of pancreatitis in IRF2 knock-out mice. In Chapter 7, the 
functional effects of SPINK1 promoter variants are tested in diverse cell models. One 
important question here is how these data out of cell lines can be used for under -
standing the pathophysiology of chronic pancreatitis in humans.
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Abstract
Chronic pancreatitis (CP) is a clinical situation with persisting inflammation leading 
to destruction of the pancreas ensuing endocrine and exocrine failure. There are 4 
subtypes: hereditary, idiopathic, alcoholic and tropical pancreatitis. Genetic factors 
can explain a significant proportion of CP cases. The PRSS1 gene, encoding cationic 
trypsinogen, was found to be correlated with hereditary CP. This signalled the exten-
sive search for other candidate genes within the trypsin pathway. Genes like SPINK1 
and CTRC are associated with CP and should be considered as important contrib-
uting factors rather than causative. The search for candidate genes not part of the 
trypsin pathway has been less successful and the only gene consistently associated 
with CP is the Cystic Fibrosis Transmembrane Regulator. In this review we will discuss 
the various CP subtypes in relation to the respective genetic variants. This review will 
also address the implications of genetic testing in daily clinical practice.
Introduction
This review aims to give an overview of the genes and mutations that play a role in the 
pathogenesis of chronic pancreatitis (CP). It has become clear over the past several 
years that the molecular underpinnings of CP are driven by genetic mutations in the 
trypsin enzyme cascade. Indeed, the elucidation of genes that are associated with 
CP has greatly improved our understanding of the disease.
This review will provide insight in the historical background that comes with the 
 discovery of these genetic mutations. In addition we will discuss how these genetic 
mutations contribute to the pathogenesis of the various forms of CP and lastly we 
aim to delineate some of the implications these discoveries have for current clinical 
practice. The mutations will be discussed in context of the different subtypes of CP 
such as alcoholic (ACP), idiopathic (ICP), hereditary (HCP) and tropical (TCP) CP.
How are candidate genes discovered
The genes involved in CP have been discovered through a mix of genetic approach-
es. The PRSS1 gene that has been linked to HCP, was discovered by classical for-
ward genetic linkage analysis.1, 2 This approach is hypothesis free and assumes no 
prior knowledge on the pathogenesis of the disease. Here linkage analysis with poly-
morphic markers is used to detect linkage between markers and a disease locus 
within a family. Once a locus has been detected, sequencing of the genes from the 
linked interval is needed to discover the disease gene. Alternatively, researchers use 
genetic candidate studies. This approach has been successful for the detection of 
a number of genes. It assumes prior knowledge of the function of a candidate gene 
and screens a population of patients and compares results with a control population. 
Examples of CP genes that have been discovered are PRSS1, CTRC and SPINK1. 
The disadvantage is that large cohorts are needed in order to find associations. 
More recently, with the introduction of genome wide association studies (GWAs), it 
has become possible to analyse hundreds of thousands of single nucleotide poly-
morphisms (SNP’s) throughout the entire genome in order to find associations in a 
case/control approach. In 2012 the first GWAs in CP led to the discovery of the new 
susceptibility locus CLDN2-MORC4.3 
An explanation of widely used terms in the field of genetic research will be given in 
textbox 1. 
Historical Background
More than a century ago, it was Dr. Chiari who postulated in 1896 that pancreatitis 
is caused by premature activated trypsin resulting in auto-digestion of the pancreas. 
An important observation, 65 years later, that contributed to the discovery of the HCP 
30 31
CHAPTER 2 REVIEW; GENETIC ASPECTS OF CHRONIC PANCREATITIS
2
Whitcomb sequenced 2 of the functional trypsinogen genes and discovered a 
 disease causing mutation in the cationic trypsinogen (PRSS1) gene, (p.R122H).7 Sub-
sequently, this was confirmed by other studies.8-10  
Figure 1 shows the normal trypsinogen pathway, textbox 2 further explains the 
 trypsinogen cascade and table 1 gives an overview of the trypsinogen genes.
The discovery of the trypsinogen gene mutations supported the century-old hypothesis of 
Dr. Chiari but the story did not end with the discovery of the PRSS1 mutations. While 
the large majority of HCP families carried a PRSS1 mutations, the molecular back-
ground of other non-inherited forms of CP was yet to be discovered. Other  candidate 
genes part of the trypsin activation cascade came into view. In 2000, variants in ser-
ine protease inhibitor Kazal type 1 (SPINK1) were found in ICP patients,12-14 and later 
also in other forms of CP such as ACP and TCP.15-17 
gene was the finding that the disease clustered in families in an autosomal dominant 
fashion.2 Indeed, in 1996, the genetic locus for HCP was identified on chromosome 
7q35 in a large family,1 and this finding was confirmed in other families.4, 5 The identi-
fi cation of the gene responsible for HCP was aided in large part by the discovery that 
this chromosomal stretch contained 8 different trypsinogen genes.6 
Textbox 1  Definitions
Allele frequencies The human genome contains 2 copies of each gene,
a paternal and a maternal allele. The allele frequency 
describes the fraction or percentage of an allele in a 
population.
Compound heterozygous 
mutation
Two different mutations in the paternal and maternal allele.
Copy number variations A normal variation in DNA due to variation in the number of 
copies of a sequence within the DNA. Large-scale copy 
number polymorphisms are common and widely distributed 
in the human.
Frameshift mutation A genetic mutation caused by a deletion or insertion in a DNA 
sequence that shifts the way the sequence is read.
Gain-of-function mutation A mutation resulting in a gene product with an increased or 
abnormal function (neomorphic mutation). 
Heterozygous mutation A mutation of one allele.
Homozygous mutation An identical mutation of both genes.
Loss-of-function mutation A mutation resulting in a gene product with a decreased or no 
function. A null allele has a complete loss-of-function 
(amorphic mutation). 
Missense mutation A point mutation in which a single nucleotide is changed, 
resulting in a codon that codes for a different amino acid 
(non-synonymous mutation). This can render the resulting 
protein non-functional. In case of an amino acid replacement 
by an amino acid of very similar chemical properties the 
protein may still function normally (quiet, neutral or 
conservative mutation).
Nonsense mutation A point mutation resulting in a premature stop codon leading 
to a truncated, incomplete and non-functional protein.
Polymorphism The occurrence of multiple alleles of a gene within a 
population leading to a diverse morphology.
Single nucleotide 
polymorphism (SNP’s)
Also known as bi-allelic marker. Represents a natural genetic 
variability with an alternate nucleotide in a gene location at a 
high density in the human genome (1% in a population). It 
may occur in non-coding as well as coding regions. In coding 
regions SNP’s may alter protein function.
Wild-type A homozygous non-mutated state, neither allele is mutated.
Figure 1  Trypsinogen physiology
Trypsinogen is secreted by the pancreatic acinair cell and activated to trypsin by enteropeptidase within the 
duodenum. Trypsin itself then acts as a trigger enzyme to initiate the cascade activation of other pancreatic 
digestive pro-enzymes as well as trypsinogen itself ultimately leading to the digestion of food. Very low 
amounts of trypsinogen become active within the pancreas. To prevent auto digestion, SPINK1, CTRC and 
trypsin itself inhibit and degrade all trypsin’s and trypsinogens.
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gene.19, 20 A second isoform of trypsinogen, anionic trypsinogen (PRSS2), showed no 
correlations with CP in several studies.21, 22 However, one PRSS2 variant, (p.G191R), 
was enriched in controls compared with CP patients and thereby suggested to act 
as a protecting factor.23 Apart from components in the trypsinogen cascade there 
 appears to be  another important player on the genetic CP field. Patients with Cystic 
 Fibrosis (CF), an autosomal recessive disease, have chronic obstructive pulmonary 
disease and can present with pancreatitis and exocrine pancreas insufficiency. 
CF is caused by loss-of-function mutations in the Cystic Fibrosis Transmembrane 
Conductance Regulator gene (CFTR).The association between CF and CP was 
 established in 1998.24, 25 
Pancreatitis subtypes and their genes 
In this section the different subtypes of CP are outlined together with the genetic 
mutations that are the most important in their aetiology. 
Hereditary pancreatitis
Phenotype 
HCP is diagnosed when there are recurrent episodes of pancreatitis from childhood, 
a positive family history with at least 2 affected members and as other causes of 
pancreatitis such as alcohol abuse, gallstones, trauma, medication, infections and 
metabolic disorders have been excluded. The median age of onset is 10 years.26 
As outlined, HCP is caused by PRSS1 gene mutations resulting in an alteration of 
the normal trypsinogen cascade. 
PRSS1 
This section will discuss the most relevant PRSS1 gene mutations. For an elaborate 
overview we refer the reader to Table 2 and Textbox 3 (Derived from: http://pancreas-
genetics.org and www.uni-leipzig.de/pancreasmutation/db).
The p.R122H was the first identified PRSS1 mutation and is up to now the most 
 commonly found mutation in HCP.7 Interestingly, there are 2 distinct nucleotide 
 substitutions that lead to the p.R122H mutation (c.365G>A, and c.365-366GC>AT), 
the latter is also associated with ICP.27, 28 
In a large collaborative European study (European Registry of Hereditary  Pancreatitis 
and Pancreatic Cancer) an effort was made to delineate the clinical  characteristics 
of HCP patients.29 There was a clear genotype-phenotype correlation were p.R122H 
carriers presented with a younger age of onset. Position 122 of the PRSS1 gene 
 appears to be susceptible for mutations as in 2001 and 2002, 3 different study groups 
revealed a p.R122C (c.364C>T) mutation in HCP patients albeit with a lower 
 penetrance.30-32 The effect of the resulting mutation p.R122C is less severe than 
p.R122H which has a larger gain-of-function. (Textbox 3, Figure 2) 
In 2007 another enzyme, chymotrypsin C (CTRC), was identified as responsible for 
trypsin degradation in the pancreas.18 Subsequent genetic case control studies in ICP, 
TCP and ACP patients confirmed the role of CTRC as a new pancreatitis  susceptibility 
Table 1  Trypsinogen genes
Gene Chromosome Protein
T1 (Pseudogene) 7q35
T2 (Relic gene) 7q35
T3 (Pseudogene) 7q35
T4 (PRSS1) 7q35 Cationic trypsinogen
T5 (Pseudogene) 7q35
T6 (expressed) 7q35 No protein
T7 (Pseudogene) 7q35
T8 (PRSS2) 7q35 Anionic trypsinogen
T9 (PRSS3) 9p13 Mesotrypsinogen
Textbox 2  The trypsinogen cascade
Out of the 9 trypsinogen genes there are 3 functional proteins that can be isolated from 
human pancreatic juice, i.e. cationic trypsinogen, anionic trypsinogen and mesotrypsinogen 
(PRSS3). (Table 1) All three genes consist of 5 exons and are synthesized in the pancreatic 
acinair cells as pre-trypsinogens on the ribosomes attached to the rough endoplasmic 
reticulum (RER). Trypsinogen is formed after removal of a 15-amino acid signal peptide 
in the RER and is then transported to the Golgi-complex, concentrated and stored within 
secretory granules. After secretion into the pancreatic duct and release into the duodenum, 
trypsin is activated by enteropeptidase trough cleavage of an 8-amino acid activation 
peptide. Trypsin then acts as a trigger enzyme to initiate the cascade activation of other 
pancreatic digestive pro-enzymes as well as trypsinogen itself. (Figure 1) The enzymatic 
activity of trypsin is highly specific and directed towards the carboxyl groups of arginine 
or lysine residues. Other triggers for the activation of trypsinogen in the pancreas are 
lysosomal enzyme cathepsin B, neutrophil enzymes, reflux of bile or duodenal fluid, 
disturbance of pancreatic duct flow and inflammation. Calcium inhibits the degradation of 
activated trypsin. Only very low amounts of trypsinogen become active within the pancreas. 
To prevent auto-digestion, the pancreas has extra lines of defence; the first is SPINK1 that 
inhibits up to 20% of the trypsin activity. The second enzyme is CTRC which degrades all 
trypsin’s and trypsinogens. In addition, trypsin itself catalyses trypsin degradation.11 (Figure 1) 
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p.N29I is the second most frequent detected PRSS1 gene mutation.8 In the same 
vein as R122, different nucleotide changes have been identified in HCP that cause 
change of asparagine to change into isoleucine (c.86A>T, N29I) or threonine 
(c.86A>C, N29T) although the former mutation is much more common.31 The p.A16V 
mutation, the third most common mutation, has been detected in HCP but also in 
ICP.33, 34  Other missense gain-of-function mutations in HCP are: p.D19A,35 p.D22G,35 
and p.K23R.10, 36 These have only been found in single cases or single families. The 
situation is less clear for the p.E79K mutation which has been associated with HCP, 
but without complete penetration within families.37 
A gene dosage effect in HCP
As the most mutations in the PRSS1 gene seemed to be responsible for a gain-of-
function of trypsin, others hypothesized that trypsinogen was sensitive for a gene 
dosage effect. In 2006 a French cohort of 34 families were analysed and indeed a 
triplication of the trypsinogen genes on chromosome 7 was present in all affected 
subjects, some asymptomatic subjects but absent in controls.38
Textbox 3  Functionality of PRSS1 gene mutations
Gain-of-function mutation
p.A16V The A16 position is the cleavage site of the signal peptide and the activation 
peptide. Hypothesized was that loss of this cleavage site would result in a disturbed 
secretion of pre-proteins and a possible intracellular activation or formation of 
trypsin instead of an inactive precursor. Another suggestion was a conformational 
change of the activation peptide with increased auto-activation.34, 35 This mutation 
showed a 4 times faster stimulation of trypsin by the CTRC protein.43
p.D19A
p.D22G
p.K23R
These mutations are all responsible for a mutation in a 4 aspartic acids residue 
at the N-terminal peptide of the cationic trypsinogen. This is the cleavage site for 
activation by enterokinase but also for auto-activation.44 All mutations showed 
enhanced auto-activation intra- and extracellulair.44, 45 The effect on enterokinase 
although was different; p.D19A showed no effect, p.K23R stimulated and p.
D22G inhibited enterokinase mediated trypsinogen activation. 
p.N29I The exact mechanism of the p.N29I mutation is still speculative. Functional 
analysis showed an enhanced auto-activation but no inhibition of autolysis.46 
The p.N29I substitution leads to conformational changes influencing the R122 
lysis site and making it insensitive for trypsinolysis.47 
p.N29T The p.N29T mutation, together with the p.N29I mutation showed a decreased 
activation by enterokinase. The p.N29T further showed an increased stability 
and an enhanced auto-activation.48
p.E79K The p.E79K mutation showed a decreased auto-activation but a two-fold better 
activation of anionic trypsinogen.37
p.R116C This mutation leads to incorrect intracellular folding with reduced secretion (20%) 
and ultimately endoplasmic reticulum (ER) stress. In case of a correctly folded 
purified p.R116C mutant, the activation and degradation characteristics are 
comparable to wild type trypsinogen.45
p.R122H The arginine (R) at position 122 is the primary autolysis site of trypsin. Because 
of the substitution of R by histidine (H) in this mutation, this autolysis site gets lost 
and trypsin gets resistant against inactivity mechanisms.7 (Figure 1) Further, 
active and inactive trypsin get more stabilized and shows more auto-activation.46 
Transgenic mice with the p.R122H mutation showed development of inflammation 
and fibrosis ultimately leading to CP.49
p.R122C This mutation causes a changed folding pattern of the protein through disulphide 
bonds with a decrease in secretion of up to 20%. Biochemical analysis of 
correctly folded purified p.R122C mutant revealed unchanged activation and 
degradation characteristics compared to wildtype.36 Another study showed a 
decreased protein activity by activation upon bovine enterokinase. On the other 
hand it showed a more rapid auto-activation and more resistance to autolysis. 
So this mutation could be compatible with a loss or a gain-of-function hypothesis.8 
p.G208A The p.G208A mutation causes a moderate secretion defect leasing to ER stress.50 
Loss-of-function mutations
p.A121T This mutation has a significantly increased trypsin cleavage rate leading to a 
loss-of-function of trypsin.40 
Figure 2  Functional consequences of PRSS1 gene mutations
Gain-of-function mutations result in an increasing amount of trypsin within the pancreas leading to auto-di-
gestion and thereby CP. Causes are increased stability of the enzyme, loss of the autolysis site, increased 
auto-activation and intra-cellular retention and activation of trypsin.
36 37
CHAPTER 2 REVIEW; GENETIC ASPECTS OF CHRONIC PANCREATITIS
2
Ta
b
le
 2
  P
R
SS
1 
m
ut
at
io
ns
R
eg
io
n
N
uc
le
ot
id
e 
ch
an
g
e
A
m
in
o 
ac
id
 c
ha
ng
e
N
r. 
of
 C
P
 c
ar
rie
rs
N
r. 
of
 n
on
-C
P
 c
ar
rie
rs
P
at
ho
g
en
ic
P
R
S
S
1 
du
pl
ic
at
io
n
7
Ye
s
P
R
S
S
1 
tri
pl
ic
at
io
n
26
2
Ye
s
5 
pr
im
e
c.
-4
08
C
>
T
C
om
m
on
 p
ol
ym
or
ph
is
m
C
om
m
on
 p
ol
ym
or
ph
is
m
P
ro
te
ct
iv
e
5 
pr
im
e
c.
-2
04
C
>
A
C
om
m
on
 p
ol
ym
or
ph
is
m
C
om
m
on
 p
ol
ym
or
ph
is
m
N
o
5 
pr
im
e
c.
-3
6G
>
A
1
U
nk
no
w
n
5 
pr
im
e
c.
-3
0_
-2
8d
el
TC
C
1
U
nk
no
w
n
in
tro
n 
1
c.
40
+
1G
>
A
1
P
ro
te
ct
iv
e
in
tro
n 
1
c.
40
+
40
de
lC
1
U
nk
no
w
n
in
tro
n 
1
c.
41
-4
9C
>
T
1
U
nk
no
w
n
ex
on
 2
c.
47
C
>
T
p.
A
16
V
43
24
Ye
s
ex
on
 2
c.
56
A
>
C
p.
D
19
A
1
Ye
s
ex
on
 2
c.
62
A
>
C
p.
D
21
A
3
Ye
s
ex
on
 2
c.
65
A
>
G
p.
D
22
G
2
1
Ye
s
ex
on
 2
c.
68
A
>
G
p.
K
23
R
2
Ye
s
ex
on
 2
c.
63
_7
1d
up
p.
K
23
_I
24
in
sI
D
K
3
Ye
s
ex
on
 2
c.
86
A
>
T
p.
N
29
I
29
3
18
Ye
s
ex
on
 2
P
R
S
S
1-
P
R
S
S
2 
hy
br
id
p.
N
29
I +
 p
.N
54
S
7
1
Ye
s
ex
on
 2
c.
86
A
>
C
p.
N
29
T
5
Ye
s
ex
on
 2
c.
10
7C
>
G
p.
P
36
R
2
N
o
ex
on
 2
c.
11
1C
>
A
p.
Y3
7X
1
P
ro
te
ct
iv
e
ex
on
 2
c.
11
6T
>
A
p.
V3
9E
1
N
o
ex
on
 2
c.
11
6T
>
C
p.
V3
9A
7
Ye
s
ex
on
 2
c.
12
5A
>
G
p.
N
42
S
1
U
nk
no
w
n
in
tro
n 
2
c.
20
0+
1G
>
A
1
P
ro
te
ct
iv
e
in
tro
n 
2
c.
20
0+
61
_6
5d
el
C
A
G
C
C
4
3
U
nk
no
w
n
ex
on
 3
c.
23
5G
>
A
p.
E
79
K
13
6
Ye
s?
ex
on
 3
c.
24
1C
>
A
p.
L8
1M
4
U
nk
no
w
n
ex
on
 3
c.
24
8G
>
A
p.
G
83
E
1
N
o
ex
on
 3
c.
26
3T
>
A
p.
I8
8N
1
N
o
ex
on
 3
c.
27
3C
>
A
p.
A
91
=
1
U
nk
no
w
n
ex
on
 3
c.
27
6G
>
T
p.
K
92
N
2
Ye
s
ex
on
 3
c.
29
2C
>
A
p.
Q
98
K
1
N
o
ex
on
 3
c.
29
8G
>
C
p.
D
10
0H
2
3
Ye
s
ex
on
 3
c.
31
0C
>
G
 
p.
L1
04
V
4
U
nk
no
w
n
ex
on
 3
c.
31
1T
>
C
p.
L1
04
P
1
3
Ye
s
ex
on
 3
P
R
S
S
1-
P
R
S
S
3P
2 
hy
br
id
p.
S
11
5T
 +
 p
.R
11
6P
 +
 p
.R
12
2H
2
1
Ye
s
ex
on
 3
c.
34
6C
>
T
p.
R
11
6C
25
4
Ye
s
ex
on
 3
c.
36
1G
>
A
p.
A
12
1T
14
6
N
o
ex
on
 3
c.
36
4C
>
T
p.
R
12
2C
36
25
Ye
s
ex
on
 3
c.
36
5G
>
A
p.
R
12
2H
81
6
69
Ye
s
ex
on
 3
c.
36
5_
36
6G
C
>
AT
p.
R
12
2H
3
Ye
s
ex
on
 3
c.
36
7G
>
A
p.
V1
23
M
1
N
o
ex
on
 3
c.
36
7G
>
T
p.
V1
23
L
1
N
o
ex
on
 3
c.
37
1C
>
T
p.
S
12
4F
1
Ye
s
ex
on
 3
c.
40
3A
>
G
p.
T1
35
A
1
U
nk
no
w
n
ex
on
 3
c.
41
0C
>
T
p.
T1
37
M
9
1
N
o
ex
on
 3
c.
41
5T
>
A
p.
C
13
9S
12
Ye
s
ex
on
 3
c.
41
6G
>
T
p.
C
13
9F
3
1
Ye
s
ex
on
 3
c.
41
7C
>
T
p.
C
13
9=
1
U
nk
no
w
n
ex
on
 3
c.
44
3C
>
T
p.
A
14
8V
1
U
nk
no
w
n
in
tro
n 
3
c.
45
4+
10
A
>
C
5
U
nk
no
w
n
in
tro
n 
3
c.
45
4+
36
T>
C
1
U
nk
no
w
n
in
tro
n 
3
c.
45
4+
75
A
>
G
24
4
U
nk
no
w
n
in
tro
n 
3
c.
45
4+
12
7A
>
T
1
U
nk
no
w
n
in
tro
n 
3
c.
45
4+
15
7C
>
A
1
U
nk
no
w
n
38 39
CHAPTER 2 REVIEW; GENETIC ASPECTS OF CHRONIC PANCREATITIS
2
Lastly, combinations of PRSS1 and PRSS2 mutations through non-allelic homologous 
recombination do occur but are very rare.39 
Loss-of-function variants in HCP
Distinct from gain-of-function mutations several loss-of-function mutations with different 
effects on the development of CP have been found. The p.A121T mutation was originally 
found in 3 single Chinese patients, and this finding was confirmed in a HCP family.40, 41 
As this mutation is located near p.R122H, a similar mechanism of action was assumed, 
but molecular modelling was compatible with a loss-of-function.40 
A case control study took the opposite hypothesis and examined whether PRSS1 loss-
of-function mutations may actually protect, but did not find any of these mutations 
in their sample. In contrast, they discovered a novel loss-of-function splicing mutation 
(IVS2+1G>A) and a nonsense mutation (p.Y37X) in 2 CP patients but none of the 
controls.42 The interpretation of these findings is unclear, but these mutations apparently 
lead to a misbalance in trypsinogen composition and are in rare instances associated 
with CP. 
PRSS2
Because it resembles cationic trypsinogen, anionic trypsinogen (PRSS2) was an 
obvious candidate gene. Anionic trypsinogen shares the same physiological activity 
with cationic trypsinogen but it is synthesized in lower amounts, has less auto-activation 
and the autolysis is more rapidly.51 Until now however, no HCP associated PRSS2 
mutations have been found.7, 21, 22 On the contrary, a single PRSS2 mutation appears 
to protect against pancreatitis. The p.G191R mutation causes a complete loss-of-
function by generating a new trypsin cleavage site in the anionic trypsinogen thereby 
becoming hypersensitive to autolysis. The mutation was found in 2 cohort studies 
with the following frequencies; 3.4%/5.4% of controls and 1.3%/0.7% of CP patients.23, 52 
SPINK1
The association of SPINK1 with HCP is controversial. Though mutations are detected 
in CP families or individuals with a positive family history, its contribution to HCP is 
unclear.53-56
Other genes 
CFTR was only investigated in one cohort of HCP patients. There were two new 
variants but the gene was declared as disease modifying instead of disease causing.57 
Next to CFTR, also the CTRC gene was considered as a non-disease-causing gene 
in HCP.19 Furthermore a study was done for mutations in glutathione s-transferase 
(GST’s), one of the detoxification systems that prevent the cell from oxidative stress. 
Also here no dominant causal factor for HCP was found.58
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on chromosome 4 making it unlikely that SPINK1 mutations are responsible for 
autosomal dominant HCP. 
On the other hand, these researchers too found that there was a high proportion of 
p.N34S carriers in the ICP population, which confirmed the role of this mutation.14
A meta-analysis for SPINK1 p.N34S mutation showed an allele frequency from 9.1 to 
24.7 percent in 14 studies.65 However, multiple efforts have failed to assign a functional 
role to p.N34S, as the mutant variant behaves similarly to wild type SPINK1. (Textbox 4) 
Idiopathic chronic pancreatitis
Phenotype
In about one third of CP patients no clear etiological factor can be detected after 
exhaustive examinations including laboratory studies, imaging and assessment of 
environmental risk factors. ICP comprises two clinically distinct entities characterised 
as an early and a late age of onset.  In the early age of onset, patients develop 
symptoms, mainly severe pain, during the first 2 or 3 decades. The development of 
morphological and functional pancreas damage is not as pronounced as in the late 
onset where patients develop symptoms in their fifth decade of life. Here, the 
development of exocrine and endocrine insufficiency is more prominent and often 
the first symptom of presentation. Moderate alcohol intake below the range that is 
proposed to cause ACP perhaps affects the onset and severity of ICP. Further are 
SPINK1 mutations, and CFTR alleles predominantly associated with ICP.59
PRSS1
Although mutations of this gene have been particularly implicated in hereditary 
pancreatitis, their presence in ICP has also been reported, especially in younger 
patients.60 A variable incidence of 0-19% was found in different study populations.60-64 
SPINK1
SPINK1 was an obvious candidate gene for CP; It prevents the activation of digestive 
enzymes in the pancreas by inhibiting trypsin, it is produced by the pancreatic acinair 
cells and it acts as a first line of defence against prematurely activated trypsin by 
binding and inhibiting its activity up to 20%.13 As a corollary, the hypothesis was that 
loss-of-function mutations in the SPINK1 gene would increase the amount of active 
trypsin causing pancreatitis. (Textbox 4, Figure 3) 
An early case control study identified 7 SPINK1 polymorphisms in a set of HCP 
and ICP patients. These mutations though did not perfectly segregate with the 
disease as controls appeared to be carriers as well. As these SPINK1 variants do 
not have a profound effect on the SPINK1 enzyme the finding was discarded as 
 non-relevant.12
In a subsequent study with 96 ICP children, Witt et al detected the p.N34S mutation 
in 18/96 ICP patients; 6 in a homozygous state, while 12 were heterozygous carriers. 
The phenotype was similar between heterozygous and homozygous patients and 
between p.N34S carriers and wild type patients. They too detected p.N34S in 
controls, albeit at a much lower frequency.13 This landmark study established the role 
of p.N34S in ICP.
Spurred by these findings, others screened their HCP and ICP patients for SPINK1 gene 
mutations.14 A linkage analysis excluded linkage between HCP and the SPINK1 locus 
Textbox 4  Functionality of SPINK1 mutations 66, 67
p.N34S 
p.N55S
The amino acid substitution leads to similar physiological properties without 
changes in expression pattern.
p.R65Q Gives a substitution of a positively charged amino acid by a non-charged amino 
acid causing a 60% reduction of protein expression. 
p.D50E
p.Y54H
p.R67C
p.G48E
The change of amino acid causes a complete or nearly loss-of-function of the 
SPINK1 protein expression. Probably this is caused by intracellular retention and 
degradation. 
Figure 3  Functional consequences of SPINK1 mutations
SPINK1 prevents the premature activation of trypsin within the pancreas by inhibiting its activity up to 20%. 
Hypothesized was that loss-of-function mutations in the SPINK1 gene increase the amount of active trypsin 
thereby causing CP.
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This has led to the current thinking that p.N34S acts as a disease modifier instead of a 
disease initiating gene with lowering the threshold for the development of pancreatitis. 
Next to the most prevalent p.N34S mutation there are also another missense 
mutations like the p.N55S, p.D50E, p.Y54H, p.R65Q, p.R67C and p.G48E.66  
An overview of all SPINK1 mutations is shown in Table 3. Derived from: http://pancreas-
genetics.org and www.uni-leipzig.de/pancreasmutation/db 
Chymotrypsin C (CTRC)
In 2007 CTRC, previously described as enzyme Y,68 came into view as a candidate 
gene. At low calcium levels this enzyme cleaves a peptide bond within the calcium 
binding loop of the cationic trypsin resulting in rapid degradation and loss of trypsin 
activity. As a result of these findings, CTRC was assigned a role as the second line of 
defence against premature trypsin activation.18 A comprehensive screen for CTRC 
variants was performed in a large cohort of ICP and HCP patients and this led to the 
discovery of 11 missense and 2 deletion variants, mostly located in exon 2, 3 and 7. 
The 2 most frequent variants, p.R254W and p.K247_R254del, were significantly more 
expressed in CP patients (3.3%) than in controls (0.7%). Functional analysis 
demonstrated a nearly complete loss-of-function for the p.K247_R254del mutation 
and a 50% decrease of function for the p.R254W mutation.20 
Another study searched for CTRC variants in ICP and detected 19 rare variants next 
to 2 common synonymous polymorphism; c.180C>T (p.G60G) and c.285C>T 
(p.D95D). All variants were more frequently seen in patients than in controls but only 
the p.R254W mutation was really associated with ICP. In addition, a nonsense 
mutation (p.W55X) and a micro-deletion mutation (p.K247_R254del) were detected, 
both resulting in a reduced secretion and/or reduced catalytic activity of the protein.19
In 2010, a complete new pathophysiological mechanism for CTRC mutations came 
into view; CTRC mutations not only have an impact on the trypsinogen pathway but 
they can also cause ER stress and subsequent cell death by mutation-induced 
misfolding of the protein.69 
CTRC can be seen as a disease contributor and is found in approximately 4.1% of 
patients with ICP.64, 70
CFTR
Mutations in the CFTR gene are associated with cystic fibrosis in which patients present 
at a young age with chronic obstructive pulmonary disease, congenital bilateral 
absence of the vas deference (CBAVD) or ICP. The CFTR gene encodes a cAMP- 
activated chloride channel in the membrane of epithelial cells.71 In the pancreas, 
CFTR is responsible for bicarbonate secretion into the duct lumen which accounts for 
diluting and alkalising the acinair pancreas secretions and preventing the formation 
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but also a proportion of homozygous carriers.16 In contrast, the carrier rate in controls 
was below 2%. 
Whereas the association of p.N34S mutation was clear, patients with and without the 
variant had a similar clinical phenotype.16
A more comprehensive study in Bangladesh with 37 TCP patients confirmed the high 
proportion of p.N34S mutations in FCDP patients (55%) and TCP (20%).77 Later 
studies from different tropical regions essentially confirmed these data.17, 78 On 
balance it is clear that the association of p.N34S is the most evident for TCP compared 
to other CP subtypes with an allele frequency from 8.8 to 41.6 percent.79 
CTRC 
The first case control study for CTRC variants in ICP and HCP patients also investigated 
TCP patients; 14.1% of TCP patients and only 1.2% controls showed CTRC alterations. 
The p.A73T missense mutation and the p.I64LfsX69 frameshift mutation were the 
most frequently found variants. The p.A73T mutation reduces CTRC secretion and 
causes a near complete loss-of-function.20 These data were confirmed in a replicative 
cohort study which showed presence of 3 synonymous variants among a sample of 
150 TCP patients. Only the c.180C>T variant was significantly enriched in patients. 
There were other rare variants, and one (p.G61R) found in a single TCP patient, 
caused a complete loss-of-function of CTRC.78 These studies show spreaded 
prevalence’s of CTRC variants in TCP patients. The latest comprehensive analysis in 
a large cohort of TCP patients stated that genetic alterations in the CTRC gene are 
different from the Caucasian population; with the p.V235I as the most common 
variant (5.3% TCP patients vs. 0.7% in controls) and the p.A73T mutation as the 
second most common variant. The further detection of 7 novel variants underlined 
the genetic background of TCP.80 
CFTR
Only a few studies investigated the effect of CFTR variants in TCP. In overall a mutation 
frequency of 11-27% was found.81, 82
Cathepsin B (CTSB)
The lysosomal hydrolase CTSB mediates activation of trypsinogen within the acinair 
cells. In 306 TCP patients, the p.L26V polymorphism was significantly associated 
with TCP.80, 83 This association was not found in European ICP patients.84
of protein plugs in the ducts. Until now, more than 1000 mutations in the CFTR gene 
are associated with CF, the  p.F508 mutation being the most common. 
In 1998 two studies showed a correlation between CFTR mutations and ICP.24, 25 The 
first study revealed that 10/27 ICP patients carried a CFTR mutation and/or the 
so-called 5T allele. 
The 5T allele reduces the expression of functional CFTR and is associated with 
patients with CBAVD.24  In the same year another case study investigated 134 CP 
patients, 71 patients with ACP, 60 patients with ICP and 3 with metabolic CP. Eighteen 
patients, of which 12 were ICP patients, had a mutation.25 
Because these study groups only tested for the most common mutations in the CFTR 
gene, others tried to screen the whole gene sequence for more rare mutations and 
variants. As a result of this extensive search, other mutations were found and stated 
was that ICP was associated with the presence of 2 CFTR gene mutations sometimes 
in combination with a SPINK1 mutation.72
In 2002, a systematic analysis of the entire CFTR coding gene in 39 ICP patients led 
to 18 ‘abnormal’ CFTR alleles in 14 subjects. They identified 10 new alleles by this 
method.73 Since then more studies confirmed the association of CFTR gene mutations 
and ICP with a frequency of ~13-37%.  
Tropical chronic pancreatitis
Phenotype
TCP is a form of ICP which is unique to the tropics. Patients present at a very young 
age with recurrent abdominal pain and develop diabetes earlier than other CP patient’s, 
often even before the age of 30 years (fibro-calculous pancreatic diabetes, FCPD). 
The aetiology of TCP is unclear, but a major hypothesis includes the consumption of 
cassava, a large source of carbohydrates in some tropical regions. This hypothesis 
has been refuted as TCP is not consistently present in all tropical regions with high 
cassava consumption. Other factors that were proposed include malnutrition and 
micronutrient deficiency. Because 8% of the TCP cases have a familial clustering also 
genetic factors were taken responsible.17 The genetic risk profile is completely distinct 
from HCP in Europe. There appears to be no association between PRSS1/PRSS2 and 
TCP.16, 22, 74 In contrast, SPINK1 and CTRC mutations that have been associated with 
ICP in the Western world were also detected in TCP suggesting a similar genetic 
aetiology for ICP in the west and TCP in the tropics and it even has been called a 
misnomer.17, 75
SPINK1
The first association between SPINK1 and TCP was made in a preliminary report with 
patients from Bangladesh.76 Subsequent studies in TCP patients confirmed this and 
detected the p.N34S mutation in almost ~50% of patients, most often heterozygous, 
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the most active enzyme in the alcohol metabolism, and by alcohol dehydrogenase 
(ADH) and aldehyde dehydrogenase (ALDH). (Figure 4) Phase II detoxification is 
done by antioxidants like glutathione S-transferases (GST’s), NADPH-quinone oxido-
reductase 1/2 (NQO1/2), N-acetyl-transferase (NAT2), catalase (CAT), microsomal epoxide 
hydrolase (EPHX1), Human serum paraoxonase (PON1), manganese–super oxide 
dismutase (MnSOD) and uridine 59-diphosphate glucuronyltransferases (UGT’s). 
(Table 4) Mutations and/or polymorphisms in these enzymes were hypothesized as 
being responsible for the development of ACP or other alcohol related organ damage. 
Alcoholic chronic pancreatitis
Phenotype
Alcohol usage is the major cause of CP in all continents. It is defined as an ethanol 
consumption of more than 80 gram a day for a period of more than a few (mostly 2) 
years. The development of ACP is a multistep process that starts with single episodes 
of acute pancreatitis which will develop in a more chronic presentation with continuous 
pain and a subsequent loss of pancreatic function ensuing in steatorrhea, diabetes 
and pancreatic calcifications. Only a minority of people (≤10%) classified as heavy 
drinkers develop pancreatitis. This increases the likelihood that individual genetic or 
environmental susceptibility factors play a role.85 
PRSS1
Several studies investigated the presence of PRSS1 variants in ACP patients, but no 
associations have been found in most of them.86-88 Only one case-control study from 
Poland showed a very high frequency PRSS1 mutations in 11 out of 33 patients.63 A 
recent analysis in a large European study also found an association for the PRSS1 
single-nucleotide polymorphisms rs10273639.89
 
SPINK1
A relative low frequency of SPINK1 mutations is seen in ACP patients. A comprehensive 
study in 274 ACP patients demonstrated that 5,8% of ACP patients were SPINK1 
carriers compared to only 0,8% in controls.15 The same findings were confirmed by 
others.55, 56, 90 Though the findings are statistically significant, the presence of SPINK1 
mutations is not deemed to be a dominant factor.
CTRC
There is only study for CTRC variants in ACP patients. A total of 10 CTRC mutations 
were found with a significant enrichment of the p.R254W and the p.K247_R254del 
mutation in a German cohort of 348 ACP subjects. This significantly differed from the 
control population, patients with alcohol induced liver disease.
CFTR 
Initial studies on the role of CFTR mutations and the 5T allele in ACP patients refuted 
a correlation.91-93 Subsequent studies however did detect an association (10-18%) 
between CFTR and ACP.87, 94 All in all, CFTR mutations seem to have a role in ACP but 
the results are controversial.  
Alcohol metabolizing enzymes
Alcohol requires metabolic activation and detoxification after intake. Phase I 
detoxification is performed by cytochrome p450 enzymes (CYP’s), with CYP2E1 being 
Figure 4  Metabolic activation and detoxification of alcohol
Phase I detoxification is performed by different enzyme systems. Firstly there are the cytochrome p450 
enzymes (CYP’s), with CYP2E1 being the most active in the alcohol metabolism. The CYP enzyme system 
converts alcohol into reactive oxygen species (ROS). These result in oxidative stress and are also further 
broken down to protein and DNA adducts.
The other detoxification system contain alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALD) 
which respectively break alcohol down to acetalde - hyde and acetate. Acetate on his turn will be part of the 
Krebs cycle. Different study groups investigated if mutations in one of the systems increases the susceptibility 
to develop ACP.
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approach. The interpretation of this study is being hampered by the small size and 
the low density of microsatellite markers, but again this pilot supports genome wide 
scans in ACP using high throughput platforms.113
Other genes associated with CP
Calcium sensing receptor (CASR)
CASR mutations cause familial hypocalciuric hypercalcemia (FFH). The calcium 
sensing receptor is important for appropriate parathormone and calcitonin secretion 
and thus responsible for the calcium homeostasis. Because some patients with FFH 
and patients with hypercalcemia develop CP it was postulated that CASR mutations 
could play a role. In a kindred with FFH and prominent CP the missense mutation 
p.L173P (c.518T>C) in the CASR gene was transheterozygous with SPINK1 p.N34S.113 
A subsequent study found 3 novel mutations next to several polymorphisms in 72 ICP 
patients out of 19 families: an intronic polymorphism (c.493-19 G_/A, 13,8%) and 3 
exon mutations (p.R896H 4%, p.E870E 2.7%, p. F391F 1.4%).114 In 35 TCP patients, 4 
novel mutations were detected. Twenty-two percent of these TCP had a mutation in 
the CASR gene, 6% patients had also a SPINK1 p.N34S mutation.115 
Sequencing of the CASR gene in an American population led to the finding that   the 
p. R990G variant is significantly enriched in alcoholic CP with an odds ratio of 3.12 
(95% CI 1.14-9.13).116 The CASR gene has thus a minor but proven role in some CP 
patients.
Carboxypeptidase A1
In 2014 carboxypeptidase A1 came into view, a chosen candidate gene based on the 
fact that it is the second largest component of pancreatic juice after the trypsinogens.117 
A total of 34 different mutations were found in a group of non-alcoholic CP patients. 
Three variants were significantly enriched and seemed to be associated with a 
younger age of onset. The possible mechanism that leads to CP here is endoplasmic 
reticulum stress induced by misfolding of the protein.118 
Keratin 8
In the pancreas only the keratins 8 and 18 are expressed. Transgenic mice with 
keratin 8 overexpression showed pancreatic changes comparable to CP like 
dysplasia, loss of acinair structure, inflammation, fibrosis and substitution of exocrine 
tissue by adipose tissue.119 In a small study, a keratin 8 p.G61C mutation was identified 
in 6/67 CP patients. Transfected cells with this mutation showed a limited keratin 
filament reorganization in case of oxidative stress.120 A role for p.G61C was refuted by 
a subsequent cohort study with 2,436 CP patients and 5,726 controls.121
Small associations were found with the GSTP1 val/val allele,95 the ADH1B*1 allele96 
and the UGT1A7*3 allele97 but this were no real robust causative relations.95-107 (Table 4) 
Only one glutathione variant, the GSTMu null allele resulting in an absent gene 
product is consistently underrepresented in ACP patients compared to healthy 
controls and alcoholics without disease and as a consequence proposed as 
protecting factor against ACP.95, 97, 102
Another single association study focused on the carboxylester lipase (CEL) gene 
which is responsible for the catalyzation of fatty acid ethylesters (FAEE’s) that 
accumulate in the pancreas after alcohol intake. A lower frequency of the wild type 
and an increase in the L allele in the CEL gene was seen in 100 ACP patients.108
Human leukocyte antigens (HLA) 
HLA antigens were proposed as inherited factors to develop alcohol misuse and 
ultimately ACP. The first study in ACP patients, in 1984, detected the HLA bw39 (locus 
B16) as associated.111 A meta-analysis of 9 relevant studies identified 3 HLA subtypes 
(A1, B13 and B18) are more common in ACP than controls.112
Other genes in ACP
To identify new possible ACP related genes, a genome-wide-analysis with micro-
satellite markers was performed in 65 ACP patients resulting in 10 new candidate 
susceptibility regions and 5 protecting regions in the whole genome. This is an 
encouraging step, as this is one of the first studies that has adopted a hypothesis free 
Table 4  Phase II detoxification enzymes
Enzyme Gene Allele References
Glutathione S-transferases GSTs GSTM1 95, 96, 98, 109 
GSTT1  95, 96, 98, 101, 106 
GSTP1 95, 101, 105, 106 
NADPH-quinone oxidoreductase 1/2 NQO1/2 NQO1 96
NQO2 110
N-acetyl-transferase NAT2 96
Catalase CAT 106
Microsomal epoxide hydrolase EPHX1 104
Manganese–superoxide dismutase MnSOD 105, 106  
Human serum paraoxonase PON1 107
Uridine 59-diphosphate glucuronyltrans-
ferases
UGT’s UGT1A7 97, 101  
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Alpha-1- antitrypsin (A1AT) / Alpha-2-macroglobulin (A2M)
A1AT is a serum anti-proteinase, it inhibits serine proteases by acting as a competitive 
substrate. A2M is a more broader inhibitor of proteinases including trypsinogen and 
chymotrypsinogen. Alterations in functional serum anti-proteinases were supposed 
to influence the clinical presentations in acute pancreatitis. In 1975, the first study 
established an association between A1AT deficiency and CP in 110 CP patients.122 
Others detected an A1AT variant in CP patients possibly causing a younger age of 
onset. Replication studies failed to substantiate this link with CP,123 or with ACP.124 A2M 
was rejected as a candidate in a large cohort study.125
New strategy; Genome Wide Association studies (GWAs)
In 2012 the results of a first GWAs were published and pushed the field of genetics 
and CP in a complete different direction. While the search for new candidate genes in 
the area of the trypsinogen pathway was still ongoing, this hypothesis-free analysis 
showed a new susceptibility locus; the CLDN2-MORC4 gene. CLDN2 is a tight 
junction protein that has a role in the para-cellular water and cationic transport but up 
to now it is still not clear how that leads to CP in vivo. Two SNP’s at this locus showed 
genome wide significant association; rs7057398 (OR 1,321± 0,049) and rs12688220 
(OR 1,385 ± 0,054).89 
Genome wide association studies are of big importance to the field of genetics and 
their role in complex diseases. Before these GWA studies, candidate genes were 
analysed based on their possible pathophysiological role or earlier detected associations. 
These studies were done in well-defined, often small populations and brought us the 
more rare variants that cause diseases that inherit in a Mendelian order. Now we are 
searching for more smaller effect size variants that not directly cause the disease but 
increase the susceptibility by a combination of several genetic and/or environmental 
factors. These variants are not only detected in the patient group but also in the 
control population. (Figure 5)126 
Other genes investigates but not associated with CP
Analysing other candidate genes like the ACE gene, genes encoding cytokines, the 
HFE, PRSS3, PAP and the REG1A gene did not find any new associations with CP. 
(Table 5)
Implications for diagnosis, management and prognosis
Diagnosing CP, especially just after the onset of the disease, is a very difficult task. 
The diagnosis is often made only several years after the first pancreatitis attack when 
functional and structural abnormalities of the pancreas are detected with laboratory 
studies and imaging. 
Table 5  Genes investigated but not associated with CP
Gene Protein Pathophysiological mechanism Ref.
 ACE Angiotensin converting enzyme - Role in proliferation of 
mesangial cells, fibroblasts and 
extracellular matrix
- Elevated during acute 
pancreatitis
- Ace inhibitors decrease 
inflammation in experimental CP 
models
127, 128
Cytokines - Transforming growth factor  
beta-1 (TGF- β1)
- IL-1b, IL6, IL-8, IL-10
- Tumour necrosis factor (TNFα)
- Vascular endothelial growth 
factor (VEGF)
- Intracellular cell adhesion 
molecule 1(ICAM-1)
- Monocyte chemotactic protein 
(MCP-1)
- Heatshock proteins (HSP)
- CP is an inflammatory disease
- Some cytokines can cause 
pancreatic fibrosis
129-132
HFE Human hemochromatosis protein - Gene associated with hereditary 
hemochromatosis (HH)
- Accumulation of iron in several 
organs with loss of function
- Patients with HH develop DM
133
PRSS3 Mesotrypsin - Influence on the trypsin pathway 21, 134, 135
PAP Pancreas associated protein - Acute phase protein, responsible 
for bacteriostasis and reducing 
severity of pancreatitis
- Serum concentrations correlated 
with histological severity
136
REG1A Regenerating protein 1A,
Identical to pancreatic stone 
protein (PSP)
- Part of exocrine pancreatic 
secretion
- Associated with pancreatic islet 
regeneration
- Component of protein matrix in 
pancreatic calculi
137
ATP8B1 Probable phospholipid-
transporting ATPase IC
(associated with progressive 
familial intrahepatic cholestasis 
type 1)
- High expression in the pancreas
- Function in membrane 
organisation
- 2 out of 10 individuals affected 
with ATP8B1 deficiency had 
chronic pancreatitis
138
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Summary
We have shown that a variety of genetic variations in genes that are implicated in the 
trypsin pathway are responsible for a large proportion of HCP, TCP and ICP cases. 
Apart from genes such as PRSS1, SPINK1, CTRC that have been consistently linked 
to various CP categories, CFTR is a gene that underlies a significant proportion of 
ICP, but also ACP patients. 
Other genes have yielded inconsistent results or are only responsible for a subset of 
CP patients. It is to be expected that future CP genes will have less effect on the 
phenotype and will be associated with less than 5% of CP cases. (Figure 5)
The biggest challenge is to find the candidate genes that are responsible for ACP, the 
most common form of CP.
But what about genetic testing? Until now genetic testing in CP patients is not part of 
any standard diagnostic procedure, with the possible exception of PRSS1 mutations 
in HCP cases. 
The presence of a genetic mutation however provides more insight in the cause of the 
disease. This is important for caregivers but also for patients, who are often hold 
culpable of alcohol abuse. Genetic testing however raises questions: Do all reported 
genes need to be tested or only those with the highest associations? Should the 
mutational analysis only be performed by specialised centres? What to do if a 
mutation is found, should we screen the whole family? Does a mutation change 
anything to the prognosis or the management of the disease?
In April 2001 during the Third International Symposium of Inherited Diseases of the 
Pancreas a consensus conference was held. Here the following recommendations 
were made:
“In patients with unexplained recurrent acute pancreatitis, unexplained chronic 
pancreatitis, or a family history of pancreatitis and in children suffering from an unexplained 
episode of pancreatitis, testing for PRSS1 mutations should be performed. Genetic 
testing for all other genes associated with pancreatitis, including testing for SPINK1 
mutations, should be performed only in Research Ethics Committee–approved 
protocols.”
In this review however we showed that not only PRSS1 gene mutations are associated 
with CP. Since 2001 several other genes and mutations were investigated that show 
correlations with CP, like the p.N34S SPINK1 mutation. Therefore in view of these 
findings it will be necessary that these recommendations stemming from 2001 shall 
be discussed again and revised.  
Another important aspect of genetic testing is counselling. Patient should be informed 
about the general and specific aspects of genetic testing. It should be clear to the 
patient that the presence of a mutation does not predict the course of the disease nor 
affects the clinical management. 
In case of HCP, the risk of inheriting the PRSS1 gene and developing pancreatitis 
should be explained. It is after al an autosomal dominant disease with a high risk of 
developing pancreatitis. Further should not be forgotten that the presence of a PRSS1 
gene mutation increase the lifetime risk of pancreatic cancer by 40%.29, 139, 140  Advices 
about lifestyle are necessary because consuming alcohol, smoking and eating fat 
food can influence the expression of the disease. It is especially important to quit 
smoking because it can increase the severity of the pancreatitis attacks and also the 
risk of developing pancreatic cancer in HCP.140  
Figure 5  
The detection of the PRSS1 gene in 1996 gave us the first insights in the pathogenesis of hereditary 
pancreatitis. Mutations like this inherit in a Mendelian trait, are often only detected in small defined patient 
group and have a large disease causing effect. Later variants with a higher allele frequency but a lower 
disease causing effect were detected in genes like SPINK1, CTRC, CFTR and CPA1. Hypothesized is that 
these genes are more disease modifying instead of disease causing. With the new approach of GWA 
studies we hope to find more and new susceptibility loci that will have a lower pathogenic effect and are 
more common in the normal population but that will give us new insights in the complex pathogenesis of this 
disease.
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Abstract
AIM
Study the genetic, clinical and morphological features of hereditary pancreatitis, 
a rare type of chronic pancreatitis with an early age of onset caused by mutations in 
the PRSS1 gene.
METHODS
Out of 496 patients (27.375 person years) that were referred for genetic analysis to the 
Radboud UMC, Nijmegen, the Netherlands in the period of 2000-2007, a total of 61 
patients with a positive family history for hereditary pancreatitis were selected. With 
complete gene sequencing we searched for PRSS1-gene mutations. Clinical data 
were gathered by a thorough investigation of patient files and by a structured 
questionnaire. 
RESULTS
Out of 25 families, 61 patients were included (2047 person years). Mutations 
in the PRSS1 gene were found in 52 patients (85.2%): p.R122H (67.2%), p.N29I (14.8%), 
p.E79K (1.6%), p.N29T (1.6%). Of 40 patients the clinical data were available; the 
median age of onset was 10.5 year (range 0-42 years). Pain was found in 28 patients 
(70%) and one or more hospital admission was necessary for 27 patients (67.5%). 
Exocrine and endocrine dysfunction was diagnosed in 6 patients (15%) and surgical 
intervention was needed in 24 patients (60%). The most frequent intervention was a 
pancreaticojejunostomy (25%). A positive family history for pancreatic carcinoma was 
found in 5 patients (12.5%). 
CONCLUSION
The percentage of PRSS1-gene mutations is high in this Dutch cohort with hereditary 
pancreatitis (85.2%). Most of the patients though suffered from little pain.
Introduction
Chronic pancreatic (CP) is a chronic inflammation of the pancreas that causes a 
chronic abdominal pain and frequent hospital admissions. For most of the cases 
alcohol abuse is the underlying etiological factor. In 5-10% of the patients, heredity 
seems to play an important role, so called hereditary chronic pancreatitis (HCP). 
In HCP, an autosomal dominant disease, patients present at a young age with 
recurrent pancreatitis attacks without a clear etiological factor 1-4  The recurrent 
inflammation of the pancreas causes calcifications, morphological changes, fibrosis and 
also diabetes mellitus, malnutrition and eventually even pancreatic cancer.5-10 Until now 
112 European and only 2 Dutch families are known that have a hereditary form of CP.11 
Hereditary pancreatitis is caused by mutations in the gene encoding for trypsinogen; 
PRSS1.5-14  Normally, trypsinogen production in the pancreas is stimulated by intake 
of nutrition. It becomes metabolic active when it arrives in the small intestine and after 
cleavage by enteropeptidase to trypsin. 
Because of gain-of-function mutations in the PRSS1 gene, trypsinogen gets already 
metabolized in the pancreas itself leading to auto-digestion of the pancreas. The 2 
most frequent PRSS1 mutations are the p.R122H and the p.N29I mutation.12-16 Besides 
PRSS1, also mutations in the SPINK1 gene are a risk factor for developing pancreatitis. 
The SPINK1 protein inhibits trypsinogen auto-activation inside the pancreas and mutations 
inside this gene can cause idiopathic chronic pancreatitis.17, 18 Although the genetic 
pathophysiology of hereditary pancreatitis seems to be largely revolved, it is unclear 
if there is a relation between genetic alterations and the clinical course of hereditary 
pancreatitis. In this study we investigated the genetics, the clinical and morphological 
features of a Dutch cohort of hereditary pancreatitis patients. 
Materials and methods
Subjects
Between 2000 and 2007, patients with chronic patients were selected after they were 
referred to Radboud UMC in Nijmegen for molecular testing for hereditary pancreatitis 
(Figure 1). A total of 496 patients with chronic pancreatitis were included with a total 
of 27.375 person years. A positive family history was found in 61 patients (26 males, 
35 females). Hereditary chronic pancreatitis is defined as the presence of 2 first- 
degree relatives (father, mother, brothers and sisters) or 3 or more second-degree 
relatives in two or more generations with recurrent acute pancreatitis and/or CP for 
which there were no known precipitating factors. The study protocol was approved by 
the local medical ethic review committee from the Radboud UMC in Nijmegen. All 
patients gave their informed consent.
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Questionnaire
With a structured questionnaire, patients were asked for details of their pancreatitis 
attacks; amount and duration of attacks, pain, diabetes mellitus and exocrine insufficiency. 
Further we were interested in smoking, alcohol use, medications, medical history, 
surgical interventions and the family history for cystic fibrosis and pancreatic carcinoma. 
The questionnaire is a Dutch version of an English questionnaire derived from the 
European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer 
(EUROPAC) (www.europac-org.eu). EUROPAC investigates the prevalence and 
clinical aspects of patients with hereditary pancreatitis in Europe and is especially 
interested in PRSS1 mutations and genotype-phenotype correlations. 
Beside the questionnaire, clinical information was also obtained from systematic 
research of the patient files.
Genotyping
From all patients genomic DNA was extracted from whole blood using the Puregene® 
genomic DNA isolation kit (Gentra Systems, Minneapolis, USA). 
All exons of the PRSS1 gene and exon 3 of the SPINK1 gene were sequenced.
Statistical methods
For comparison of genotypes in the patients with hereditary pancreatitis, the U-test 
of Mann Whitney was used. Statistical significance was defined as p < 0.05. 
For descriptive statistical analysis, Graphpad Prism 4.0 software (Graphpad software; 
San Diego, USA)  
Results
Patient characteristics 
A questionnaire was sent to 52 of the 61 selected patients (2047 person years). Of the 
9 other patients there was no actual address known or they had passed away. For all 
patients of Radboud UMC, a complete patient file investigation was performed. For 
patients from other outpatient clinics, the clinical data was obtained through their own 
physician. Finally the clinical data were complete for 40 patients (Figure 1).
This figure represents the selection of patients with hereditary chronic pancreatitis. 
A total of 496 patients underwent genetic testing for PRSS1 and SPINK1 mutations. 
In 61 patients hereditary pancreatitis was diagnosed based on the family history 
and the presence of a mutation in the above mentioned genes. Nine patients could 
not be included because there was no address or they already passed away. For 40 
patients we were able to gather the complete clinical data.
Mutation analysis
In 52 of the 61 patients with a positive family history for hereditary chronic pancreatitis 
a PRSS1 mutation was found (85%). Four unique mutations were detected; the p.N29I 
(n = 9; 14.8%), p.R122H (n = 41; 67.2%), p.E79K (n = 1; 1.6%) and the p.N29T (n = 1; 
1.6%) variant. Further we found a SPINK1 p.N34S polymorphism in a homozygous 
state in a brother and a sister, but also in a heterozygous state next to a PRSS1 p.N29I 
mutation. One patient was already known with a heterozygous CFTR gene mutation. 
Pancreatitis
Duration and length of pancreatitis attacks
The median age of onset was 10.5 years (range 0-42 years). In patients with a PRSS1 
or a SPINK1 mutation, the age of onset was almost 10 years earlier; at a median age 
of 10 years versus 25 years (p = 0.09) (Figure 2).The presence of a genetic mutation 
had no influence on the amount of pancreatitis attacks; patients with a PRSS1 or a 
SPINK1 mutation had median 10 attacks compared to 8 attacks for patients without 
any mutation (p = 0.78) (Table 1).
An attack had a median duration of 5 days (range 1-42 days) for patients with and 
without a mutation. (p = 0.57). Of all 40 patients, 30 were admitted to a hospital 
before. Patients with a genetic mutation had more hospital admission; 8.2 times 
compared to 5.0 times for patients without a mutation (p = 0.45).
Figure 1  Patient selection
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Symptoms
Thirty patients had a combination of symptoms like nausea, vomiting and pain. In 3 
patients, pain was the only symptom. Pain was mainly located in the epigastric and 
umbilical region. For 4 patients this pain was described as a continues feeling of 
pressure accompanied with diarrhoea. 
Almost 30 patients describe that psychological stress, large or fatty meals and 
alcohol intake induce the symptoms. A high number of patients, 27 of the 40 patients 
(67.5%) used medication for the pain; acetaminophen (n=18, 30%), non-steroidal 
 anti-inflammatory drugs (NSAID’s) (n=2; 7%), opioids (n=4; 11%) or a combination of 
these (n=6; 22.5%). The use of opioids was not depend of the presence of a genetic 
mutation (p = 0.96). In 3 patients, one 10 years old, there were no complaints despite 
a PRSS1 mutation.
Natural course
Diabetes mellitus was found in 7 patients of which only 1 had no genetic mutation. 
Several patients used pancreas enzymes, not only for exocrine failure but also for 
pain relief. Only 6 patients had real steatorrhea and therefore an indication for the use 
of pancreas enzymes. 
Radiological changes were found in several patients; calcifications in 10 patients and 
cysts or pseudocysts in 14 patients. Surgical interventions were needed in 24 patients 
of which most of them needed a pancreaticojejunostomy (n=10). Others had a 
resection of a pancreatic cyst (n=2), a cholecystectomy (n=5) or an appendectomy 
(n=3). Four patients had a thoracic splanchnic nerve denervation for treatment of 
their pain. The presence of a genetic mutation had no significant influence on one of 
these parameters. 
There were no patients with a pancreatic carcinoma though there was a positive 
family history in 5 patients out of 3 families. 
Intoxications
Of the 40 patients, 9 smoked and 6 had a previous history of smoking with a mean 
amount of 13.5 pack years. Fourteen patients use alcohol with a median intake of 4 
units a week. The presence of a PRSS1 mutation had no influence on alcohol or 
nicotine use. 
Discussion
A high proportion (85%) of patients with hereditary pancreatitis have a PRSS1 gene 
mutation. This is in accordance with the results from an European study were they 
found a mutation frequency of 81%.11 Although there are several intronic and exonic 
variants, we only found 4 different ones in our cohort. 
The p.R122H and the p.N29I were the most frequent mutations. One patient had the 
p.E79K mutation which is a more rare variant causing an increased activation and a 
fast degradation of trypsinogen.19  The last detected variant was the p.N29T who just 
like the p.N29I and the p.R122H mutation lead to a decreased auto-activation and 
autolysis of trypsinogen.4
Figure 2  Median age of diagnosis of pancreatitis
This figures shows that patients with a PRSS1 mutation are diagnosed earlier in life with pancreatitis than 
patients without a mutation. This difference is not significant. (P-value 0.09)
0 10 20 30 40 50
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Table 1  Clinical features of hereditary pancreatitis patients (n=61)
Features PRSS1 mutation
Yes  (n =52) No (n=9)
Mean amount of pancreatitis attacks (nr.) 10 8
Median duration of pancreatitis attack (days) 5 5
Complications
Diabetes mellitus (n) 6 1
Steatorrhea (n) 6 0
Pancreatic calcifications (n) 7 3
Pancreatic (pseudo)cysts (n) 12 2
Median hospital admission a year (nr.) 8,2 5
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We searched for a correlation between the clinical presentation and the presence of 
a PRSS1 gene mutation in hereditary pancreatitis. Earlier results showed that patients 
with a p.R122H mutation present themselves at an earlier age and with more pain.20 
In our cohort we also saw more pancreatitis attacks and more complications in 
patients with a PRSS1 mutation (table). The small number of patients and the high 
mutation frequency though make it difficult to compare these 2 groups. Real 
conclusions about phenotype-genotype correlations can hardly be made based on 
these results.
Remarkable was that a large amount of patients only had few pain symptoms when 
compared with other, non-hereditary forms of pancreatitis. Pain developed early in life 
but occurred only once a year or less. 
Literature describes that the frequency of hospital admissions, pancreatic calcifications 
and endocrine and exocrine insufficiency for hereditary pancreatitis seems to be 
lower than in non-hereditary pancreatitis.21
In our cohort we found similar results regarding the finding of pancreatic calcifications 
and pseudocysts compared to other studies with hereditary pancreatitis.4, 5 No 
patients with a pancreatic carcinoma were included.  
And although pain was described as not having a high impact on daily life, 25% of the 
patients used opioids chronically. This is an important aspect because it gives a 
better understanding in the real amount of pain and pain sensation but also should 
keep us aware of the high risk for developing opioid dependency in this population.22, 23 
Hereditary pancreatitis is a rare disease but it should certainly be considered in 
(young) patients with recurrent pancreatitis attacks, with and without a positive family 
history. Finding genetic variants in the PRRS1 gene sets the diagnosis. 
The value of this genetic diagnosis is that a positive result makes it more 
understandable for patients as well as for physicians. In our survey patients made 
clear that it is very important that they found a cause and explanation for their disease. 
This also helped them to make important lifestyle adjustments to decrease the risk of 
new pancreatitis attacks and the development of complications. They tried to eat 
healthier, to drink none or less alcohol and to stop with smoking. 
Conclusion
Hereditary pancreatitis is a rare form of chronic pancreatitis. In case of recurrent 
pancreatitis attacks or severe abdominal pain in young patients or in patients with a 
positive family history, it is important to consider this diagnosis and screen for possible 
genetic underlying mutations in genes that have proven to be related to hereditary 
pancreatitis.
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Abstract
BACKGROUND
Tropical calcific pancreatitis (TCP) is a relatively common form of chronic pancreatitis 
in parts of Asia and Africa. The SPINK1 variant p.N34S is strongly associated with 
TCP but other genetic factors remain to be identified. Chymotrypsinogen C (CTRC) 
degrades trypsinogen and loss-of-function variants have been found in European 
patients with chronic pancreatitis. Preliminary data indicate that CTRC might increase 
the risk for TCP.
METHODS
We selected 150 Indian TCP patients and 150 Indian controls to perform mutational 
screening of the complete coding region of CTRC and exon 3 of SPINK1. We performed 
in-silico analysis and functional studies of novel CTRC variants.
RESULTS
We identified eight variants in this cohort; three were synonymous and the c.180 C >T 
was significantly enriched in patients (odds ratio = 2.09; 95% confidence interval = 
1.19–3.67; P = 0.03). We identified a novel non-synonymous CTRC (p.G61R) variant 
in one of 146 patients (0.7%), but it was absent from controls. In-silico analysis 
showed that this variant affected a conserved residue and functional analysis showed 
that p.G61R results in a complete loss of CTRC secretion from transiently transfected 
human embryonic kidney 293T cells. SPINK1 p.N34S was present in 31.8% of patients 
compared with 4.7% in controls. There was no significant co-segregation with CTRC 
variants.
CONCLUSION
The contribution of CTRC variants to TCP is relatively small but the identification of a 
novel loss-of-function variants (p.G61R) underscores the importance of the trypsinogen 
pathway in causing TCP.
Introduction
Tropical calcific pancreatitis (TCP) is a form of chronic pancreatitis (CP) unique to 
the tropics, and classically it presents at a young age with recurrent abdominal pain 
and maldigestion leading to steatorrhea and fibrocalculous pancreatic diabetes.1-5 
It is endemic in southern India where the prevalence has been estimated at 125 per 
100 000.3 
Etiological factors proposed for TCP include malnutrition, dietary toxins, micronutrient 
deficiency, and genetic factors.6-8 Familial aggregation is seen in up to 8% of cases. 
The young age at presentation suggests a role for genetic factors in its aetiopatho-
genesis, but a clear Mendelian inheritance pattern is lacking.9 
This indicates that there may be genetic risk factors that affect the susceptibility to 
TCP, but do not necessarily cause the disease. Genetic risk factors in TCP may not 
be similar to CP in the European population. This was evident when cationic trypsinogen 
(PRSS1) gene mutations, which are proven risk factors for autosomal dominant 
hereditary CP,10 failed to show any association with TCP.11-13 
In contrast, SPINK1, a potent pancreatic protease inhibitor that prevents inappropriate 
trypsinogen activation, appears to play a role in idiopathic CP in the Western 
population as well as in TCP. One common mutation, p.N34S, has been found in up 
to 20% of idiopathic CP cases in Western Europe14, 15 and in 50% of TCP.11, 16-19 These 
findings fuelled further search for genetic factors in TCP. 
Recently, chymotrypsin C (CTRC) entered the field as an interesting candidate gene 
for CP (Figure 1). 
CTRC degrades all human trypsin and trypsinogen isoforms with high specificity and 
therefore has a putative protective role against pancreatitis by eliminating prematurely 
activated intra-pancreatic trypsin.20 
The CTRC gene consists of eight exons and, to date, several loss-of-function CTRC 
variants have been discovered that impair the activity or secretion of the protective 
enzyme.21, 22 We speculated that (functional) CTRC variants may predispose to TCP in 
the Indian population and set out to evaluate the frequency of CTRC variants relative 
to the p.N34S SPINK1 allele in a large cohort of TCP patients.
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Methods
Participants
One hundred and fifty patients (50 female, 100 male) with a mean age of 29.7 years 
(range 5–61 years) were recruited from Christian Medical College and Hospital, 
Vellore, India from January 2003 to October 2006. This cohort consists of patients 
mainly from eastern and southern India. TCP was diagnosed on the basis of early 
onset of recurrent abdominal pain and imaging studies showing dilated pancreatic 
ducts, large pancreatic intraductal calculi, and pancreatic calcification in the absence 
of other known etiological factors.
Exocrine or endocrine deficiency may or may not be present.6 We recruited 150 
controls (48 female, 102 male) with a mean age of 30.2 years (range 14–57 years). 
Informed consent was obtained from patients and controls, before enrolment. The 
study was approved by the research and ethics committee of Christian Medical 
College and Hospital, Vellore, India.
DNA sequencing
The complete CTRC coding region and exon 3 of the SPINK1 gene were sequenced 
using primer pairs complementary to flanking intronic sequences. DNA was extracted 
from peripheral blood samples by the phenol chloroform method. The PCR reaction 
mix (50 ml) consisted of 200 ng genomic DNA, 0.25 mmol/l of each dNTP, 5.0 U 
Taq-DNA-polymerase, 200 nmol/l of each primer, 10 mmol/l Tris–HCl (pH 9.0), 
50mmol/l KCl, 0.1% triton and indicated concentrations of MgCl2 (primer sequences 
are available upon request). PCR cycling conditions include a 5-min step of 
denaturation at 95°C, followed by 40 cycles of denaturation at 95°C for 30 seconds, 
annealing at 60-69°C for 30 seconds, elongation at 72°C for 1 min, and a final 
extension step for 5 min at 72°C. Identification was carried out after purification of the 
PCR product from a 1.5% agarose gel using the QIAEXII Gel Extraction Kit (Qiagen, 
Hilden, Germany). Reaction products were loaded onto an Applied Biosystems 3730 
capillary automated sequencer (Applied Biosystems, Boston, Massachusetts, USA).
Nomenclature
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of 
the ATG translation initiation codon in the reference sequence. Amino acid residues 
in the CTRC sequence are numbered according to their position in the native 
pre-proenzyme, starting with Met1.
Prediction analysis of amino acid substitutions
PolyPhen software (http://genetics.bwh.harvard.edu/pph/) was used to predict the 
possible impact of amino acid substitutions on the protein. The program is based on 
sequence comparison with homologous proteins; profile scores, and position-spe-
cific independent counts (PSIC) are generated for the allelic variants and represent 
the logarithmic ratio of the likelihood of a given amino acid occurring at a particular 
site relative to the likelihood of this amino acid occurring at any site (background 
frequency). PSIC score differences above 2 indicate a damaging effect; scores 
between 1.5 and 2 suggest that the variant is possibly damaging, whereas scores 
below 0.5 indicate that the variant is benign.
Enzymatic analysis
Plasmid construction and mutagenesis
The p.G61R variant CTRC plasmid was generated by overlap extension PCR mutagenesis 
and ligation into the previously constructed pcDNA3.1(-)_CTRC expression plasmid.20
Cell culture and transfection
Human embryonic kidney (HEK) 293T cells were cultured in six-well tissue culture 
plates (106 cells per well) in Dulbecco’s modified Eagle’s medium (Sigma, St Louis, 
Figure 1  The pathophysiological model of chronic pancreatitis
Sustained premature conversion of trypsinogen to trypsin (encoded mainly by the PRSS1 and PRSS2 
genes) plays a central role in the pathogenesis of chronic pancreatitis in humans. PRSS1 mutations increase 
trypsinogen auto-activation, while a variant in the PRSS2 gene enhances auto-degradation of trypsin and 
thereby protects against pancreatitis. There are two protective mechanisms for trypsin inactivation: SPINK1 
is a potent inhibitor of trypsin, whereas CTRC is capable of degrading trypsin(ogen). Variants in the SPINK1 
and CTRC genes result in diminished amounts of these protective molecules and are associated with 
various forms of CP.
78 79
CHAPTER 4 TROPICAL CHRONIC PANCREATITIS AND CTRC AND SPINK1 VARIANTS 
4
Missouri, USA) supplemented with 10% fetal bovine serum, 4mmol/l glutamine, and 
1% penicillin/ streptomycin solution at 37°C in a humidified atmosphere containing 
5% CO2. Transfections were carried out using 4 µg pcDNA3.1(-) CTRC wild-type/
variant plasmid and 10 µl Lipofectamine 2000 (Invitrogen, Carlsbad, California, USA) 
in 2 ml Dulbecco’s modified Eagle’s medium (Sigma). After overnight incubation at 
37°C, cells were washed and the transfection medium was replaced with 2 ml 
OptiMEM. Time courses of expression were measured starting from this medium 
change and were followed for 48 h.
Protein assays
CTRC activity in the conditioned media, supplemented with 0.1 mol/l Tris–HCl (pH 
8.0) and 10mmol/l CaCl2, was determined after activation with 100 nmol/l human 
cationic trypsin (final concentration) for 20 min at 37°C. Chymotrypsin activity was 
measured with the synthetic chromogenic substrate Suc-Ala-Ala-Pro-Phe-p-nitro-
anilide (0.15mmol/l final concentration) in 200 µl final volume. For gel experiments, 
aliquots (0.15ml) of media from transfected HEK 293T cells were precipitated with 
10% trichloroacetic acid (final concentration) and analysed by SDS/15% poly-
acrylamide gel electrophoresis and Coomassie Blue staining.
Statistical analysis
Fisher’s exact test was used to estimate differences between categorical variables 
and a two-tailed P value of less than 0.05 was taken to be significant. Odds ratio (OR) 
with 95% confidence interval (95% CI) for manifestation of TCP was calculated for the 
various gene alterations. To estimate differences between continuous variables the χ2 
test was used. All statistical analyses were performed using GraphPad Prism 4 
(Version 4.02, GraphPad Software Inc., San Diego, California, USA).
Results
CTRC variant detection by targeted sequencing
We initiated a comprehensive analysis of the complete CTRC coding region using 
genomic DNA from all 300 participants. We sequenced all eight exons that constitute 
CTRC and identified eight variants. These variants are clustered in five exons with the 
exception of a single variant found in the 5’-untranslated region. Four variants had 
only a very low frequency (approximately 1%) among TCP patients and controls. 
Among the three synonymous CTRC variants detected, only the c.180 C>T variant 
was significantly enriched in patients (OR=2.09; 95% CI=1.19–3.67; P=0.03). The 5’-
untranslated region variant c.1-1C>T was present in one of 128 patients but absent in 
55 controls. (Table 1)
Five of the identified variants are non-synonymous resulting in a change of the amino 
acid composition. (Table 2) We found two non-synonymous gene variants in our 
sample, not detected by earlier studies. In one of the 144 TCP patients tested (and 
none of the 144 controls) we identified a variant that replaces guanine for adenine at 
position 181; this variant results in a glycine to arginine change at codon 61 (p.G61R) 
of the protein.
Another novel non-synonymous variant was detected in exon 7 where guanine was 
replaced for adenine at position 679, which changes the amino acid composition of 
CTRC at codon 227 from glycine to serine (p.G227S).
This variant was present in one of the 150 control participants, but absent in the set 
of 148 TCP patients.
Table 1  Synonymous CTRC variants
Exon Nucleotide 
change
Patients Controls P value OR 95% CI
1 c.1-1 C>T 1/128 (0.8%) 0/55 (0%) 1.00 1.31 0.05 - 32.58
3 c.180 C>T 43/146 (29%) 24/144 (17%) 0.01 2.09 1.19 - 3.67
4 c. 285 C>T 7/139 (5%) 12/149 (8.1%) 0.35 0.60 0.23 - 1.57
Table 1 indicates the synonymous variants that were found in our cohorts. The numbers in the column 
labelled patients and controls indicated the number of patients. Note that only the results are given from 
patients in whom an unequivocal test result was obtained.
Table 2  Non-synonymous CTRC variants
Exon Nucleotide 
change
Amino acid 
change
Patients Controls P value OR 95% CI
3 c.181 G>A (p.G61R) 1/146 (0.7%) 0/144 (0%) 0.93 3.63 0.15 - 90.24
3 c.217 G>A (p.A73T) 4/146 (2.7%) 1/144 (0.7%) 0.6 3.02 0.31 - 29.40
6 c.514 A>G (p.K172E) 1/149 (0.7%) 2/146 (1.4%) 0.99 0.49 0.04 - 5.43
7 c. 679 G>A (p.G227S) 0/148 (0%) 1/150 (0.7%) 0.41 0.49 0.02 - 12.14
7 c. 703 G>A (p.V235I) 4/148 (2.7%) 2/150 (1.3%) 0.44 2.06 0.37 - 11.40
Table 2  indicates the non-synonymous variants that were found in our cohorts.  The numbers in the 
column labelled patients and controls indicated the number of patients. Note that only the results are 
given from patients in whom an unequivocal test result was obtained.
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SPINK1 p.N34S detection
We detected the p.N34S variant in 47 of 148 patients (31.8%): 40 were heterozygous 
and seven were homozygous. This contrasts with the low prevalence of SPINK1 
p.N34S in the control group of 4.7% (OR=9.51; 95% CI=4.13–21.89; P<0.0001).
Bioinformatics
To test the validity of these novel variants, we adopted a bioinformatics approach and 
subjected the mutated sequence to in-silico analysis with PolyPhen (see Methods). 
The CTRC p.G61R variant was predicted to be ‘probably damaging’ (PSIC score 
difference: 2.782) but the p.G227S variant was characterized as ‘probably benign’ 
(PSIC score difference: 0.573).
Multiple alignment
To assess the relative importance of the p.G61R predicted to be ‘probably damaging’, 
we decided to perform a multiple alignment of the protein sequence of CTRC. (Table 
3) Sequences related to CTRC were identified by BLAST searches (http://www.ncbi.
nlm.nih.gov/BLAST/). These sequences included Homo sapiens, Pan troglodytes, 
Macaca mulatta, Canis lupus familiaris, Ornithorhynchus anatinus, Rattus norvegicus, 
Bos taurus, Mus musculus, Equus caballus, Monodelphis domestica. Table 3 shows 
the amino acids in the vicinity of codon 61. Interestingly, the glycine at position 61 is 
conserved in all shown mammalian sequences. This suggests that the p.G61R 
variant affects structurally and/or mechanistically important residues in the sequence 
of CTRC.
Functional analysis
Therefore, we proceeded to functional experiments to investigate the consequences 
of the p.G61R missense alteration on CTRC secretion. We expressed wild-type and 
the non-synonymous variant CTRC proteins in HEK 293T cells through transient 
transfection and compared CTRC activity and secretion in the conditioned medium 
of transfected cells. We found that the secretion of the p.G61R variant protein was 
severely diminished relative to wild-type protein, as evidenced by the complete loss 
of secreted CTRC activity in the conditioned media (Figure 2). 
SDS–polyacrylamide gel electrophoresis of media showed that the variant CTRC 
protein is hardly visible, suggesting that the functional defect in this variant is because 
of decreased production rather than impaired activity (Figure 3).
Table 3  Multiple alignment of the protein sequence of CTRC
Homo sapiens LKNDTWRHTC G GTLIASNFVLT
Pan troglodytes LKNDTWRHTC G GTLIASNFVLT
Macaca mulatta LKNNTWWHTC G GTLIASNFVLT
Canis lupus familiaris LKNGVWRHTC G GTLIANNYVLT
Ornithorhynchus anatinus KNDAWGHTC G GTLIASNYVLT
Rattus norvegicus LKDDTWRHTC G GSLITTSHVLT
Bos taurus LRDNTWRHTC G GTLITPNHVLT
Mus musculus LRDDTWRHTC G GSLITTSHVLT
Equus caballus LRDDTWRHTC G GTLITDRHVLT
Monodelphis domestica LKDDTFRHTC G GSLISSQHVLT
Patient LKNDTWRHTC R GTLIASNFVLT
Table 3 lists the 22 amino acids surrounding codon 61 of the human CTRC protein. The p.G61R CTRC 
variant detected in this study is indicated in bold, and for comparison the corresponding amino acids 
from various species are included. Note that the G at position 61 is highly conserved among a wide 
range of species.
Figure 2  Chymotrypsin C activity in the media of HEK 293T 
HEK 293T cells were transfected with wild type and variant CTRC constructs. We withdrew aliquots of 
conditioned media at the given times and measured CTRC activity after activation with trypsin and expressed 
as percentage of the maximal activity.
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Genetic association analysis
Next, we adopted a case–control approach. None of the found variants deviated 
from the Hardy–Weinberg equilibrium. Collectively, CTRC variants were present in 
40% of all TCP samples compared with 28% of the controls (OR=1.71; 95% 
CI=1.06–2.78; P=0.03). The distribution of the non-synonymous CTRC variants was 
statistically balanced among the groups. Two frequent synonymous CTRC variants 
(c.180 C>T and c.285 C>T) were found. Upon testing, c.180 C>T variant was detected 
in 43 of 146 TCP patients (29%) and in 24 of 144 controls (17%) (OR=2.09; 95% 
CI=1.19–3.67; P=0.01). The second variant, c.285 C>T, was not enriched in patients. 
(Table 1)
SPINK1
We then compared the distribution of p.N34S relative to that of CTRC variants. The 
patient who possessed the p.G61R variant also carried a heterozygous p.N34S allele. 
(Table 4) Although patients with c.180 C>T were frequent carriers of a p.N34S allele, 
the difference with the control population was non-significant (OR=0.88; 95% 
CI=0.099–7.57). We found that three of seven (43%) TCP patients with a c.285 C>T 
CTRC variant also had the SPINK1 p.N34S variant. Only one of four (25%) TCP 
patients with the p.A73T variant also possessed a p.N34S allele (OR=0.70; 95% 
CI=0.07–7.02).
Discussion
We performed a comprehensive screen of CTRC in TCP patients using genomic 
sequencing. We detected a novel p.G61R variant. In-silico analysis with PolyPhen 
shows that this variant was predicted to be ‘probably damaging’ (PSIC score 
difference: 2.782) and multiple alignment suggests that the p.G61R variant affects 
structurally and/or mechanistically important residues in the sequence. Indeed, 
functional analysis showed that introduction of the p.G61R variant leads to complete 
secretion defect of the CTRC protein. 
The detection of a loss of function variant CTRC is important because it reinforces the 
pivotal role of the equilibrium between trypsin and trypsin inhibitors in the pathogenesis of 
CP in general and TCP in particular. (Figure 1)
In this study, we detected eight different variants in the CTRC gene. (Tables 1 and 2) 
We found one common synonymous c.180 C>T variant that was enriched in the TCP 
population. (OR=2.09; P=0.01). Analysis with the CpG island searcher (http://
cpgislands.usc.edu/cpg.aspx) shows that c.180 C>T is located in a cytosine–guanine 
dinucleotides (CpG)-rich island. CpG-rich regions are genomic islands that contain a 
high frequency of cytosine–guanine dinucleotides often found near promoters of 
housekeeping genes.23  The cytosine base of these dinucleotides can be methylated 
and cause an inhibition of the gene expression, especially when the CpG region is 
located near a promoter region. 
The c.180 C>T is intragenically located and there is evidence suggesting24 that 
intragenic CpG methylation may affect gene expression by changing the chromatin 
structure and reducing the efficiency of polymerase II. This suggests to some extent 
that c.180 C>T may act as a pathogenic variant. 
Figure 3  Coomassie Blue stained -gel of secreted CTRC protein 
Western blot. (a) Coomassie blue staining from HEK293 cells that have been transfected with wild type 
CTRC or variant (p.G91R) CTRC. The left lane identifies a clear band at 35 kDa for CTRC (arrow) present in 
extract from wild type HEK293 cells, while the gel at right lane fails to stain a clear band denoting absence 
of mutant CTRC. The molecular weight markers are indicated left of the figure.
Table 4  SPINK1 p.N34S allele and CTRC variants in TCP patients
CTRC variant SPINK1 p.N34S 
(Wild-type)
SPINK1 p.N34S 
(Heterozygous)
SPINK1 p.N34S 
(Homozygous)
P-value
p.A73T (exon 3) 3/4 (75%) 1/4 (25%) 0/4 (0%) 0,6209
p.G61R (exon 3) 0/1 (0%) 1/1 (100%) 0/1 (0%) 0,6942
The SPINK1 p.N34S carrier rate among those patients who possessed a bonafide CTRC variant (p.A73T 
or p.G61R).
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Rosendahl et al provided robust experimental evidence that the non-synonymous 
p.A73T had a complete loss of function and the p.V235I had a reduced CTRC function 
of approximately 65%.21 
We also detected these variants in this cohort, but were unable to detect differences 
in allele frequencies between TCP patients and controls. This can be explained by the 
relatively low allele frequency relative to the size of our cohort. In contrast, if we lump 
data from the study of Rosendahl with our results, the picture becomes clearer. The 
p.A73T variant is significantly enriched in the TCP population. This variant was 
identified in a total of eight in 217 (3.69%) TCP patients in comparison to one of 228 
(0.44%) controls (OR=8.689; CI=1.077–70.099; P=0.018). By contrast, the allele 
frequency of p.V235I was similar among TCP patients (five of 219; 2.3%) and controls 
(two of 234; 0.9%) (OR=2.71; 95% CI=0.52–14.1; P=0.27).
In line with many other studies, we found that the SPINK1 p.N34S variant is strongly 
associated with TCP.11, 16, 18, 19 Given the major role of the SPINK1 p.N34S variant in 
TCP, it is important to relate this variant to new discovered genetic variants. In our 
cohort, two of four patients with a loss-of-function CTRC allele were also heterozygous 
carriers of the p.N34S SPINK1 variant. These data preclude a valid judgment as to 
whether CTRC variants occur independent of p.N34S. 
The results of this study underscore the central role of trypsin inhibitors in the 
pathogenesis of TCP. The role of trypsin seems to be of lesser importance given the 
studies that failed to detect an association between TCP and PRSS1 or PRSS2.25-27 In 
view of these findings, it might be speculated that novel TCP-associated genes 
encode proteins that inhibit the action or secretion of trypsin. 
One of the limitations of this study is the relatively small group of patients and controls 
we have used. In view of the low CTRC allele frequency, this might limit the robustness 
of the results. 
In contrast, we were able to replicate the findings of Rosendahl et al. and we found a 
novel CTRC null variant.21 
The search for other genetic factors in TCP does not stop here, and other genetic or 
environmental risk factors that can be responsible for this disease are probably 
present.
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Abstract
BACKGROUND
Several genetic risk factors have been identified for non-alcoholic chronic pancreatitis 
(NACP). A genome-wide association study reported an association of chronic 
pancreatitis (CP) with variants in PRSS1–PRSS2 (rs10273639; near the gene encoding 
cationic trypsinogen) and CLDN2–MORC4 loci (rs7057398 in RIPPLY1 and rs12688220 
in MORC4). We aimed to refine these findings in a large European cohort.
METHODS
We studied 3062 patients with alcohol-related CP (ACP) or NACP and 5107 controls. 
Also, 1559 German patients with alcohol-associated cirrhosis or alcohol dependence 
were included for comparison. We performed several meta-analyses to examine 
genotype – phenotype relationships. 
RESULTS
Association with ACP was found for rs10273639 (OR, 0.63; 95% CI 0.55 to 0.72). ACP 
was also associated with variants rs7057398 and rs12688220 in men (OR, 2.26; 95% 
CI 1.94 to 2.63 and OR, 2.66; 95% CI 2.21 to 3.21, respectively) and in women (OR, 
1.57; 95% CI 1.14 to 2.18 and OR 1.71;95% CI 1.41 to 2.07, respectively). Similar results 
were obtained when German patients with ACP were compared with those with alcohol- 
associated cirrhosis or alcohol dependence. In the overall population of patients with 
NACP, association with rs10273639 was absent (OR, 0.93; 95% CI 0.79 to 1.01), 
whereas rs7057398 of the X- chromosomal single nucleotide polymorphisms was 
associated with NACP in women only (OR, 1.32; 95% CI 1.15 to 1.51). 
CONCLUSION
The single-nucleotide polymorphisms rs10273639 at the PRSS1–PRSS2 locus and 
rs7057398 and rs12688220 at the CLDN2–MORC4 locus are associated with CP and 
strongly associate with ACP, but only rs7057398 with NACP in female patients.
Introduction
The genetic susceptibility to chronic pancreatitis (CP) is best illustrated by the 
discovery of cationic trypsinogen mutations (PRSS1, HGNC:9475) in families with 
autosomal-dominant inherited pancreatitis.1 There is also strong evidence that 
genetic variants contribute to cases of CP without a clear inheritance pattern. Indeed, 
idiopathic CP (ICP) is associated with genetic alterations in CFTR (HGNC:1884), 
SPINK1 (HGNC:11244), PRSS2 (HGNC:9483), CTRC (HGNC:2523) and CPA1 
(HGNC:2296).2-7 The association of genetic variants and disease susceptibility is less 
clear for alcohol-related CP (ACP). There is a low enrichment of SPINK1 (p.N34S) and 
CTRC (p.R254W) alleles in ACP populations but no other consistent genetic risk 
contributors have been described.5, 8 Similar to ICP, the PRSS2 p.G191R variant 
protects against ACP development.3 All these associations have been discovered 
through candidate-driven genetic association studies.
A recent paper described a different approach and reported novel risk and protecting 
loci for CP identified through a genome-wide association study (GWAS). A number of 
variants in the PRSS1-PRSS2 but also the CLDN2–MORC4 locus (Claudin 2; HGNC: 
2041; RIPPLY1, ripply transcriptional repressor 1, HGNC:25117; MORC4, MORC family 
CW-type zinc finger 4, HGNC:23485) were captured as risk factors for CP.9  This 
study investigated patients with different types of CP as well as recurrent acute 
pancreatitis (RAP) and stratified individuals into alcohol-related and alcohol-unrelated 
pancreatitis groups. In a first screening cohort, three single nucleotide polymorphisms 
(SNPs) rs10273639 (in the PRSS1–PRSS2 locus on chromosome 7, in perfect linkage 
disequilibrium with rs2011216 in intron 1 and rs6667 in exon 5 of PRSS1), rs7057398 
and rs12688220 (both in a new locus, CLDN2–MORC4 on the X chromosome) 
reached genome-wide significance. After scrutiny, the PRSS1–PRSS2 rs10273639 T 
allele appeared to protect against CP, whereas RIPPLY1 rs7057398 C allele and MORC4 
rs12688220 T allele increased disease susceptibility.9 There is some biological 
plausibility for the association with the PRSS1–PRSS2 locus as it may disturb the 
balance of pancreatic proteases and anti-proteases in favour of the former.10, 11 
Claudin 2 represents a tight junction protein involved in low-resistance cation- 
selective ion and water transport between endothelial cells.12, 13  One might speculate 
that CLDN2–MORC4 locus variants lead to miss-localization of pancreatic CLDN2 
that hampers its biological function. However, this speculation warrants further 
experimental support. 
Prior to the design of experimental studies that focus on the biological role of these 
variants, it is crucial that GWAS results are replicated. 
This is needed to prove that results are valid and reliable to determine generalizability and 
to better judge the effect size of the discovered association.14 
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We investigated the association of PRSS1–PRSS2 and CLDN2–MORC4 locus variants 
in a large European cohort of ACP and non-alcoholic CP (NACP) to confirm the 
former finding. In order to assess the effect of alcohol consumption, we further refined 
our analyses by including cohorts of patients with alcohol-associated cirrhosis (ALC) 
as well as with alcohol dependence (AD) without hepatic or pancreatic disease.
Materials and methods
Study subjects
The respective medical ethical review committees of all participating centres approved 
the study protocol and all patients gave written informed consent. The diagnosis of 
CP was based on two or more of the following findings: (a) presence of a typical 
history of recurrent pancreatitis or (b) recurrent abdominal pain typical for CP, (c) 
calcifications and/or (d) pancreatic ductal irregularities revealed by imaging of the 
pancreas.15 ACP was diagnosed in patients who had consumed at least 80 g ethanol 
per day for at least 2 years in men or 60 g per day for women. We labelled patients 
with NACP in the absence of exogenous factors such as alcohol. ALC was diagnosed 
by a history of habitual ethanol intake (see ACP diagnosis above, duration at least 
10 years), typical findings in liver biopsy or clinical and laboratory findings indicative 
for liver disease. Such laboratory and clinical findings included abnormal levels 
of  aminotransferases, gamma glutamyl transpeptidase, coagulation tests, serum 
albumin concentration, platelet count, complications related to liver cirrhosis such as 
oesophageal varices, ascites, hepatic encephalopathy and typical liver morphology 
in imaging studies. Other aetiologies of liver cirrhosis were excluded by standard 
laboratory tests. Patients with AD were recruited from psychiatric and addiction 
medicine departments in different cities across southern and central Germany. 
AD was diagnosed per DSM-IV criteria by consensus of two clinical psychiatrists. 
All patients were of self-reported German ancestry and did not suffer from CP or 
ALC.16 The study included 1866 patients (male, n=1567) with ACP and 1196 patients 
(male, n=596) with NACP from different European countries. In addition, we enrolled 
5107 controls (male, n=2287), 661 German patients with ALC (male, n=480) and 
898 Germans with AD (male, n=797). Characteristics of the patients and controls 
are summarised in Table 1 and 2.
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Genotyping
Genomic DNA was extracted from peripheral blood leukocytes. Polymerase chain 
reaction (PCR) was conducted using 0.75 U AmpliTaq Gold polymerase (Applied 
Biosystems), 400 µM dNTPs, 1.5 mM MgCl2 and 0.1 µM F-Primer as well as 0.1 µM 
R-primer (0.4 µM R-primer for the PRSS1–PRSS2 SNP) in a total volume of 25 µl. 
Cycle conditions were an initial denaturation for 12 minutes at 95°C followed by 35 
cycles of 20 seconds denaturation at 95°C, 40 seconds annealing (temperatures see 
below), 90 seconds primer extension at 72°C, and a final extension for 2 minutes at 
72°C in an automated thermal cycler (Applied Biosystems). Primers and simple 
probes were synthesised according to the published nucleotide sequences (PRSS1: 
GenBank: NG_001333; CLDN2: GenBank: NG_022934 and NG_016392). Primer 
sequences for PCR were as follows: rs10273639 (PRSS1–PRSS2): 5’-ATAAGACT-
TTGCTCCTCTCATGTG-3’ and 5’-AGAATGGCCTAGCTGTTTACAA-3’, (annealing 
temperature 55°C); rs7057398 (RIPPLY1): 5’-GGATCATTCTTGGTCATCGTTAACA-3’ 
and 5’-CAGAGAGGTTAAGGGACTTTGC-3’ (annealing at 58°C); rs12688220 
(MORC4): 5’-TGGGATTCATTATATTGTTTTCTG-3’ and 5’- CCAATCTTTTAACTTTTT-
GATAGTC-3’ (annealing at 53°C).
Genotyping was performed using the LightCycler480 system (Roche Diagnostics). 
SimpleProbe oligomers were diluted in H2O to a final concentration of 1 µM. For 
genotyping, we used the following probes: 5’-ACCAACGCTTGCCCT XI TCCTT-PH-3’ 
(rs10273639), 5’-CGTTAACAA XI TGCCTCCAGAAAAG--NH2-3’ (rs7057398) and 
5’-TGAGCA XI TCATTTTTTACCCCCATTGG-PH-3’ (rs12688220) (XI = dye modified 
base, PH = phosphate).
As quality controls, 3% of all samples were genotyped in duplicates blinded to the 
investigator. The concordance rate was >98%. Call rates for rs10273639, rs7057398 
and rs12688220 in the European samples were 99.1% (9641/9730), 99% (9636/9730) 
and 98.8% (9609/9730), respectively.
Statistical analysis
Quality of SNP genotypes was assessed by study-wise call rate and exact test for 
Hardy–Weinberg equilibrium in controls (female controls only for the X chromosomal 
SNPs). We also calculated overall statistics and performed stratified tests of Hardy–
Weinberg equilibrium according to Troendle and Yu.17
According to these measures, genotype qualities were excellent throughout. Study- 
wise genetic effects were determined by logistic regression analysis assuming an 
additive model of inheritance. For X chromosomal SNPs, we analysed the subgroups 
of men and women separately. 
Following the approach of Loley et al,18 we also determined combined effects by 
either assuming a model of complete X inactivation (XIA) or no X inactivation (nXIA) 
at all. 
The major purpose of our study is to compare allele frequencies of risk variants 
between different subgroups of patients (ACP, NACP) and controls (healthy, alcohol 
dependent, patients with cirrhosis). Corresponding contrasts of interest are listed in 
Table 3. Study-wise effects were pooled by standard meta-analysis techniques as 
implemented in the package ‘meta’ of the statistical software ‘R 3.0.1’ (ww.r-project.org). 
Heterogeneity between studies was assessed using Q-statistics. Due to occasionally 
observed study heterogeneity, we calculated random-effect models throughout. For 
the purpose of model diagnostics, we analysed and compared likelihoods of XIA, 
nXIA and sex interaction. In Figures 1, 2 A, B, 3, 4 A, B and 5, we present forest plots 
of our meta-analysis results as well as other features. Finally, we performed a stratified 
analysis regarding age of onset in the German population. Forest plots were generated 
using GraphPad Prism (V.6.0a) (San Diego). p Values <0.05 were considered 
statistically significant. Figures 6 A, B and 7 A, B display the results of X chromosomal 
analysis assuming models of complete or no X inactivation.
Table 3  Analysed phenotypical contrasts
Group 
comparisons
Issue to be addressed Table/Figure
1 vs. 2 Difference between ACP and NACP? Table 14
3 vs. 5 ALC gene? Data not shown
3+5 vs. 4 AD gene? Data not shown
1+2 vs. 3+4+5 CP (NACP+ACP) gene?
(Comparable to Whitcomb et al., Nat Genet 2012)
Table 14
1 vs. 3 Association ACP specific?
(not present in other alcohol related disease)
Figure 1, 2A/B, 
4A/B, 6A/B, 7A/B
1 vs. 4 ACP gene? (Comparison against healthy controls) Figure 1-7
1 vs. 5 Association ACP specific? 
(not present in alcohol dependence)
Figure 1, 2A/B, 
4A/B, 6A/B, 7A/B
2 vs. 4 NACP gene? Figure 1, 3, 5, 
6A/B, 7A/B
1 vs. 3+5 ACP gene? (Increase of power) Table 14
Analysed phenotypical contrasts. Comparison; 1 = ACP, 2 = NACP, 3 = ALC, 4 = controls, 5 = AD
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Results
PRSS1–PRSS2 locus (rs10273639)
In meta-analysis, rs10273639 showed the strongest association with ACP (OR 0.63, 
95% CI 0.55 to 0.72, p value 8.5×10−11). No association was observed for NACP (OR 
0.93, 95% CI 0.79 to 1.08, p value 0.3). An association was also observed for the 
comparison between German patients with ACP and patients with ALC (OR 0.58, 
95% CI 0.50 to 0.66, p value 2.6×10−12). The association was also found in comparison 
of German patients with ACP with German patients with AD (OR 0.55, 95% CI 0.47 to 
0.63, p value 2.3×10−16). Similar frequencies of the SNP were observed in AD, ALC 
and healthy controls. 
For patients with ACP coming from individual European countries, an association 
was apparent for Germany, France, the Netherlands, Hungary, Italy, Romania and the 
UK (Germany OR 0.59, 95% CI 0.52 to 0.66, p value 2.9×10−19; France OR 0.64, 95% 
CI 0.47 to 0.88, p value 0.007; the Netherlands OR 0.56, 95% CI 0.43 to 0.72, p value 
6.3×10−6; Hungary OR 0.43, 95% CI 0.18 to 0.94, p value 0.04; Italy OR 0.77, 95% CI 
0.60 to 0.97, p value 0.03; Romania OR 0.41, 95% CI 0.23 to 0.69, p value 0.001; the 
UK OR 0.53, 95% CI 0.30 to 0.91, p value 0.02). 
The logistic regression and meta-analysis results of rs10273639 are summarised in 
Figure 1, while the genotype frequencies for the groups are given in Tables 4 and 5. 
The TT genotype was underrepresented in all European patients with ACP (all patients 
9.5% vs all controls 18.1%, p value 9.6×10−33, except for the samples from Poland 
(12.9% patients vs 12.4% controls, p value 0.99)). In the NACP cohorts, this under-
representation was found only in German patients (patients 13.8% vs controls 17.9%, 
p value 0.01).
Table 4  Genotype distribution of rs10273639 (PRSS1) in NACP
Country ID CC CT TT p-value HWE
Germany 
(n=690)
Pat. 274 (39.7%) 321 (46.5%) 95 (13.8%) 0.01 0.9
Germany 
(n=2825)
Con. 985 (34.9%) 1335 (47.3%) 505 (17.9%) 0.4
France 
(n=415)
Pat. 130 (31.3%) 189 (45.5%) 96 (23.1%) 0.3 0.2
France 
(n=1064)
Con. 316 (29.7%) 530 (49.8%) 218 (20.5%) 1.0
Netherlands 
(n=87)
Pat. 28 (32.2%) 47 (54%) 12 (13.8%) 0.9 0.5
Netherlands 
(n=434)
Con. 146 (33.6%) 222 (51.2%) 66 (15.2%) 0.5
All (n=1192) Pat. 432 (36.2%) 557 (46.7%) 203 (17%) 0.2 0.6
All (n=4323) Con 1447 (33.5%) 2087 (48.3%) 789 (18.3%) 0.8
Genotype distribution of rs10273639 (PRSS1) in NACP. Genotype distribution of rs10273639 (PRSS1) in 
NACP patients and controls from Germany, France, and The Netherlands, and summarized for all 
investigated samples. Calculations were performed using the Chi-square test. Abbreviations: NA-
CP=non-alcoholic chronic pancreatitis, ID=identification, Con.=controls, Pat.=patients, HWE=Har-
dy-Weinberg disequilibrium (p-value). 
Figure 1  
Meta-analysis results for rs10273639 (PRSS1–PRSS2) in patients with non-alcoholic chronic pancreatitis 
(NACP), alcohol-related chronic pancreatitis (ACP) and comparison of German ACP patients with alcohol- 
associated cirrhosis (ALC) and with alcohol-dependent (AD) patients. Results are presented in a semi-log 
scale.
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RIPPLY1 (rs7057398)
In meta-analysis, significant associations were found for rs7057398 in male patients 
with ACP (OR 2.26, 95% CI 1.94 to 2.63, p value 5.4×10-26) and in female patients (OR 
1.57, 95% CI 1.14 to 2.18, p value 0.007). 
Upon stratification by countries, we detected a significant association with male 
patients with ACP originating from Germany, France, Spain, the Netherlands, Italy, 
Romania and the UK (p values 1.6×10-12, 0.0007, 0.03, 3.0×10-5, 3.1×10-5, 0.002 and 
0.02, respectively). We obtained similar results for female patients with ACP from 
Germany, Poland and the UK (p value 0.004, 0.0005 and 0.04). 
We then assessed the strength of the association by comparison of the results 
obtained from patients with ALC and AD. Indeed, rs7057398 was overrepresented in 
ACP relative to other alcohol-related disorders. This was especially apparent for the 
cohort of male German patients with ACP in comparison with ALC (OR 2.32, 95% 
CI 1.80 to 3.01, p value 1.1×10−10) as well as with AD (OR 2.03, 95% CI 1.64 to 2.51, 
p value 1.2×10-10). In addition, the SNP is not associated with risk of cirrhosis or AD, 
neither for men nor for women. Figure 2 A, B summarises the results of the meta- 
analysis of rs7057398 in patients with ACP. Results of XiA and nXiA are summarised 
in Figure 3 A, B. 
Table 5  Genotype distribution of rs10273639 (PRSS1) in ACP
Country ID CC CT TT p-value HWE
Germany 
(n=864)
Pat. 433 (50.1%) 358 (41.1%) 73 (8.4%) 1.3x10-18 1.0
Germany 
(n=2825)
Con. 985 (34.9%) 1335 (47.3%) 505 (17.9%) 0.4
France  
(n=90)
Pat. 36 (40%) 45 (50%) 9 (10%) 0.02 0.6
France 
(n=1064)
Con. 316 (29.7%) 530 (49.8%) 218 (20.5%) 1.0
Spain (n=195) Pat. 85 (43.6%) 89 (45.6%) 21 (10.8%) 0.4 1.0
Spain (n=46) Con. 16 (34.8%) 22 (47.8%) 8 (17.4%) 1.0
Netherlands 
(n=232)
Pat. 115 (49.6%) 102 (44%) 15 (6.5%) 2.9x10-5 0.5
Netherlands 
(n=434)
Con. 146 (33.6%) 222 (51.2%) 66 (15.2%) 0.5
Hungary 
(n=29)
Pat. 17 (58.6%) 10 (34.5%) 2 (6.9%) 0.09 1.0
Hungary 
(n=35)
Con. 11 (31.4%) 19 (54.3%) 5 (14.3%) 0.8
Italy  
(n=256)
Pat. 107 (41.8%) 114 (44.5%) 35 (13.7%) 0.07 0.9
Italy  
(n=325)
Con. 106 (32.6%) 163 (50.2%) 56 (17.2%) 0.9
Romania 
(n=68)
Pat. 37 (54.4%) 26 (38.2%) 5 (7.4%) 0.003 1.0
Romania 
(n=68)
Con. 18 (26.5%) 38 (55.9%) 12 (17.6%) 0.6
Poland (n=85) Pat. 33 (38.8%) 41 (48.2%) 11 (12.9%) 0.99 1.0
Poland (n=89) Con. 35 (39.3%) 43 (48.3%) 11 (12.4%) 0.9
United 
Kingdom 
(n=35)
Pat. 19 (54.3%) 11 (31.4%) 5 (14.3%) 0.02 0.3
United 
Kingdom 
(n=179)
Con. 53 (29.6%) 91 (50.8%) 35 (19.6%) 0.9
Table 5  Continued
Country ID CC CT TT p-value HWE
All (n=1854) Pat. 882 (47.6%) 796 (42.9%) 176 (9.5%) 9.6 x10-33 1.0
All (n=5065) Con. 1686 (33.3%) 2463 (48.6%) 916 (18.1%) 1.0
Germany 
(n=864)
Pat. 433 (50.1%) 358 (41.1%) 73 (8.4%) 5x10-16 1.0
Germany 
(n=887)
AD 281 (31.7%) 456 (51.4%) 150 (16.9%) 0.3
Germany 
(n=864)
Pat. 433 (50.1%) 358 (41.1%) 73 (8.4%) 6.6x10-12 1.0
Germany 
(n=643)
ALC 226 (35.1%) 296 (46%) 121 (18.8%) 0.4
Genotype distribution of rs10273639 (PRSS1) in ACP patients and controls from Europe and summarized 
for all investigated samples. At the bottom of the table comparison between German ACP patients and 
patients with ALC or AD are presented. Calculations were performed with the Chi-square test. 
Abbreviations: ACP=alcoholic chronic pancreatitis, AD=alcohol dependence, ALC=alcoholic liver cirrhosis, 
ID=identification, Con.=controls, Pat.=patients, HWE=Hardy-Weinberg disequilibrium (p-value).
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The genotype and allele frequencies of rs7057398 in patients with ACP are presented 
in Tables 6 and 7. The C allele was more frequent in male patients with ACP from all 
European countries investigated (43.8% vs controls 27.5%, p value 10×10-25) and the 
C allele was significantly overrepresented (p value 0.0001) in female patients with 
ACP (35.2%) compared with controls (27.3%). We detected a significant association 
for rs7057398 with NACP upon  logistic regression in female patients (OR 1.30, 95% 
CI 1.14 to 1.49, p value 1.3×10-4), but not in male patients (Figure 4). 
Estimated genetic effect sizes are always smaller than for ACP. As shown in Tables 8 
and 9, the C allele was slightly overrepresented in male patients with NACP (all 
patients: 32.6% vs 28.3%, p value 0.04; German patients: 33.3% vs 27.1%, p value 
0.03). Subgroup analyses revealed that in German women and in the overall female 
patients with NACP there was an overrepresentation of CC genotype (patients 10.1% 
vs controls 7.8%, p value 2.6×10-4; patient’s 10.3% vs controls 8.6%, p value 4.2×10-5.
Figure 2 A, B  Meta-analysis results for rs7057398 (RIPPLY1) in patients with alcohol- 
related chronic pancreatitis (ACP) and comparison of German ACP patients with 
alcohol- associated cirrhosis (ALC) and with alcohol-dependent (AD) patients. Results 
are presented in a semi-log scale.Figure 2A
Figure 2B  
Meta-analysis results for rs10273639 (PRSS1–PRSS2) in patients with non-alcoholic chronic pancreatitis 
(NACP), alcohol-related chronic pancreatitis (ACP) and comparison of German ACP patients with alcohol- 
associated cirrhosis (ALC) and with alcohol-dependent (AD) patients. Results are presented in a semi-log 
scale.
104 105
CHAPTER 5 POLYMORPHISMS AT PRSS1-PRSS2 AND CLDN2-MORC4 LOCI IN CHRONIC PANCREATITIS
5
Figure 3A
Figure 3B  
Meta-analysis results for rs7057398 (RIPPLY1) in patients with non-alcoholic chronic pancreatitis (NACP), 
alcohol-related chronic pancreatitis (ACP), and comparison of German ACP patients with alcohol-associated 
cirrhosis (ALC) and with alcohol dependent (AD) patients obtained with a model assuming X inactivation 
(S1a) and no X inactivation (S1b). Results are presented in a semi-log scale.
Table 6  Allele distribution of rs7057398 (RIPPLY1) in male ACP patients
Country ID C T p-value
Germany (n=730) Pat. 312 (42.7%) 418 (57.3%) 5.5x10-12
Germany (n=1225) Con. 332 (27.1%) 893 (72.9%)
France (n=76) Pat. 39 (51.3%) 37 (48.7%) 0.001
France (n=552) Con. 173 (31.3%) 379 (68.7%)
Spain (n=169) Pat. 67 (39.6%) 102 (60.4%) 0.02
Spain (n=21) Con. 3 (14.3%) 18 (85.7%)
Netherlands (n=180) Pat. 89 (49.4%) 91 (50.6%) 7.7x10-5
Netherlands (n=159) Con. 43 (27%) 116 (73%)
Hungary (n=24) Pat. 9 (37.5%) 15 (62.5%) 0.2
Hungary (n=25) Con. 5 (20%) 20 (80%)
Italy (n=212) Pat. 93 (43.9%) 119 (56.1%) 1.6x10-5
Italy (n=90) Con. 26 (17.8%) 61 (82.2%)
Romania (n=60) Pat. 31 (51.7%) 29 (48.3%) 0.001
Romania (n=44) Con. 9 (20.5%) 35 (79.5%)
Poland (n=71) Pat. 24 (33.8%) 47 (66.2%) 0.3
Poland (n=41) Con. 10 (24.4%) 31 (75.6%)
United Kingdom (n=27) Pat. 15 (55.6%) 12 (44.4%) 0.02
United Kingdom (n=95) Con. 29 (30.5%) 66 (69.5%)
All (n=1549) Pat. 679 (43.8%) 870 (56.2%) 10x10-25
All (n=2252) Con. 620 (27.5%) 1632 (72.5%)
Germany (n=730) Pat. 312 (42.7%) 418 (57.3%) 9.1x10-11
Germany (n=791) AD 213 (26.9%) 578 (73.1%)
Germany (n=730) Pat. 312 (42.7%) 418 (57.3%) 1.2x10-10
Germany (n=473) ALC 115 (24.3%) 358 (75.7%)
Allele distribution of rs7057398 (RIPPLY1) in male ACP patients and controls from Europe and 
summarized for all investigated samples. At the bottom of the table comparison between German ACP 
patients and patients with ALC or AD are presented. Calculations were performed using the Chi-square 
test. Abbreviations: ACP=alcoholic chronic pancreatitis, AD=alcohol dependence, ALC=alcoholic liver 
cirrhosis, ID=identification, Con.=controls, Pat.=patients. Note: 5 equivocal genotyped samples were 
excluded (Control group: Germany n=2, Netherlands n=1), and 2 from the ALC group).
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Table 7  Allele distribution of rs7057398 (RIPPLY1) in female ACP patients
Country ID CC CT TT p-value HWE
Germany 
(n=120)
Pat. 15 12.5%) 55 (45.8%) 50 (41.7%) 0.01 1.0
Germany 
(n=1609)
Con. 125 (7.8%) 606 (37.7%) 878 (54.6%) 0.4
France 
(n=14)
Pat. 0 9 (64.3%) 5 (35.7%) 0.13 0.2
France 
(n=512)
Con. 50 (9.8%) 202 (39.5%) 260 (50.8%) 0.5
Spain (n=25) Pat. 2 (8%) 13 (52%) 10 (40%) 0.3 0.7
Spain (n=19) Con. 0 8 (42.1%) 11 (57.9%) 0.5
Netherlands 
(n=55)
Pat. 4 (7.3%) 29 (52.7%) 22 (40%) 0.4 0.4
Netherlands 
(n=264)
Con. 29 (11%) 115 (43.6%) 120 (45.5%) 1.0
Hungary 
(n=5)
Pat. 1 (20%) 3 (60%) 1 (20%) 0.2 0.9
Hungary 
(n=8)
Con. 2 (25%) 1 (12.5%) 5 (62.5%) 0.1
Italy (n=44) Pat. 2 (4.5%) 17 (38.6%) 25 (56.8%) 0.9 0.9
Italy (n=206) Con. 10 (4.9%) 78 (37.9%) 118 (57.3%) 0.8
Romania 
(n=8)
Pat. 0 6 (75%) 2 (25%) 0.06 0.2
Romania 
(n=25)
Con. 2 (8%) 7 (28%) 16 (64%) 0.7
Poland 
(n=14)
Pat. 6 (42.9%) 6 (42.9%) 2 (14.3%) 2.9x10-4 1.0
Poland 
(n=48)
Con. 3 (6.2%) 13 (27.1%) 32 (66.7%) 0.6
United 
Kingdom 
(n=8)
Pat. 1 (12.5%) 6 (75%) 1 (12.5%) 0.09 0.4
United 
Kingdom 
(n=85)
Con. 4 (4.7%) 37 (43.5%) 44 (51.8%) 0.6
Table 7  Continued
Country ID CC CT TT p-value HWE
All (n=293) Pat. 31 (10.6%) 144 (49.1%) 118 (40.3%) 9.7x10-5 0.4
All (n=2776) Con. 225 (20.4%) 1067 (29.5%) 1484 (53.5%) 0.2
Germany 
(n=120)
Pat. 15 (12.5%) 55 (45.8%) 50 (41.7%) 0.008 1.0
Germany 
(n=101)
AD 12 (11.9%) 27 (26.7%) 62 (61.4%) 0.01
Germany 
(n=120)
Pat. 15 (12.5%) 55 (45.8%) 50 (41.7%) 0.03 1.0
Germany 
(n=177)
ALC 17 (9.6%) 58 (32.8%) 102 (57.6%) 0.1
Genotype distribution of rs7057398 (RIPPLY1) in female ACP patients and controls from Europe and 
summarized for all investigated samples. At the bottom of the table comparison between German ACP 
patients and patients with ALC or AD are presented. Calculations were performed using the Chi-square 
test. Abbreviations: ACP=alcoholic chronic pancreatitis, AD=alcohol dependence, ALC=alcoholic liver 
cirrhosis, ID=identification, Con.=controls, Pat.=patients, HWE=Hardy-Weinberg disequilibrium (p-value). 
Figure 4  
Meta-analysis results for rs7057398 (RIPPLY1) in patients with non-alcoholic chronic pancreatitis (NACP). 
Results are presented in a semi-log scale. Y-axis intersects x-axis at 1
108 109
CHAPTER 5 POLYMORPHISMS AT PRSS1-PRSS2 AND CLDN2-MORC4 LOCI IN CHRONIC PANCREATITIS
5
MORC4 (rs12688220)
Similar to the results obtained for rs7057398 in ACP, rs12688220 was significantly 
associated in male (OR 2.66, 95% CI 2.21 to 3.21, p-value 1.1×10-24) and female 
patients (OR 1.71, 95% CI 1.41 to 2.07, p value 3.3×10-8) with ACP (Figure 5 A, B). The 
association was also statistically significant in individual male cohorts from Germany, 
France, Spain, the Netherlands, Italy and Romania (p value 1.2×10-16, 8.4×10-6, 0.02, 
2.5×10-6, 5.4×10-6 and 0.001, respectively), as well as in the female cohorts from 
Germany, Poland and the UK (p value 0.0003, 0.003 and 0.03). Results of XiA and 
nXiA are summarised in Figure 6 A, B. Tables 10 and 11 summarise the genotype and 
allele distribution of rr12688220 in ACP. The T allele was overrepresented in all 
European male cohorts (men: all patients 43.9% vs all controls 25.1%, p value 
4.6×10-33), while in female ACP cohorts from Germany, Poland and the UK as well as 
in the overall female group the overrepresentation of the TT genotype was statistically 
significant (women: all patients 10.4% vs all controls 6.7%, p value 2.4×10-7). In the 
meta-analysis, we detected no significant association in the overall male and female 
NACP group (p value 0.2 and 0.1). Again, genetic effect sizes are clearly smaller than 
for ACP. In single-study analyses, significant differences were found in the German 
NACP female group (OR 1.41, 95% CI 1.18 to 1.68, p value 0.0002) and in the male 
NACP groups from Germany (OR 1.34, 95% CI 1.03 to 1.75, p value 0.03) and the 
Netherlands (OR 2.09, 95% CI 1.05 to 4.12, p value 0.03) (Figure 7). 
Again, no differences were observed between the three control groups. Genotype 
and allele distributions of this variant can be found in Tables 12 and 13.
Additional analyses
We pooled our cases and control groups in order to compare our results with the 
analysis published by Whitcomb et al. Results are summarised in Table 14 for all 
SNPs. Strong associations were observed for all variants, that is, the results of 
Whitcomb et al are clearly replicated. To analyse whether effect sizes of X chromosomal 
variants are different between male and female patients, we performed sex-interac-
tion analysis but interaction terms were not significant throughout (results not shown). 
We also compared the models of XIA and nXIA and observed a non-significant trend 
that XIA is more likely. Finally, in order to better understand the lack of associations 
for NACP, we performed a stratified analysis of the German cohort regarding age of 
onset. Interestingly, we observed a trend towards higher genetic effect sizes in groups 
of later age of onset. This could explain, for example, the lack of associations in the 
French cohort in which the age range is 1–20 years (see Table 15).
Table 8  Allele distribution of rs7057398 (RIPPLY1) in male NACP patients
Country ID C T p-value
Germany (n=336) Pat. 112 (33.3%) 224 (66.7%) 0.03
Germany (n=1225) Con. 332 (27.1%) 893 (72.9%)
France (n=210) Pat. 65 (31%) 145 (69%) 0.9
France (n=552) Con. 173 (31.3%) 379 (68.7%)
Netherlands (n=46) Pat. 16 (34.8%) 30 (65.2%) 0.4
Netherlands (n=159) Con. 43 (27%) 116 (73%)
All (n=592) Pat. 193 (32.6%) 399 (67.4%) 0.04
All (n=1936) Con. 548 (28.3%) 1388 (71.7%)
Allele distribution of rs7057398 (RIPPLY1) in male NACP patients and controls from Germany, France 
and The Netherlands, summarized for all investigated samples. Calculations were performed using the 
Chi-square test. Abbreviations: NACP=non-alcoholic chronic pancreatitis, ID=identification, Con.= 
controls, Pat.=patients. Note: 6 equivocal genotyped samples were excluded (3 patient group; Germany 
n=2, Netherlands n=1; 3 control group; Germany n=2, Netherlands n=1).
Table 9  Genotype distribution of rs7057398 (RIPPLY1) in female NACP patients
Country ID CC CT TT p-value HWE
Germany 
(n=356)
Pat. 36 (10.1%) 168 (47.2%) 152 (42.7%) 2.6x10-4 0.6
Germany 
(n=1609)
Con. 125 (7.8%) 606 (37.7%) 878 (54.6%) 0.4
France 
(n=205)
Pat. 25 (12.2%) 92 (44.9%) 88 (42.9%) 0.2 1.0
France 
(n=512)
Con. 50 (9.8%) 202 (39.5%) 260 (50.8%) 0.5
Netherlands 
(n=39)
Pat. 1 (2.6%) 23 (59%) 15 (38.5%) 0.1 0.09
Netherlands 
(n=264)
Con. 29 (11%) 115 (43.6%) 120 (45.5%) 1.0
All (n=600) Pat. 62 (10.3%) 283 (47.2%) 255 (42.5%) 4.2x10-5 0.4
All (n=2385) Con. 204 (8.6%) 923 (38.7%) 1258 (52.7%) 0.2
Genotype distribution of rs7057398 (RIPPLY1) in female NACP patients and controls from Germany, 
France, and The Netherlands, and summarized for all investigated samples. Calculations were 
performed using the Chi-square test. Abbreviations: NACP=non-alcoholic chronic pancreatitis, 
ID=identification, Con.=controls, Pat.=patients, HWE=Hardy-Weinberg disequilibrium (p-value).
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Figure 5A
Figure 5B  
Meta-analysis results for rs12688220 (MORC4) in patients with alcohol-related chronic pancreatitis (ACP) 
and comparison of German ACP patients with alcohol-associated cirrhosis (ALC) and with alcohol-depend-
ent (AD) patients. Results are presented in a semi-log scale.
Figure 6A
Figure 6B  
Meta-analysis results for rs12688220 (MORC4) in patients with non-alcoholic chronic pancreatitis (NACP), 
alcohol-related chronic pancreatitis (ACP), and comparison of German ACP patients with alcohol-associat-
ed cirrhosis (ALC) and with alcohol dependent (AD) patients obtained with a model  assuming X inactivation 
(6A) and no X inactivation (6B). Results are presented in a semi-log scale.
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Table 10  Allele distribution of rs12688220 (MORC4) in male ACP patients
Country ID C T p-value
Germany (n=742) Pat. 416 (56.1%) 326 (43.9%) 2.6x10-16
Germany (n=1222) Con. 908 (74.3%) 314 (25.7%)
France (n=76) Pat. 36 (47.4%) 40 (52.6%) 4.1x10-6
France (n=552) Con. 404 (73.2%) 148 (26.8%)
Spain (n=168) Pat. 107 (63.7%) 61 (36.3%) 0.005
Spain (n=20) Con. 19 (95%) 1 (5%)
Netherlands (n=177) Pat. 89 (50.3%) 88 (49.7%) 8.6x10-6
Netherlands (n=163) Con. 123 (75.5%) 40 (24.5%)
Hungary (n=24) Pat. 16 (66.7%) 8 (33.3%) 0.2
Hungary (n=25) Con. 21 (84%) 4 (16%)
Italy (n=212) Pat. 118 (55.7%) 94 (44.3%) 2.1x10-6
Italy (n=97) Con. 81 (83.5%) 16 (16.5%)
Romania (n=60) Pat. 30 (50%) 30 (50%) 0.001
Romania (n=44) Con. 36 (81.8%) 8 (18.2%)
Poland (n=71) Pat. 47 (66.2%) 24 (33.8%) 0.1
Poland (n=39) Con. 31 (79.5%) 8 (21.5%)
United Kingdom (n=27) Pat. 15 (55.6%) 12 (44.4%) 0.2
United Kingdom (n=98) Con. 69 (70.4%) 29 (29.6%)
All (n=1557) Pat. 874 (56.1%) 683 (43.9%) 4.6x10-33
All (n=2260) Con. 1692 (74.9%) 568 (25.1%)
Germany (n=742) Pat. 416 (56.1%) 326 (43.9%) 2.2x10-15
Germany (n=789) AD 594 (75.3%) 195 (24.7%)
Germany (n=742) Pat. 416 (56.1%) 326 (43.9%) 4.7x10-12
Germany (n=464) ALC 354 (76.2%) 110 (23.7%)
Allele distribution of rs12688220 (MORC4) in male ACP patients and controls from Europe and 
summarized for all investigated samples. At the bottom of the table comparison between German ACP 
patients and patients with ALC or AD are presented. Calculations were performed using the Chi-square 
test. Abbreviations: ACP=alcoholic chronic pancreatitis, AD=alcohol dependence, ALC=alcoholic liver 
cirrhosis, ID=identification, Con.=controls, Pat.=patients. Note: 8 equivocal genotyped samples were 
excluded (1 patient group (Netherlands), 7 control group (Netherlands n=2, Germany n=3, Poland n=1), 
and 1 from the ALC group).
Table 11  Genotype distribution of rs12688220 (MORC4) in female ACP patients
Country ID CC CT TT p-value HWE
Germany 
(n=124)
Pat. 51 (41.1%) 59 (47.6%) 14 (11.3%) 0.004 0.9
Germany 
(n=1614)
Con. 924 (57.2%) 588 (36.4%) 102 (6.3%) 0.8
France  
(n=14)
Pat. 3 (21.4%) 10 (71.4%) 1 (7.1%) 0.04 0.2
France 
(n=512)
Con. 274 (53.5%) 200 (39.1%) 38 (7.4%) 1.0
Spain (n=26) Pat. 11 (42.3%) 12 (46.2%) 3 (11.5%) 0.3 1.0
Spain (n=20) Con. 13 (65%) 6 (30%) 1 (5%) 1.0
Netherlands 
(n=55)
Pat. 18 (32.7%) 30 (54.5%) 7 (12.7%) 0.06 0.6
Netherlands 
(n=262)
Con. 131 (50%) 102 (38.9%) 29 (11.1%) 0.4
Hungary 
(n=5)
Pat. 1 (20%) 4 (80%) 0 0.1 0.3
Hungary 
(n=9)
Con. 6 (66.7%) 2 (22.2%) 1 (11.1%) 0.6
Italy (n=44) Pat. 27 (61.4%) 16 (36.4%) 1 (2.3%) 0.6 0.7
Italy (n=214) Con. 145 (67.8%) 62 (29%) 7 (3.3%) 1.0
Romania 
(n=8)
Pat. 3 (37.5%) 5 (62.5%) 0 0.07 0.4
Romania 
(n=25)
Con. 18 (72%) 5 (20%) 2 (8%) 0.3
Poland  
(n=14)
Pat. 3 (21.4%) 7 (50%) 4 (28.6%) 0.004 1.0
Poland  
(n=48)
Con. 33 (68.8%) 12 (25%) 3 (6.3%) 0.5
United 
Kingdom 
(n=8)
Pat. 1 (12.5%) 6 (75%) 1 (12.5%) 0.07 0.4
United 
Kingdom 
(n=86)
Con. 47 (54.7%) 35 (40.7%) 4 (4.7%) 0.7
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Table 11  Genotype distribution of rs12688220 (MORC4) in female ACP patients
Country ID CC CT TT p-value HWE
All (n=298) Pat. 118 (39.6%) 149 (50%) 31 (10.4%) 2.4x10-7 0.3
All (n=2790) Con. 1591 (57%) 1012 (36.3%) 187 (6.7%) 0.3
Germany 
(n=124)
Pat. 51 (41.1%) 59 (47.6%) 14 (11.3%) 0.002 0.9
Germany 
(n=101)
AD 64 (63.4%) 26 (25.7%) 11 (10.9%) 0.01
Germany 
(n=124)
Pat. 51 (41.1%) 59 (47.6%) 14 (11.3%) 0.004 0.9
Germany 
(n=175)
ALC 106 (60.6%) 56 (32%) 13 (7.4%) 0.4
Genotype distribution of rs12688220 (MORC4) in female ACP patients and controls from Europe and 
summarized for all investigated samples. At the bottom of the table comparison between German ACP 
patients and patients with ALC or AD are presented. Calculations were performed using the Chi-square 
test. Abbreviations: ACP=alcoholic chronic pancreatitis, AD=alcohol dependence, ALC=alcoholic liver 
cirrhosis, ID=identification, Con.=controls, Pat.=patients, HWE=Hardy-Weinberg disequilibrium (p-value).
Figure 7  
Meta-analysis results for rs12688220 (MORC4) in patients with non-alcoholic chronic pancreatitis (NACP). 
Results are presented in a semi-log scale. Y-axis intersects x-axis at 1.
Table 12  Allele distribution of rs12688220 (MORC4) in male NACP patients
Country ID C T p-value
Germany (n=334) Pat. 222 (67.9%) 105 (32.1%) 0.09
Germany (n=1222) Con. 908 (74.3%) 314 (25.7%)
France (n=210) Pat. 158 (75.2) 52 (24.8%) 0.6
France (n=552) Con. 404 (73.2%) 148 (26.8%)
Netherlands (n=47) Pat. 28 (59.6%) 19 (40.4%) 0.08
Netherlands (n=163) Con. 123 (75.4%) 40 (24.5%)
All (n=591) Pat. 414 (70.1%) 177 (29.9%) 0.1
All (n=1937) Con. 1435 (74.1%) 502 (25.9%)
Allele distribution of rs12688220 (MORC4) in male NACP patients and controls from Germany, France, 
and The Netherlands, and summarized for all investigated samples. Calculations were performed using 
the Chi-square test. Abbreviations: NACP=non-alcoholic chronic pancreatitis, ID=identification, 
Con.=controls, Pat.=patients. Note: 6 equivocal genotyped samples were excluded (1 patient group 
(Germany), 5 control group (Germany n=3, Netherlands n=2).
Table 13  Genotype distribution of rs12688220 (MORC4) in female NACP patients
Country ID CC CT TT p-value HWE
Germany 
(n=354)
Pat. 165 (46.6%) 155 (43.8%) 34 (9.6%) 0.002 1.0
Germany 
(n=1614)
Con. 924 (57.2%) 588 (36.4%) 102 (6.3%) 0.8
France 
(n=205)
Pat. 107 (52.2%) 81 (39.5%) 17 (8.3%) 0.9 1.0
France 
(n=512)
Con. 274 (53.5%) 200 (39.1%) 38 (7.4%) 1.0
Netherlands 
(n=39)
Pat. 17 (43.6%) 20 (51.3%) 2 (5.1%) 0.3 0.4
Netherlands 
(n=262)
Con. 131 (50%) 102 (38.9%) 29 (11.1%) 0.4
All (n=598) Pat. 289 (48.3%) 256 (42.8%) 53 (8.9%) 0.01 0.9
All (n=2388) Con. 1329 (55.6%) 890 (37.3%) 169 (7.1%) 0.5
Genotype distribution of rs12688220 (MORC4) in female NACP patients and controls from Germany, 
France, and The Netherlands, and summarized for all investigated samples. Calculations were 
performed using the Chi-square test. Abbreviations: NACP=non-alcoholic chronic pancreatitis, 
ID=identification, Con.=controls, Pat.=patients, HWE=Hardy-Weinberg disequilibrium (p-value).
116 117
CHAPTER 5 POLYMORPHISMS AT PRSS1-PRSS2 AND CLDN2-MORC4 LOCI IN CHRONIC PANCREATITIS
5
Ta
b
le
 1
4 
 M
et
a-
an
al
ys
is
S
N
P
C
ou
nt
ry
P
at
ie
nt
/C
on
tr
ol
s
C
om
p
ar
is
on
p-
va
lu
e
O
R
95
%
 C
I
W
hi
tc
om
b
 e
t a
l
rs
10
27
36
39
PR
S
S1
G
, N
, F
11
86
/1
19
2 
(a
ll)
1 
vs
. 2
2.
3x
10
-9
0.
67
0.
59
-0
.7
7
n.
a.
G
, N
, P
, H
, R
, S
, 
U
K
, F
, I
30
46
/6
59
5 
(a
ll)
1+
2 
vs
. 3
+
4+
5
3.
1x
10
-5
0.
71
0.
61
-0
.8
4
0.
73
, 0
.0
29
G
86
4/
15
30
 (a
ll)
1 
vs
. 3
+
5
9.
7x
10
-1
9
0.
56
0.
49
-0
.6
4
n.
a.
rs
70
57
39
8
R
IP
PL
Y1
G
, N
, F
98
6/
59
2 
(m
al
es
)
1 
vs
. 2
8.
1x
10
-5
1.
69
1.
30
-2
.2
0
n.
a.
G
, N
, P
, H
, R
, S
, 
U
K
, F
, I
21
41
/3
51
6 
(m
al
es
)
1+
2 
vs
. 3
+
4+
5
2.
9x
10
-8
2.
14
1.
64
-2
.8
0
n.
a.
G
73
0/
12
64
 (m
al
es
)
1 
vs
. 3
+
5
1.
7x
10
-1
4
2.
13
1.
76
-2
.5
8
n.
a.
G
, N
, F
18
9/
60
0 
(fe
m
al
es
)
1 
vs
. 2
0.
66
1.
06
0.
81
-1
.3
9
n.
a.
G
, N
, P
, H
, R
, S
, 
U
K
, F
, I
89
3/
30
54
 (f
em
al
es
)
1+
2 
vs
. 3
+
4+
5
0.
00
3
1.
43
1.
13
-1
.8
2
n.
a.
G
12
0/
27
8 
(fe
m
al
es
)
1 
vs
. 3
+
5
0.
01
1.
50
1.
10
-2
.0
4
n.
a.
G
, N
, F
11
75
/1
19
2 
(X
 
in
ac
tiv
at
io
n)
1 
vs
. 2
2.
6x
10
-5
1.
25
1.
13
-1
.3
9
n.
a.
G
, N
, P
, H
, R
, S
, 
U
K
, F
, I
30
34
/6
57
0 
(X
 
in
ac
tiv
at
io
n)
1+
2 
vs
. 3
+
4+
5
2.
4x
10
-1
0
1.
46
1.
30
-1
.6
5
1.
32
, 0
.0
49
G
85
0/
15
42
 (X
 
in
ac
tiv
at
io
n)
1 
vs
. 3
+
5
5.
9x
10
-1
6
1.
46
1.
33
-1
.6
0
n.
a.
G
, N
, F
11
75
/1
19
2 
(n
o 
X 
in
ac
tiv
at
io
n)
1 
vs
. 2
0.
00
03
1.
38
1.
16
-1
.6
4
n.
a.
G
, N
, P
, H
, R
, S
, 
U
K
, F
, I
30
34
/6
57
0 
(n
o 
X 
in
ac
tiv
at
io
n)
1+
2 
vs
. 3
+
4+
5
6.
2x
10
-9
1.
80
1.
47
-2
.1
9
1.
32
, 0
.0
49
G
85
0/
15
42
 (n
o 
X 
in
ac
tiv
at
io
n)
1 
vs
. 3
+
5
3.
9x
10
-1
5
1.
93
1.
64
-2
.2
8
n.
a.
rs
12
68
82
20
M
O
R
C
4
G
, N
, F
99
5/
59
1 
(m
al
es
)
1 
vs
. 2
0.
00
3
2.
00
1.
26
-3
.1
6
n.
a.
G
, N
, P
, H
, R
, S
, 
U
K
, F
, I
21
48
/3
51
6 
(m
al
es
)
1+
2 
vs
. 3
+
4+
5
2.
5x
10
-8
2.
34
1.
74
-3
.1
6
n.
a.
rs
12
68
82
20
M
O
R
C
4
G
74
2/
12
53
 (m
al
es
)
1 
vs
. 3
+
5
2.
46
x1
0-
19
2.
44
2.
00
-2
.9
6
n.
a.
G
, N
, F
19
3/
59
8 
(fe
m
al
es
)
1 
vs
. 2
0.
05
1.
31
1.
01
-1
.7
1
n.
a.
G
, N
, P
, H
, R
, S
, 
U
K
, F
, I
89
6/
30
66
 (f
em
al
es
)
1+
2 
vs
. 3
+
4+
5
0.
00
06
1.
45
1.
18
-1
.8
0
n.
a.
G
12
4/
27
6 
(fe
m
al
es
)
1 
vs
. 3
+
5
0.
00
2
1.
67
1.
22
-2
.3
0
n.
a.
G
, N
, F
11
88
/1
18
9 
(X
 in
ac
tiv
at
io
n)
1 
vs
. 2
0.
00
3
1.
43
1.
13
-1
.8
0
n.
a.
G
, N
, P
, H
, R
, S
, 
U
K
, F
, I
30
44
/6
57
9
 (X
 in
ac
tiv
at
io
n)
1+
2 
vs
. 3
+
4+
5
9.
2x
10
-1
0
1.
55
1.
35
-1
.7
9
1.
38
, 0
.0
54
G
86
6/
15
29
 
(X
 in
ac
tiv
at
io
n)
1 
vs
. 3
+
5
1.
61
x1
0-
21
1.
57
1.
43
-1
.7
2
n.
a.
G
, N
, F
11
88
/1
18
9 
(n
o 
X 
in
ac
tiv
at
io
n)
1 
vs
. 2
0.
00
5
1.
79
1.
20
-2
.6
8
n.
a.
G
, N
, P
, H
, R
, S
, 
U
K
, F
, I
30
44
/6
57
9 
(n
o 
X 
in
ac
tiv
at
io
n)
1+
2 
vs
. 3
+
4+
5
3.
8x
10
-9
1.
94
1.
56
-2
.4
2
1.
38
, 0
.0
54
G
86
6/
15
29
 
(n
o 
X 
in
ac
tiv
at
io
n)
1 
vs
. 3
+
5
1.
34
x1
0-
20
2.
20
1.
86
-2
.6
0
n.
a.
Th
e 
ta
bl
e 
su
m
m
ar
iz
es
 fu
rt
he
r 
m
et
a-
an
al
ys
es
 p
er
fo
rm
ed
 in
 o
ur
 c
oh
or
ts
. T
he
 c
om
pa
ris
on
 b
et
w
ee
n 
al
l A
C
P
 c
oh
or
ts
 (1
) 
an
d 
al
l N
A
C
P
 c
oh
or
ts
 (
2)
 d
em
on
st
ra
te
s,
 th
at
 
de
sp
ite
 fo
r f
em
al
es
 in
 b
ot
h 
X 
ch
ro
m
os
om
al
 S
N
P
s 
th
e 
S
N
P
s 
sh
ow
 a
 s
ig
ni
fic
an
tly
 d
iff
er
en
t d
is
tr
ib
ut
io
n 
in
 th
es
e 
co
ho
rt
s.
 N
ex
t w
e 
ru
le
d 
ou
t t
ha
t t
he
 S
N
P
s 
m
ig
ht
 re
p
re
se
nt
 
A
LC
 o
r 
A
D
 v
ar
ia
nt
s 
(c
om
pa
ris
on
 o
f 
3 
vs
. 
5 
an
d 
3+
5 
vs
. 
4)
 (
da
ta
 n
ot
 s
ho
w
n,
 p
-v
al
ue
 in
si
gn
ifi
ca
nt
). 
To
 m
ak
e 
ou
r 
da
ta
 c
om
pa
ra
bl
e 
to
 t
he
 a
pp
ro
ac
h 
pu
bl
is
he
d 
by
 
W
hi
tc
om
b 
et
 a
l. 
w
e 
co
m
bi
ne
d 
bo
th
 p
at
ie
nt
 c
oh
or
ts
 (1
+
2)
 a
nd
 c
al
cu
la
te
d 
st
at
is
tic
al
 d
iff
er
en
ce
s 
ag
ai
ns
t a
ll 
co
nt
ro
ls
 (3
+
4+
5)
. I
n 
th
e 
la
st
 c
ol
um
n 
th
e 
re
su
lts
 o
f W
hi
tc
om
b 
et
 a
l. 
ar
e 
sh
ow
n 
fo
r 
co
m
pa
ris
on
 (
O
R
, s
e(
O
R
)),
 w
he
re
 c
om
pa
ra
bl
e.
 T
o 
in
cr
ea
se
 p
ow
er
 fo
r 
ca
lc
ul
at
io
ns
 w
ith
 th
e 
A
C
P
 (1
) 
gr
ou
p,
 w
e 
co
m
bi
ne
d 
th
e 
A
LC
 (
3)
 a
nd
 A
D
 (
5)
 
gr
ou
p,
 in
 a
dd
iti
on
. R
es
ul
ts
 a
re
 p
re
se
nt
ed
 s
ep
ar
at
el
y 
fo
r m
al
es
 a
nd
 fe
m
al
es
 a
nd
 w
ith
 a
nd
 w
ith
ou
t X
 in
ac
tiv
at
io
n 
fo
r b
ot
h 
X 
ch
ro
m
os
om
al
 S
N
P
s.
 A
bb
re
vi
at
io
ns
: C
ou
nt
ry
: 
G
=
G
er
m
an
y,
 N
=
N
et
he
rla
nd
s,
 P
=
P
ol
an
d,
 H
=
H
un
ga
ry
, 
R
=
R
om
an
ia
, 
S=
S
pa
in
, 
F=
Fr
an
ce
, 
I=
Ita
ly
; 
C
om
pa
ris
on
: 
1=
A
C
P,
 2
=
N
A
C
P,
 3
=
A
LC
, 
4=
C
on
tro
ls
, 
5=
A
D
; 
n.
a.
=
no
t a
pp
lic
ab
le
.
118 119
CHAPTER 5 POLYMORPHISMS AT PRSS1-PRSS2 AND CLDN2-MORC4 LOCI IN CHRONIC PANCREATITIS
5
Discussion
This case–control study replicates and refines a robust association between a 
PRSS1–PRSS2 locus variant (rs10273639) and CP. This is particularly strong in ACP 
and not apparent in NACP. The effect is independent from alcohol consumption as 
the difference in allele frequency remained upon comparison with other alcohol-related 
disorders (ALC and AD). The risk reduction by rs10273639 was higher in our overall 
ACP cohort (OR 0.63, CI 0.55 to 0.72) compared with the overall GWAS data (OR 
0.73, seOR 0.029), which might be explained by the mixture of different aetiologies of 
patients with CP and RAP in the recent publication.9 When using a comparable 
analysis strategy, similar results were obtained (see Table 14; OR 0.71, CI 0.61 to 
0.84). Thus, the T allele confers protection against the development of ACP, but not 
against NACP. The protective effect of the T allele was observed for all single studies 
except for the samples from Poland. Genetic effect sizes vary between OR=0.41 
(Romania) to OR=1.0 (Poland). However, this can be explained by small sample sizes 
rather than ethnic differences. 
What is the biological background of our findings? The PRSS1–PRSS2 locus SNP 
rs10273639 (c.−408T>C) is located 408 nucleotides upstream of the ATG start codon 
of PRSS1 and as such might influence PRSS1 expression. Indeed, the SNP seems to 
correlate with PRSS1 mRNA levels in 69 pancreas tissue samples pointing towards its 
role in the regulation of PRSS1 expression.9 Trypsinogen expression was lowest in TT 
genotypes, which suggests that this genotype might protect against pancreatitis 
development. However, the normalised gene expression data from pancreatic tissue 
had high SEs and a p-value of 0.01 after removal of two outliers and, therefore, 
probably warrant further evidence to support this assumption.9 In addition, SNPs 
rs2011216 and rs6667 were found to be in linkage disequilibrium with rs10273639 
and as such the biological effect might be related to those or even other SNPs. 
We obtained similar results for the CLDN2–MORC4 locus SNPs. We discovered that 
an association of both the RIPPLY1 and the MORC4 SNP with ACP was present in 
men and in women. Genetic effect sizes in men were somewhat higher than in women 
(OR=2.66 compared with OR=1.71 for MORC4 and OR=2.27 compared with 
OR=1.56 for RIPPLY1), but no significant SNP–sex interactions were found. The 
associations with NACP were weaker throughout and not significant except for the 
RIPPLY1 variant in female patients. 
In older epidemiological studies, it was shown that women developed ACP at an 
earlier age and after consumption of a lower total amount of alcohol than men.19, 20  It 
is a matter of debate whether genetic effects at chromosome X can explain this 
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observation. However, in our study, the genetic effect sizes of men and women were 
not significantly different for the variants considered. Moreover, by comparing models 
with and without assuming X inactivation, we did not receive a clear preference 
towards one of these assumptions. In view of these results, the X chromosomal 
CLDN2-MORC4 locus variants do not even partly explain the higher ACP risk in men. 
The role of CLDN2/RIPPLY1/MORC4 in pancreatitis is less clear. As a tight junction 
protein CLDN2 is involved in low resistance cation-selective ion and water transport 
between endothelial cells.12, 13 The functional consequence of each investigated SNP 
is rather unclear so far. The recent paper proposed an atypical localisation of CLDN2 
in acinair cells and an increase of CLDN2 expression in one investigated CP pancreas 
specimen (cDNA expression level) as well as in Western blot analyses from 19 
pancreas specimens with different genotypes. Both for MORC4 and RIPPLY1 as well 
as for TBC1D8B, another gene within the CLDN2 locus, the recent paper proposed 
no relevance for CP development.
For the X chromosomal variants, the effect sizes were smaller in a recently published 
GWAS.9 Again, this can be explained by the markedly observed stronger genetic 
effect sizes of ACP compared with NACP. 
The aetiology of AD involves environmental and genetic factors. Its heritability is 
estimated at ∼50%.21 Since patients with ACP were compared with controls without 
defined alcohol consumption in our study as well as in the published GWAS, the 
described SNPs might represent markers for alcoholism and not for ACP. However, 
when data of patients with ACP were compared with patients with alcohol-associated 
liver cirrhosis and alcohol dependence in our study, the association of all investigated 
SNPs was replicated with similar effect sizes. Therefore, we conclude that the 
association of the three SNPs is specific for ACP and is unrelated to AD or alcohol- 
related liver disease. 
In summary, our data refine the results of the recently published GWAS. The PRSS1–
PRSS2 rs10273639 T allele protects against development of ACP but not NACP. The 
X chromosomal RIPPLY1 and MORC4 SNPs showed strong association with ACP. For 
NACP, the associations are weaker and only significant for the RIPPLY1 SNP in 
women. 
The variants are not associated with the risk of AD or liver cirrhosis. The observed 
differences in SNP effects between ACP and NACP could be due to interactions of 
variants with alcohol consumption, which would amplify the risk, or they could result 
from differences in the pathophysiology of the two forms of CP. These hypotheses 
warrant future functional investigations.
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Abstract
BACKGROUND
Alterations in the trypsinogen pathway with premature activation of trypsinogen plays 
an important role in the development of chronic pancreatitis (CP). A study with 
Interferon Regulating Factor 2 (IRF2) knockout mice (-/-) showed a significant 
up-regulation of several enzymes in this trypsin pathway causing pancreatitis. 
Trypsinogen 5 (PRSS5), Trypsinogen 3 (PRSS3) and Cathepsin B (CTSB) were al 
up-regulated while the trypsinogen inhibitor Chymotrypsin C (CTRC) was down-
regulated. Further, secretion of zymogens, especially amylase, was significantly 
disturbed. We hypothesize that mutations in the IRF2 gene cause disturbances in the 
trypsinogen pathway and secretion of pancreatic enzymes thereby causing 
pancreatitis. 
METHODS
High resolution melting analysis of all 8 exons of the IRF2 gene was performed in 269 
CP patients. If melting curves deviated from wild type samples, we pursued DNA 
sequencing. For the interpretation of identified genomic variants we compared with 
the ESP6500 whole exome database and the NCBI dbSNP database.
RESULTS
Melting curves of exon 4, 7 and 9 showed a possible change in the melting pattern of 
DNA denaturation. Complete gene sequencing though, only showed 6 different 
single nucleotide variants spread over these 3 exons. Variant rs3775543 in exon 9A 
was found in 163 of 269 patients (60.5%), 38 patients were homozygous (14.9% of all 
rs3775543 variants). Similar frequencies were found in the normal population.
CONCLUSION
We found no functional mutations in the IRF2 gene that could play a role in the 
pathogenesis of pancreatitis.
Introduction 
During the last 2 decades our understanding of the genetic aspects of chronic 
pancreatitis (CP) has improved considerably.1-4 
The trypsinogen cascade has emerged as an important pathway that drives the 
association with hereditary and idiopathic forms of CP. Gain-of-function mutations in 
the cationic trypsinogen gene (PRSS1, HGNC:9475), loss-off-function mutations in 
inhibitory enzymes of this trypsinogen cascade like serine protease inhibitor 
Kazal-type 1 (SPINK1, HGNC:11244) and Chymotrypsin C (CTRC, HGNC:2523) have 
all been identified as important risk modifiers.2, 5, 6  These genes have been discovered 
through classical candidate gene studies. However, now that genome-wide association 
studies have become feasible, the question arises if there is still a need for this 
approach. We hypothesize that a well-designed case control study in an excellent 
phenotyped cohort may assist discovery of alleles that raise CP risk to a moderate 
degree. 
A recent study with Interferon Regulating Factor 2 (IRF2, HGNC:6117) knockout mice 
(-/-) demonstrated three interesting mechanisms that may have an effect on the 
development of pancreatitis in humans; (1) There was up-regulation of Trypsinogen 3 
(PRSS3, HGNC:9486), Trypsinogen 5 (PRSS5) and Cathepsin B (CTSB, HGNC:2527) 
which mirrored a down-regulation of trypsinogen inhibitor CTRC. (2) There was 
impaired cellular secretion of pancreatic zymogens such as amylase, causing in-
tra-pancreatic auto-digestion. (3) There were changes in the caspase pathway 
causing apoptosis of the cell.7 
Interferon regulating factors (IRF’s) regulate Interferons (IFN) and have a role in 
immune responses, immune modulation, hematopoietic differentiation and cell 
growth.8-12  There are 10 IRF genes (IRF 1-10) in which IRF2 is a negative regulator of 
IFN alpha/beta induced gene transcription that is needed for an optimal balance 
between the beneficial and harmful effects of IFN-alpha/beta signalling in the immune 
system.13 
Further, IRF2 expression is elevated in histopathological specimens of pancreatic 
cancer.14 
We hypothesize that loss-of-function mutations in the IRF2 gene, similar to IRF2 
knock-out-mice, cause disturbances in the trypsinogen pathway but also activation 
of cellular apoptosis leading to pancreatitis, and thereby contribute to the risk of 
human CP.
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Material and methods
Study subjects
A total of 269 Dutch patients with different aetiologies of CP were included from our 
CP database. This CP database consists of patients that visited our outpatient clinic 
of the Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, 
The Netherlands. Informed consent was obtained from patients prior to enrolment. 
The study protocol was approved by the medical ethical review committee of the 
University of Nijmegen (The Netherlands).
The clinical diagnosis of CP is based on 2 or more of the following criteria: presence of 
a typical history of recurrent pancreatitis, radiological findings such as pancreatic 
calcifications and/or pancreatic ductal irregularities revealed by endoscopic retrograde 
pancreaticography or magnetic resonance imaging of the pancreas and/or pathological 
sonographic findings. Hereditary CP was diagnosed when 2 first-degree relatives or 
3 or more second-degree relatives have recurrent acute pancreatitis (AP) or CP 
without any apparent precipitating factor. Alcohol- induced CP was diagnosed in 
patients who consumed more than 60 g (women) or 80 g (men) of ethanol per day for 
more than 2 years. Patients were classified as having ICP when precipitating factors 
such as alcohol abuse, trauma, medication, infection, metabolic disorders, and/or a 
positive family history were absent.
The study population consisted of the following origins: 100 patients with alcoholic 
CP (median age 61 years, range 43-84 years), 40 patients with hereditary CP (median 
age 46 years, range 22-100 years), 128 patients with idiopathic CP (median age 56, 
range 18-85 years). 
Strategy
We applied the following strategy; (Figure 1) All 269 CP patients were analysed with 
high resolution melting (HRM) analysis for genetic alterations in the 9 exons of the 
IRF2 gene open reading frame. Melting curves were compared to wild-type. Samples 
that gave rise to deviating melting curves were subsequently re-analysed by Sanger 
sequencing which allowed identification of SNPs. The frequency of these SNPs in the 
normal population was established through publicly available websources as the 
Exome Variant Server (ESP6500) (http://evs.gs.washington.edu/EVS) that contains 
genetic data on 6503 healthy individuals, and by using data from European ancestry 
populations derived from the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/ 
projects/SNP/).
Primer selection and testing
The IRF2 gene contains 9 exons and is located on chromosome 4, location 4q34.1-q35.1. 
Selection of primers was performed by using Exonprimer (Institute for Human genetics, 
Technical University, München, Germany) and checked for SNP’s by SNPchecker 
(NGRL, Manchester, United Kingdom). (Table 1) 
Primers were synthesized by Sigma Aldrich (St. Louis, MO) (Table 2). Optimal 
conditions for the primers were tested by polymerase chain reaction (PCR) using; 0.1 
µg DNA, 2.5 U Taq DNA-polymerase, 0.5 mM dNTPs, variable MgCl2 concentrations, 
0.2 nM Forward-primer and Reverse-primer in a total volume of 25 µL. (Table 1) Cycle 
conditions were an initial denaturation for 5 minutes at 95ºC followed by 40 cycles of 
30 seconds denaturation at 95ºC, 30 seconds annealing at temperatures between 55 
and 65 ºC, 30 seconds primer extension at 72ºC and a final extension for 7 minutes 
at 72ºC in an automated thermal cycler (Biorad Laboratories, Hercules, CA).  
High resolution melting (HRM) and DNA sequencing
Genomic DNA from subjects was extracted from peripheral blood leukocytes using 
the High Pure PCR Template Preparation Kit (Roche, Penzberg, Germany) according 
to standard protocols. The complete IRF2 gene was analysed for mutations by using 
a HRM analysis with pre-amplification of the samples in the Qiagen Rotor-Gene Q 
instrument (Qiagen, Hilden, Germany). 
Pre-amplification included an initial hold for 3 minutes at 95 ºC, followed by 45-65 
cycles of 30 seconds denaturation at 95 ºC, 30 seconds annealing at temperatures 
specific tested for each primer (58.8-64.3 ºC) and 30 seconds primer extension at 72 ºC. 
This was followed by a hold for 60 seconds at 95 ºC and a hold for 60 seconds at 
Figure 1  Flow chart for study strategy
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40 ºC. HRM followed with an initial temperature of 65 ºC, rising with 0.1ºC each step 
until a final temperature of 95 ºC was reached.Melting curves where analysed using 
Rotor-Gene ScreenClust HRM Software (Qiagen). If melting curves deviated from 
wild type samples, we pursued DNA sequencing. Sequencing was performed using 
the BigDye terminator kit and an ABI3730 capillary sequencer (Perkin Elmer Applied 
Biosystems, Boston, MA, USA). 
Table 1  SNP’s in IRF2 gene primer region
Exon Position in gene Detected SNP’s
2 195..287 rs147121139 
rs140625015 
rs151317536 
rs142409473 
3 288..387 -
4 388..564 rs148758064
rs146592173
rs144286568
rs139554090
5 565..611 -
6 612..729 rs146296001
rs149340805 
rs139625773 
7 730..894 rs150575776
rs141757669 
rs73005101 
rs187952756 
rs146966318 
8 895..941 rs77140332 
9 942..2286 rs3775543 
rs145785841
rs189887691 
rs149022805
rs145867709 
rs150270491
rs141066995
rs59219184
rs144326969
rs139637849
rs150796036
http://www.ncbi.nlm.nih.gov/nuccore/NM_002199.3 
http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?showRare=on&chooseRs=all&go=Go&lo-
cusId=3660
Table 2  Primers for high resolution melting analysis
Exon Primer sequence Optimal 
MgCl2 Conc.
Optimal 
anneal.
Temp.
Exon 2
Forward primer
TGCAGTGCAGACACCACAC 2 mmol 61.1 ºC
Exon 2
Reverse primer
CACACATACACCCACCCTGA 2 mmol
Exon 3
Forward primer
TGCTGGCTAGACCTTCACAA 2 mmol 64.3 ºC
Exon 3
Reverse primer
AAGCAAGAGTGCCTTCCTCT 2 mmol
Exon 4
Forward primer
TTTCCAGAAATTCCTTCCTCTG 2 mmol 58.8 ºC Additional 
DMSO
Exon 4
Reverse primer
GAAGAGATCACGAAGGCACG 2 mmol
Exon 5
Forward primer
TCTCTGGAGGCCCTTCG 2 mmol 61.1 ºC
Exon 5
Reverse primer
CCCAACTTTGGCTTTCTCTC 2 mmol
Exon 6
Forward primer
CAGCTAAGAGAAGGGAGGGG 2.5 mmol 63 ºC
Exon 6
Reverse primer
AGGGGGCTGCTGGTATGTAT 2.5 mmol
Exon 7
Forward primer
GGCTCTTTTGGGGAAGACTC 2 mmol 63 ºC
Exon 7
Reverse primer
TGGGTGACCCTAGACCAAAG 2 mmol
Exon 8
Forward primer
TTGAGGGACAGGAATGATGG 2 mmol 61.1 ºC
Exon 8
Reverse primer
CTTTTCCTTGGCAGCATCG 2 mmol
Exon 9 part 1
Forward primer
CCAATAGAAGGAGAAGGAAATACA 2 mmol 58.8 ºC
Exon 9 part 1
Reverse primer
TGCTCTCCTCTTTGATGGTG 2 mmol
Exon 9 part 2
Forward primer
CGTCCTTCGTCACTTCCAAC 2 mmol 63  ºC
Exon 9 part 2
Reverse primer
AAGAAGCCCCAACAACCAC 2 mmol
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Statistics
Descriptive analysis and the Chi-square test was performed using SPSS Statistics for 
Windows, Version 17.0. Chicago: SPSS Inc. 
Results
IRF2 variant detection through high resolution melting analysis  
and gene sequencing
All 269 CP patients were analysed with HRM analysis for variants in each of the 9 
exons that cover the IRF2 gene. A deviation in the melting curves from curves 
produced by wild-type samples was detected for the primer set that covered exon 2 
(n=30 patients), exon 3 (n=23 patients), exon 4 (n=48 patients), exon 5 (n=26 
patients), exon 6 (n=18 patients), exon 7 (n=33 patients), exon 9A (n=173 patients) 
and exon 9B (n=33 patients) and samples were submitted for subsequent Sanger 
sequencing. 
Sequencing of these exons led to identifications 6 different SNP’s in 4 different exons; 
rs17488241 in exon 4 (n= 34), rs74960894 in exon 7 (n=6; 1/6  homozygous), 
rs113848358 in exon 7 (n=2), rs3775543 in exon 9A (n=163;  38/163 homozygous), 
rs3775544 in exon 9A (n=1, homozygous), rs150796036 in exon 9B (n=6). An 
overview of the analysed exons, the detected SNP’s in relation to the cause of CP and 
the mean age is depicted in Table 3. 
Whole exome and NCBI dbSNP database
With the ESP6500 whole exome database (http://evs.gs.washington.edu/EVS/) we 
created an overview for IRF2 gene variants that are present in the normal population. 
Figure 2 shows how mutations in the IRF2 gene are clustered; The upper and lower 
row show the presence of missense mutations and synonymous variants respectively, 
the x-axis represents the coding sequence of the IRF2 gene and the y-axis the 
frequency of the detected mutation. Further, the third row shows that an IRF-tryptophan 
pentad repeat is located at the 5’ end of the IRF2 gene. All members of the IRF family 
share this region at the N-terminal site that serves as a DNA binding domain (DBD). 
This DBD displays a unique helix-turn-helix structure with a cluster of five highly 
conserved tryptophan residues.15, 16  
These residues have a specific affinity for interferon stimulatory response elements 
(ISRE’s) located in the promoter regions of several immune-related genes like for 
example Il-7.16 Based on the ranking of the number of rare non-synonymous variants 
per rare synonymous variants present in the ESP database of 18.424 genes, IRF2 
belongs to the 5% most intolerant genes. Genes that are intolerant to variation are 
more likely to be disease associated than other genes.17, 18  
Using the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/ projects/SNP/) it 
became clear that for all of the frequencies of all 6 SNPs, frequencies were comparable 
between samples from CP patients and normal population from European ancestry. 
(Figure 3) 
For example, rs17488241 (exon 4) is present in a frequency of 12.40% in CP patients which 
equals the frequency of 12.64 % in the normal population. Similarly, rs3775543 is 
present at comparable rates in CP patients and controls (46.47% vs. 42.00%). 
Figure 2  Distribution of mutations in the IRF2 gene
The upper and lower row show the presence of missense mutations and synonymous variants in the 
ESP6500 dataset (http://evs.gs.washington.edu/EVS/) respectively, the x-axis represents the location in the 
IRF2 gene and the y-axis the frequency of the detected mutation. The second row shows 2 mutations that 
are associated with the development of hepatocellular carcinoma; IRF2 c.412--∼6_419del and IRF2 
c.409A>C. The third row shows an IRF-tryptophan pendtad repeat that is located at the 5’ end of the IRF2 
gene.
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Table 3  Analysed exons and detected SNP’s in relation to the cause of CP
Exon Samples 
sequenced
SNP’s Causes of CP Mean age 
(range)N
Exon 2 30 No SNP’s found Alcohol 7 57.0 (44-67)
Hereditary 4 37.5 (27-43)
Idiopathic 19 56.2 (33-85)
Total 30 54.5 (27-85)
Exon 3 23 No SNP’s found Alcohol 8 56.8 (45-67)
Hereditary 4 38.8 (23-62)
Idiopathic 11 60.6 (33-85)
Total 23 55.3 (23-85)
Exon 4 48 No SNP found Alcohol 5 59.8 (53-67)
Hereditary 4 38.0 (24-58)
Idiopathic 5 57.8 (43-69)
Total 14 52.8 (24-69)
rs17488241 Alcohol 11 62.5 (45-77)
Hereditary 5 53.6 (27-93)
Idiopathic 18 61.2 (31-77)
Total 34 60.1 (27-93)
Exon 5 26 No SNP’s found Alcohol 6 61.7 (52-84)
Hereditary 6 38.5 (24-63)
Idiopathic 14 53.0 (25-75)
Total 26 51.7 (24-84)
Exon 6 18 No SNP’s found Alcohol 5 68.0 (61-80)
Hereditary 3 42.7 (27-58)
Idiopathic 10 49.7 (33-75)
Total 18 53.6 (27-80)
Exon 7 33 No SNP found Alcohol 10 62.6 (48-72)
Hereditary 4 47.8 (27-93)
Idiopathic 11 48.9 (31-70)
Total 25 55.5 (27-93)
rs74960894 Alcohol 2 74 (68-80)
Hereditary 0 -
Idiopathic 3 51.3 (32-65)
Total 5 60.4 (32-80)
rs74960894 
homozygous
Alcohol 0 -
Hereditary 0 -
Idiopathic 1 75
Total 1 75
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Discussion 
The key finding in our study is that variants in the IRF2 gene are not associated with 
CP. We identified 6 SNP s´, distributed over 4 exons in 269 CP patients, in frequencies 
comparable to the normal population. 
As illustrated by data from the whole exome database it is clear that the IRF2 gene 
does not tolerate much variation. 
 
The IRF2 gene was chosen as a promising candidate gene based on an experimental 
study in IRF2 knockout mice (-/-).7 
We were not able to translate the findings of this animal model to possible genetic 
alterations in the human IRF2 gene that could cause or influence the development of 
CP. This accords with a recent GWA study performed in pancreatitis patients that 
excludes the IRF2 gene locus as a susceptibility locus.19 (http://www.gwascentral.org/
study/HGVST1450/view#)
The fact that we did not detect any disease-related mutations may be caused by 
some limitations of our study. First of all, we selected and tested a candidate gene 
based on the results of an animal model although the trypsinogen genes of the 
mouse are not comparable with the trypsinogen genes of the human. 
The mouse has 20 trypsinogen genes (T1-T20) were only 12 express a trypsinogen 
protein, while the human gene only contains 3 trypsinogen genes (PRSS1, PRSS2 
and PRSS3).7 It was stated that the PRSS5 gene of the mouse is similar to the human 
PRSS3 gene based on the structural characteristics but we should be careful with 
extrapolating data from mice studies because despite large similarities there are also 
large differences in physiological mechanisms.20, 21 Another limitations is that we only 
searched for SNP’s in the coding regions of the IRF2 gene, but it could also be 
possible that the increased expression is caused by alterations in for example 
non-coding regions like the promoter region. 
Further, it is also possible that not the IRF2 gene is of importance here, but another 
gene that is highly regulated by IRF2 or that regulates IRF2 itself. Many physical 
pathways are influenced by several different genes that all separately contribute only 
to a small amount of the overall risk. These highly complex interactions make it 
difficult to identify single genetic variants that contribute independently to these 
pathways unless the study population is very large. 
Here we tested only a relatively small cohort of Dutch CP patients what might result in 
a type 2 error in determining associated risk factors. Expanding the pool of patients 
or analysing another cohort of patients may identify rare IRF2 variants that are 
associated with CP. 
Table 3  Continued
Exon Samples 
sequenced
SNP’s Causes of CP Mean age 
(range)N
Exon 7 33 rs113848358 Alcohol 0 -
Hereditary 1 91
Idiopathic 1 53
Total 2 72.0 (53-91)
Exon 8 12 No SNP’s found Alcohol 5 63.4 (52-70)
Hereditary 1 93
Idiopathic 6 49.4 (32-70)
Total 12 58.8 (32-93)
Exon 9A 173 No SNP found Alcohol 1 61
Hereditary 0 -
Idiopathic 8 58.4 (32-76)
Total 9
rs3775543 Alcohol 37 60.1 (43-80)
Hereditary 19 44.5 (22-100)
Idiopathic 69 55.8 (25-84)
Total 125 55.4 (22-100)
rs3775543 
homozygous
Alcohol 16 61.9 (45-70)
Hereditary 4 49.5 (27-91)
Idiopathic 18 55.3 (18-82)
Total 38 57.8 (18-91)
rs3775544 
homozygous
Alcohol 1 64
Hereditary 0 -
Idiopathic 0 -
Total 1 64
Exon 9B 33 No SNP found Alcohol 11 57.4 (45-75)
Hereditary 4 51.5 (32-93)
Idiopathic 12 59.1 (33-76)
Total 27 56.2 (32-93)
rs150796036 Alcohol 2 54.0 (45-63)
Hereditary 0 -
Idiopathic 4 65.7 (52-78)
Total 6 60.5 (18-100)
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The distinction with other case control studies is that we used a whole exome 
sequencing database as a “control” population to establish the prevalence of IRF2 
gene variants in the normal population. The availability of these genomic datasets 
obviates screening of large numbers of controls. What could be an interesting and 
new approach for future research in genetics and CP, is a search for genomic and 
transcriptomic composition of individual pancreatic cells. Until now, conventional 
sequencing studies rely on DNA and/or RNA extracted from blood. This is a rather 
one-dimensional approach which assumes that the genome is “static” throughout 
life. We know that genetic mutations arise with every cell division giving rise to 
genomic heterogeneity (somatic variation).22 Recent data suggest that there is an 
appreciable rate of  somatic variation than previously expected.23 This might signal 
the change of focus away from the germline to a more cellular and organ driven 
search for causative genomic alterations as well as changes in epigenetic status and 
gene expression. 
In conclusion, we did not establish an association for the IRF2 gene with CP. Although 
data obtained from studies with IRF2 (-/-) knockout-mice and data from studies with 
pancreatic cancer fuelled our hypothesis that IRF2 is a promising candidate gene, 
case control study rules this out.
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Abstract
Chronic pancreatitis is a progressive inflammatory disorder of the pancreas which 
often develops as a result of genetic predisposition. Some of the most frequently 
identified risk factors affect the serine protease inhibitor Kazal type 1 (SPINK1) gene 
which encodes a trypsin inhibitor responsible for protecting the pancreas from 
premature trypsinogen activation. 
Recent genetic and functional studies indicated that promoter variants in the SPINK1 
gene might contribute to disease risk in carriers. Here, we investigated the functional 
effects of 17 SPINK1 promoter variants using luciferase reporter gene expression 
assay in four different cell lines, including three pancreatic acinair cell lines (rat AR42J 
with or without dexamethasone-induced differentiation and mouse 266-6) and HEK 
293T cells. 
We found that most variants caused relatively small changes in promoter activity. 
Surprisingly, however, we observed significant variations in the effects of the promoter 
variants in the different cell lines. Only four variants exhibited consistently reduced 
promoter activity in all acinair cell lines, confirming previous reports that variants 
c.-108G>T, c.-142T>C, and c.-147A>G are risk factors for chronic pancreatitis and 
identifying c.-52G>T as a novel risk variant. In contrast, variant c.-215G>A, which is 
linked with the disease-associated splice-site mutation c.194+2T>C, caused 
increased promoter activity, which may mitigate the overall effect of the pathogenic 
haplotype. 
Our study lends further support to the notion that sequence evaluation of the SPINK1 
promoter region in patients with chronic pancreatitis is justified as part of the 
etiological investigation.
Introduction
Chronic pancreatitis is a progressive inflammatory disorder of the pancreas leading 
to acinair cell loss, fibrosis and impaired pancreatic function. Clinically, disease 
manifestations involve recurrent acute attacks which can progress to chronic disease 
with maldigestion, chronic pain, diabetes mellitus and increased risk for pancreatic 
cancer.1, 2 Chronic pancreatitis frequently develops on the basis of genetic susceptibility. 
Mutations in PRSS1 (human cationic trypsinogen), SPINK1 (serine protease inhibitor 
Kazal type 1), CTRC (chymotrypsin C), CPA1 (carboxypeptidase 1) and CFTR (cystic 
fibrosis transmembrane conductance regulator) can act as predisposing factors.3-6 
Chronic pancreatitis is a complex genetic disease and patients may carry several 
mutations in various susceptibility genes.
The SPINK1 gene (OMIM 167790) encodes pancreatic secretory trypsin inhibitor, a 
~6 kDa protein secreted by the pancreatic acinar cells which inhibits auto-activation 
of trypsinogen within the pancreas and thereby protects against pancreatitis.7 SPINK1 
is also expressed in extra-pancreatic tissues and various malignancies.7, 8 Mutation 
p.N34S in the SPINK1 gene was first described in 2000 and its association with 
chronic pancreatitis was demonstrated in the same year.9-11 
A large number of subsequent studies confirmed that p.N34S is a relatively strong 
and frequent (odds ratio ≥10; occurrence ≥10%) risk factor for familial, idiopathic and 
tropical chronic pancreatitis; even in alcoholic chronic pancreatitis it plays a lesser 
but still significant role.4, 7, 12 Even though p.N34S was presumed to cause a loss of 
function, the exact mechanism of action has never been identified, as no functional 
defect was demonstrated for p.N34S or any of the four intronic variants associated 
with this haplotype.13-18  In contrast, an unambiguous loss of function phenotype was 
evident for variant c.194+2T>C,4, 11, 19 the second most frequent SPINK1 mutation that 
affects a splice site in intron-3 and causes exon skipping with markedly reduced 
SPINK1 mRNA expression.15, 20 This intronic mutation is in complete linkage 
disequilibrium (i.e. found together) with the promoter variant c.-215G>A. Studies 
worldwide identified a large number of rare or private missense SPINK1 variants which 
caused loss of secretion of the SPINK1 protein either due to misfolding or impaired 
function of the secretory signal peptide.13, 16, 21, 22 Other rare genetic changes resulting in 
loss of function were also found in patients with chronic pancreatitis such as frame-shift 
mutations, splice site mutations, deletion of the SPINK1 gene or mutation of the translation 
initiation codon.23 Variants of unknown significance were also detected in the 
promoter region of SPINK1 by multiple studies. 
In 2011 Boulling et al.23 performed re-sequencing of the proximal promoter region in 
French, German and Indian patients and controls, together with functional analysis 
of 11 promoter variants. 
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Using a luciferase reporter gene expression assay followed by EMSA analysis they 
found that variants c.-53C>T, c.-142T>C and c.-147A>G caused reduced promoter 
activity while variants c.-81C>T and c.-215G>A increased activity in COLO-357 cells, 
a human cell line derived from the metastasis of a pancreatic adenocarcinoma. The 
authors proposed that variants that decrease promoter activity are likely risk factors 
for chronic pancreatitis, whereas gain-of-function variants may have a protective effect. 
More recently, the Hungarian Pancreatic Study Group published promoter sequencing 
data for their chronic pancreatitis cohort and performed limited functional analysis on 
newly identified variants using dexamethasone-differentiated AR42J rat acinair cells.24 
Statistically significant decreases in promoter activity were reported for variants 
c.-14G>A, c.-108G>T and c.-246A>G, whereas variant c.-215G>A showed 2-fold 
increased activity.
The present study was undertaken to confirm and extend previous observations in an 
attempt to clarify which SPINK1 promoter variants might be true risk factors for chronic 
pancreatitis. Because reporter gene analysis inherently suffers from methodological 
uncertainties related to selection of cell line and the arbitrary nature of the promoter 
segment studied, we sought to investigate the reproducibility of published data in 
multiple cell lines. Furthermore, compared to the 11 variants examined by Boulling 
et al.23, we studied a total of 17 variants including six variants published recently.
Materials and methods
Nomenclature 
Nucleotide numbering reflects coding DNA numbering with c.1 corresponding to the 
first nucleotide of the translation initiation codon. Promoter variants were numbered 
relative to the first nucleotide upstream of the initiation codon, which was designated 
c.-1. The genomic reference sequence used for SPINK1 was from NC_000005.9, the 
Homo sapiens chromosome 5, GRCh37.p13 primary assembly.
Construction of luciferase reporter plasmids harbouring  
the SPINK1 promoter
The DNA sequence between c.-541 and c.35 of the SPINK1 gene was cloned into the 
pGL3-Basic vector (Promega, Madison, Wisconsin) upstream of the firefly luciferase 
reporter gene using restriction sites KpnI and HindIII. 
This plasmid was designated pGL3-SPINK1. Promoter variants were generated by 
overlap extension PCR mutagenesis and cloned into the pGL3-SPINK1 plasmid. 
Note that the same construct was used recently by Hegyi et al.,24 whereas Boulling 
et al.,23 used a promoter sequence corresponding to the region from c.-1171 to c.-1 
of the SPINK1 gene. 
Cell culture and transfection
AR42J rat pancreatic acinair cells were obtained from ATCC (Manassas, Virginia; 
catalog CRL-1492) and used with or without dexamethasone-induced differentiation. 
The mouse 266-6 pancreatic acinair cell line was purchased from ATCC (catalog 
CRL-2151) and human embryonic kidney (HEK) 293T cells were from GenHunter 
Corporation (Nashville, Tennessee; catalog Q401). 
Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, 
Grand Island, New York) supplemented with 4 mM glutamine, 1% penicillin/
streptomycin and fetal bovine serum (10% for HEK 293T and 266-6, 20% for AR42J, 
purchased from Life Technologies). Before transfections, cells were seeded into 
six-well plates at a density of 1.5 million cells per well (HEK 293T and 266-6) or 1 
million cells per well (AR42J) and incubated overnight. For dexamethasone-differen-
tiated AR42J cells, treatment was performed with 100 nM dexamethasone for 48 hour 
before transfection. Transfection medium was prepared by mixing 10 µL Lipofectamine 
2000 (Life Technologies) with 2 µg pGL3-SPINK1 plasmid and 10-40 ng pRL-SV40 
renilla luciferase plasmid (Promega) in 0.5 mL OPTI-MEM medium (Life Technologies) 
and incubating the mixture for 20 min at 22 oC. Transfection was carried out by 
substituting 0.5 mL from the 2 mL DMEM medium covering the cells with the 
transfection mix. 
After incubation overnight (18 hour), the transfection medium was removed, cells 
were rinsed, covered with 2 mL OPTI-MEM medium and incubated for 30 h before 
assaying luciferase expression. For dexamethasone-differentiated AR42J cells the 
OPTI-MEM medium contained 100 nM dexamethasone.
Dual luciferase reporter gene assay
At 48 hour after transfection, cells were rinsed with phosphate-buffered saline, 
overlaid with 500 µL passive lysis buffer (Promega) and scraped from the culture 
plates. The cell suspension was then subjected to a freeze-thaw cycle in liquid 
nitrogen and incubated for 15 min at 22 oC. Cell debris was pelleted by centrifugation 
(10,000 rpm, 30 seconds) and the supernatant was collected for luciferase activity 
assay. Luciferase expression was measured using the Dual-Glo Luciferase Assay 
System (Promega). 
Aliquots of cell extracts (20 µL) were mixed with 100 µL Luciferase Assay Reagent II 
and the luminescence was measured with a Veritas luminometer (Turner Biosystems 
Inc., Sunnyvale, California, USA). After recording the firefly luciferase activity, renilla 
luciferase was measured by adding 100 µL Stop and Glo Reagent. Relative luciferase 
activity was determined by dividing the firefly and renilla luciferase luminescence 
results and expressing this firefly/renilla ratio as percent of the wild-type pGL3-SPINK1 
value.
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Statistical analysis
We used Student’s t-test to evaluate the statistical significance of the differences in 
activity between promoter variants and the wild-type SPINK1 promoter. A p-value less 
than 0.05 was considered significant.
Results
SPINK1 promoter variants studied
As shown in Table 1 and Figure 1, in our study we included SPINK1 variants that were 
found upstream of the translation initiator codon and were reported in a peer-reviewed 
publication. For simplicity, we refer to all variants collectively as promoter variants 
throughout the paper, even though some are located in the 5’ untranslated region of 
the mRNA. Variants listed in databases but not described in the scientific literature 
were excluded. All in all, 17 variants were studied; including all 11 variants investigated 
by the 2011 study by Boulling et al.23 and the three new variants recently characterized 
by the Hungarian Pancreatic Study group.24
Assessment of SPINK1 promoter activity using luciferase reporter 
gene expression 
The aim of our study was to evaluate whether the routinely used reporter gene 
expression methods are able to predict the functional and clinical effects of SPINK1 
promoter variants. To this end, we constructed an expression plasmid harbouring the 
sequence region between c.-541 and c.35 of the SPINK1 gene, placed upstream of 
the firefly luciferase reporter gene (pGL3-SPINK1). This expression plasmid was used 
to transfect various cell lines and promoter activity was then estimated by measuring 
luciferase expression levels using a luminescence assay. 
The study by Boulling et al. (2011) used the COLO-357 human pancreatic cancer cell 
line which expresses pancreatic digestive enzymes. The authors observed 11-fold 
increased expression of luciferase in this cell line driven by the SPINK1 promoter 
Figure 1  
The SPINK1 promoter sequence used in this study as cloned into the pGL3-Basic plasmid. The sequence 
corresponds to the region from c.-541 to c.35 of the human SPINK1 gene. The positions of the promoter 
variants are underlined and emboldened. The original SPINK1 translation initiation codon is highlighted in 
green. Note that this codon is not in frame with the downstream luciferase start codon. The major transcriptional 
start site at c.-60 is shown in red. Binding sites for transcription factors HNF-1 and PTF1 are indicated in blue 
and grey, respectively.
Table 1  SPINK1 promoter variants studied
Variant CP carriers Control carriers References
c.-2C>A 1 0 25
c.-7T>G 5 8 26
c.-14G>A 1 0 24
c.-22C>T 1 4 9, 10, 23, 27 
c.-41G>A 10 3 9, 25, 28 10, 27  
c.-52G>T 1 0 19
c.-53C>T 2 1 11, 19, 23   
c.-81C>T 1 0 27     
c.-108G>T 1 0 24     
c.-142T>C 5 0 23, 27          
c.-147A>G 7 1 23, 27          
c.-164G>C 5 14 23, 26       
c.-170G>A 1 0 23         
c.-215G>A 45 (11 homozygous) 4 18-20, 23, 24, 26, 29-34 
c.-215G>T 3 0 23, 25    
c.-246A>G 1 0 24
c.-253T>C common variant common variant 9, 11, 24, 26, 28, 29, 31, 35-38 
SPINK1 promoter variants studied. Note that variant c.-41G>A is in linkage with variant c.174C>T 
(p.C58=) in exon-3 and variant c.-215G>A is linked with pathogenic variant c.194+2T>C in intron-3. 
The 45 reported carriers for variant c.-215G>A included 11 homozygous (hm) subjects. CP, chronic 
pancreatitis.
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relative to the promoterless pGL3-Basic construct, whereas no increase was detected 
in HEK 293 cells.23 
In the present study we used four different cell lines, the rat acinair cell line AR42J with 
or without dexamethasone-induced differentiation, the mouse acinair cell line 266-6 
and the human embryonic kidney cell line HEK 293T. 
These cell lines are well characterized, widely used and readily available from 
commercial sources. AR42J and 266-6 cells express digestive enzymes and we 
confirmed the presence of trypsinogen and chymotrypsinogen in the conditioned 
medium (data not shown). Dexamethasone treatment induces up-regulation of the 
secretory pathway in AR42J cells with expansion of the endoplasmic reticulum, 
appearance of zymogen granules and increased digestive enzyme secretion.39 In 
contrast, HEK 293T cells do not secrete pancreatic enzymes. When the four cell lines 
were transfected with pGL3-SPINK1 or the promoterless pGL3-Basic plasmid and 
luciferase expression was compared, AR42J acinair cells grown in the absence or 
presence of dexamethasone expressed about 13-fold and 17-fold higher luciferase 
levels, respectively, driven by the SPINK1 promoter, whereas luciferase expression in 
266-6 cells and in HEK 293T cells was increased about 4-fold over control. (Figure 2)
Effect of SPINK1 promoter variants on luciferase expression 
Results for the functional analysis of SPINK1 promoter variants in four different cell 
lines are shown in Table 2 and Figures 3 and 4. Consistently with the observations by 
Boulling et al.,23 most variants caused minor, less than 2-fold changes in promoter 
activity and even the largest effect was less than 6-fold. 
Surprisingly, significant variations were detected in the effect of the promoter variants 
among the four cell lines tested and variability remained apparent even among the 
three acinair cell lines or between AR42J cells grown in the absence or presence of 
dexamethasone. 
Figure 2  Luciferase reporter gene expression by the SPINK1 promoter
The indicated cell lines were transfected with the pGL3-SPINK1 plasmid or the promoterless pGL3-Basic 
plasmid and luciferase expression was determined as described in Materials and Methods. The ratios of the 
luciferase activities (SPINK1 over control) are indicated as fold change with pGL3-Basic values arbitrarily set 
at unity. Average values ± S.D. (n = 10-45 transfections) are shown. Note that measured firefly luciferase 
activities varied among cell lines; typical values with pGL3-Basic transfections were in the 10,000-50,000 
relative light units range for AR42J, AR42J+dexa and 266-6 cells while about 2-7 million relative light units 
were detected with HEK 293T cells. Dexa, dexamethasone.
Table 2  Effect of SPINK1 promoter variants on luciferase expression (%)
Cell-lines
AR42J AR42J + dexa. 266-6 HEK 293T COLO-357
wild type 100 100 100 100 100
c.-2C>A 128 54 126 115 ND
c.-7T>G 151 118 88 76 97
c.-14G>A 147 80 118 108 ND
c.-22C>T 107 46 133 127 103
c.-41G>A 240 57 104 109 98
c.-52G>T 85 20 68 81 ND
c.-53C>T 145 31 72 64 75
c.-81C>T 177 45 85 104 130
c.-108G>T 72 31 74 136 ND
c.-142T>C 25 13 66 213 67
c.-147A>G 17 11 35 77 56
c.-164G>C 119 95 127 224 101
c.-170A>G 122 118 106 87 93
c.-215G>A 136 201 162 561 123
c.-215G>T 94 50 114 256 104
c.-246A>G 109 53 119 96 ND
c.-253T>C 122 92 107 110 ND
Effect of SPINK1 promoter variants on luciferase expression. Relative luciferase activities were expressed 
as percent of the wild-type value. Average values from 3-6 transfections are shown; experimental 
variability (S.D.) is indicated in Figure 3. Data for the COLO-357 cell line were taken from Boulling et al.23 
Dexa, dexamethasone; ND, not determined.
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When the data obtained in the acinair cells were considered as relevant to the 
pancreas, the variants fell in four groups: (i) four variants (c.-52G>T, c.-108G>T, 
c.-142T>C, and c.-147A>G) exhibited some degree of los-of function in all three 
acinair cell lines suggesting these variants are risk factors for chronic pancreatitis; (ii) 
one variant (c.-215G>A) showed a consistent gain-of-function in all acinair cell lines 
indicating a possible protective effect against pancreatitis; (iii) three variants 
(c.-164G>C, c.-170A>G, c.-253T>C) had a neutral phenotype; and (iv) nine variants 
caused variable, cell-line dependent changes in promoter activity.
In the non-acinair HEK 293T cell line none of the variants caused a substantial 
(i.e. more than 50%) loss of promoter function. In contrast, three variants (c.-142T>C, 
c.-164G>C and c.-215G>T) exhibited more than 2-fold increased activity, while 
variant c.-215G>A elicited a more than 5-fold increase in luciferase expression.
Discussion
In the present study we surveyed all published proximal promoter variants in the 
SPINK1 gene for possible functional defects using a luciferase reporter assay. Since 
SPINK1 serves as an essential defence mechanism against intra-pancreatic trypsinogen 
activation; changes in SPINK1 expression are expected to alter risk for chronic pancreatitis. 
Identification of variants causing loss or gain of promoter function, therefore, is important 
for their clinical classification as potentially pathogenic or protective. Many of these 
variants are rare and genetic analysis alone cannot conclusively determine disease 
association. 
Previously, Boulling et al.,23 investigated 11 variants using the human COLO-357 cell 
line. The authors found relatively small changes in promoter activity (see Table 2) and 
designated variants c.-53C>T, c.-142T>C, and c.-147A>G as likely pathogenic (loss 
of function) and variants c.-81C>T and c.-215G>A as protective (gain of function). More 
recently, limited characterization using dexamethasone-differentiated AR42J cells 
was described for five variants; reduced promoter activity was reported for variants 
c.-14G>A, c.-108G>T and c.-246A>G and increased activity for variant c.-215G>A.24 
Here we extended these studies and investigated a total of 17 variants and utilized 
four different cell lines.
In agreement with the earlier study by Boulling et al.,23 we found that SPINK1 promoter 
variants typically have relatively small effects on promoter activity. Unexpectedly, 
however, we observed significant cell-line dependent variability in the effects of these 
variants which makes interpretation difficult. Therefore, we took a conservative 
approach and designated only those variants functionally altered which consistently 
showed the same or similar phenotype in all three acinair cell lines tested. Four loss-
of-function variants were identified, c.-52G>T, c.-108G>T, c.-142T>C, and c.-147A>G; 
two of these (c.-142T>C, and c.-147A>G) were also studied by Boulling et al.23 and 
described as functionally impaired. Variants c.-52G>T and c.-108G>T are private 
mutations identified in a German and a Hungarian patient with chronic pancreatitis, 
respectively (Table 1). In published reports variants c.-142T>C, and c.-147A>G were 
detected more frequently in patients (five and seven occurrences, respectively), and 
only variant c.-147A>G was found in a single control subject (Table 1). Taken together, 
the available genetic information for these four loss-of-function variants is not 
conclusive but consistent with a pathogenic phenotype. 
Figure 3  Effect of SPINK1 promoter variants on luciferase expression
The indicated cell lines were transfected with SPINK1 promoter constructs and luciferase expression was 
determined as described in Materials and Methods. Relative luciferase activities were expressed as percent 
of the wild-type value. Average values ± S.D (n= 3-6 transfections) are shown. Data for four variants in the 
dexamethasone-differentiated AR42J cells were taken from Hegyi et al.24 The asterisks indicate statistical 
significance (p<0.05) using Student’s t-test. Dexa, dexamethasone.
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From a mechanistic aspect, variants c.-142T>C and c.-147A>G map to a positive 
regulatory region (see Figure 1) of the SPINK1 promoter and seem to alter binding of 
the transcription factor hepatocyte nuclear factor 1 (HNF-1).23 
Variant c.-52G>T maps in the vicinity of the transcription start site in a region that was 
found protected in a DNAse I foot-printing analysis and it may affect binding of RNAse 
polymerase II.40 Variant c.-108G>T maps upstream of a bipartite binding site for 
pancreas specific transcription factor 1 (PTF1) and it may alter binding of this 
transcription factor.23 Finally, our data did not confirm unambiguously the previously 
published finding that variant c.-53C>T caused a loss of function and was 
consequently pathogenic.23 Genetic studies are also inconclusive, as the variant was 
described in two patients and a healthy control (Table 1). However, given this variant’s 
proximity to the transcription start site (see Figure 1) and the loss of function detected 
in two of the acinair cell lines tested, we conclude that variant c.-53C>T remains a 
potential candidate for a risk factor but additional studies are required to clarify its 
significance in chronic pancreatitis. We were also unable to confirm the loss-of-func-
tion phenotype for variants c.-14G>A and c.-246A>G described recently by Hegyi et 
al.24 as reduced promoter activity was only detected in dexamethasone-differentiated 
AR42J cells but not in the other cell lines tested.
 
With respect to gain-of-function variants, only variant c.-215G>A exhibited consistently 
elevated activity in all cell lines tested. The same phenotype was reported for this 
variant by Boulling et al.23 and Hegyi et al..24 Although the higher promoter activity 
suggests a protective function, this variant is always found in complete linkage 
disequilibrium with the intron-3 splice site mutation c.194+2T>C which causes 
exon-skipping, markedly reduced SPINK1 expression and strongly increased risk for 
chronic pancreatitis. 4, 15, 20 It is intriguing to find that the negative effect of this splice 
site mutation is mitigated by a promoter mutation that increases expression. One can 
speculate that in the absence of this promoter mutation the splice mutation may not 
be compatible with life, at least not in the homozygous state as seen with SPINK3 
knock-out mice.41 It is noteworthy that variant c.-215G>T, which affects the same 
nucleotide as c.-215G>A, exhibited variable promoter activity in our acinair cell lines 
and was described as neutral by Boulling et al.23 This variant was found in three 
subjects of Indian origin with chronic pancreatitis who also carried the p.N34S variant 
(Table 1), which likely was responsible for their disease risk.42 Finally, variant c.-81C>T 
yielded conflicting results in the different acinair cell lines and thus we were unable to 
replicate the gain-of-function phenotype described by Boulling et al.23 Similarly, 
variable results were obtained for a handful of other variants (c.-2C>A, c.-7T>G, 
c.-14G>A, c.-22C>T, c.-41G>A, and c.-246A>G); hence their pathological significance 
remains indeterminate pending further studies.
Data obtained in the HEK 293T cell line is unlikely to be pertinent to the pancreas and 
chronic pancreatitis but may be relevant to extra-pancreatic tissues including tumours 
where SPINK1 expression seems to contribute to pathology. Interestingly, none of the 
variants exhibited significantly impaired activity (all were ≥64% of wild type), whereas 
four variants exhibited more than 2-fold increased activity. As discussed above, 
despite its impressive 5.6-fold increased activity variant c.-215G>A is unlikely to 
cause elevated SPINK1 expression due to its linkage with c.194+2T>C. On the other 
hand, variants c.-142T>C, c.-164G>C and c.-215G>T may act as risk factors for 
certain cancers.
In summary, we studied the functional effect of 17 SPINK1 promoter variants and 
identified four loss-of-function variants as likely predisposing factors for chronic 
pancreatitis and a gain-of-factor variant which modifies the deleterious effect of a 
linked splice-site mutation. Our data extend and refine prior studies by Boulling et al. 
and Hegyi et al. and confirm the notion that sequence evaluation of the SPINK1 
promoter region in patients with chronic pancreatitis is warranted as part of an 
etiological workup.23, 24
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Introduction
This thesis focuses on the impact of known genetic aspects of chronic pancreatitis 
(CP) and the discovery of new genetic underlying mechanisms. Chronic pancreatitis 
is an ongoing inflammation of the pancreas that ultimately leads to fibrosis and 
causes functional impairments of the pancreas. It has large implications for the 
patient; they suffer from pain, have frequent hospital admissions, there is a risk to 
develop diabetes mellitus type 3c, malnutrition and even pancreatic cancer. 
Causes for CP are diverse but excessive alcohol use, heredity, auto-immunity and 
anatomical and metabolic disorders are the main categories.1 
Nowadays it gets more and more evident that genetic factors have a role in the 
aetiology of CP even in cases where environmental factors are evidently present like 
excessive alcohol intake. During the last 20 years the genetic causes of CP got obvious, 
starting with the discovery of the PRSS1 gene which gave us insight in the trypsinogen 
pathway.2, 3 Hereafter new candidate genes were tested and a new approach was 
applied with a genome wide association study (GWAS).
To date, we are still searching for new candidate genes, new variants and new 
pathological mechanism that clarify why CP develops; Why are some patients more 
at risk than others? Why do not all alcoholics develop pancreatitis? Or what’s the 
influence of these genetic alterations on the clinical course?
In line with the variants and genes that were found during the last years, new 
pathological variants or mechanisms will probably have smaller effects than the 
already known PRSS1 mutations because they inherit in a recessive trait instead of an 
autosomal dominant one. These small modifying variants have no real impact in our 
daily clinical management but it will give us more understanding of the disease. 
 For patients with hereditary pancreatitis however, the presence of their PRSS1 
mutation has a large impact on their daily living. Genetic testing and counselling is 
necessary to inform the patient about the clinical course, the chance of heredity and 
the increased risk of pancreatic cancer. 
The hypothesis or main question that we tried to answer in this thesis is; 
Can we find new genetic susceptibility factors for CP that might have an influence on 
the development and clinical presentation of CP or otherwise increases our knowledge 
of the pathophysiological mechanisms of CP?
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In order to answer our hypothesis/main question we set up the following 4 sub- 
questions;
1. What are the known genetic underlying mechanisms of chronic pancreatitis? 
(chapter 2)
2. How do genetic variations influence the clinical course in CP patients? (chapter 3)
3. Can we discover new candidate-genes and variants that are a causal, predisposing 
or modifying factor for CP in order to complete our missing knowledge? (chapter 4, 
5 and 6)
4. What are the functional effects of variants found in CP related genes and how do 
we translate that to the function of the human pancreas in situ? (chapter 4 and 7)
In the next paragraph, each of these question will be answered and discussed 
separately. 
Discussion
What are the known genetic underlying mechanisms  
of chronic pancreatitis?
In [Chapter 2] a comprehensive review is given about the known genetic factors in 
each subtype of CP. This overview shows how many different pathological mechanisms 
play a role and how many variants are already found.
The most important mechanism, especially in hereditary pancreatitis, is the trypsinogen 
pathway where premature intra-pancreatic trypsin activation leads to auto-digestion 
of the pancreas. Several variants with different site of actions as well as mutation in other 
genes like the Cystic Fibrosis Transmembrane Regulator (CFTR) gene, alcohol 
metabolization enzymes, CAlcium Sensing Receptor (CASR), Cathepsin B (CTSB), 
CarboxyPeptidse A1 (CPA1) and the newly discovered Claudin 2 (CLDN2) locus are 
discussed. 
Writing a narrative review is important to bring together and combine the findings of 
all primary studies. 
During the last decades hundreds of studies are performed in the field of genetics and 
chronic pancreatitis making it difficult to easily get an overview, especially for 
researchers or caregivers that are not directly involved in this field. A narrative overview is 
helpful to focus on a broad question and to develop new theories. The disadvantage 
though of this kind of review is the possibility of a reference bias.4 
Unlike a systematic review we did not use a strict method with defined selection 
criteria for searching related articles. We carried out an extensive literature search 
and used all the important and high-impact data to give a complete as possible 
overview for this subject. Though there is always a chance that important studies 
were missed or were excluded based on our own opinion. 
On the other hand, the aim of this review is to create a practical overview of all the 
gathered knowledge and not to answer a highly specific question. Setting up well- 
defined criteria in the selection of literature as would be necessary in a systematic 
review can in this approach even cause loss of small but important studies.
Additionally, an update of this review was needed because the original publication 
stems from 2009 and since then new variants and genes associated with CP were 
discovered. For this update we again performed an extensive literature search where 
we added new genetic variants but also new insight in the pathophysiological 
mechanisms. 
How do genetic variations influence the clinical course in CP patients? 
What we specifically tried to answer in [Chapter 3], is if there is any relationship 
between the clinical course and the genetic underlying factors in a cohort of Dutch 
hereditary pancreatitis patients. The main finding is that if a PRSS1 mutation is 
present; patients have a younger age of onset and there are more chronic pancreatitis 
related complications like diabetes mellitus, steatorrhea and morphological changes 
like pancreatic calcifications. 
Our findings were compatible with other studies in this field.5-7 The most elaborate 
study was done in 2004 by the European Registry of Hereditary Pancreatitis and 
Pancreatic Cancer (EUROPAC).5 
They included 112 families with hereditary pancreatitis out of 14 countries and stated 
that in case of a PRSS1 mutation, patients present at a younger age, have a higher 
cumulative risk for exocrine and endocrine failure and have an increased risk for 
pancreatic cancer. 
In another study, by Hamoir et al., patients with mutations in the PRSS1, the SPINK1 
and the CFTR gene were compared with patients without a genetic alteration.6 They 
also found that the age of onset for pancreatitis was significantly lower for PRSS1 
carriers than for non-carriers or other pancreatitis-related genetic mutations. Further, 
non-significant though, was a higher presence of pancreatic calcifications and 
pancreatic cysts in the PRSS1 group. 
Remarkable in this study was the low prevalence of smokers in the PRSS1 group. 
This might be explained by the fact these patients probably had counselling about 
their risks and the expected clinical course. It is proven that smoking increases the 
risk for developing pancreatic cancer in patients with hereditary pancreatitis and it is 
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highly important to adequately inform hereditary pancreatitis patients about these 
risks.8  In this cohort there were less cases of pancreatic cancer in PRSS1 carriers 
compared to for example the CFTR carriers. The authors state that the reason for this 
probably lies in the fact that there were more males and more smokers in the CFTR 
group and that patients with a CFTR mutation had an older age.6 
Another comprehensive study of Joergensen et al. in 2010 confirmed our findings as 
well; A younger age of onset and more frequent cases of diabetes and steatorrhea 
were found when patients had a PRSS1 mutation.7
In overall, it is important to conclude that the presence of a genetic alteration in the 
PRSS1 gene has an impact on the clinical course. This could be expected looking at 
the way how strongly these gene mutations are associated with the development of 
HCP. It is easily hypothesized that if they cause the disease that they also can 
influence for example the age of onset and thereby directly or indirectly also the more 
long-term complications that can develop.
In contrast though with our findings and others, was a large French study who did not 
detect any phenotype-genotype correlations for mutations in the PRSS1 gene.9 In 78 
families they found a PRSS1 mutation rate of 68% with a penetrance of 93% but no 
relation between the clinical course and the presence of a PRSS1 mutation. 
The advantage of this study compared to ours is the large study population. We 
conducted our study in a small cohort making it difficult to really draw significant 
conclusions about phenotype-genotype interactions. 
But interesting though is that the study of Howes et al. included an even larger number 
of hereditary pancreatitis patients throughout whole Europe (418 vs 200 patients) and 
found the same clinical results as us.5 The difference between these two studies is the 
higher mutation rate in the study of Howes et al. (81% vs 67.5%) though Rebours et al. 
found a higher frequency for the p.R122H mutation (77% vs 53%). 
Another limitation of our study is the lack of available clinical data. For only 40 of the 
61 included patients, clinical data was available. Factors like loss of follow-up, 
incomplete available clinical characteristics because patients were referred to our 
clinic only for genetic testing or patients were seen by different physicians, and not 
responding to the questionnaire were responsible for this. 
This could have biased our results because patients that respond to the questionnaire 
and patients that have frequent hospital consultations probably have more disease 
related symptoms or complications than patients who never visit their physician.
This study showed us how important it is to systematically collect clinical patient data 
in order to use them for studies where genotype-phenotype correlations are 
investigated. It is difficult to gather the same information about the investigated 
patients when they are seen by different physicians with all a different approach, 
sometimes an unreadable handwriting or only a very minimal documentation.
Nowadays the use of electronic patient files and the integration of databases can be 
highly useful. Setting up an electronic or online questionnaire or an easily accessible 
database that is part of the standard patient file could in the future decrease the 
difficulties that were encountered here. With the upcoming ideas and possibilities for 
patients to have online access to their own patient files, it would be easier for them to 
complete questionnaires or add additional information in their own time. This could 
even lead to a more efficient use of the time during a consultation with the physician; 
instead of completing a questionnaire, this time can be used for other important 
things while the patient completes the rest at home, before or after the consultation. 
Can we discover new candidate-genes and variants that  
are a causal, predisposing or modifying factor for CP in order  
to complete our missing knowledge?
To answer this question we performed genetic case-control studies for new candidate 
genes. 
In [Chapter 4], Tropical calcific pancreatitis and its association with CTRC and 
SPINK1 (p.N34S) variants, we found new variants in the Chymotrypsin C (CTRC) gene 
in a cohort of Tropical CP patients (TCP). At the time of writing this article, CTRC was 
just identified as a new susceptible candidate gene in CP patients.10-12 Just like 
SPINK1, it acts as a first line of defence for the development of pancreatitis because 
it highly specific degrades trypsinogen, decreasing the risk for trypsinogen auto-ac-
tivation. 
This made it interesting to screen this gene for variants in a cohort of TCP patients 
because TCP already showed to be associated with SPINK1 variants, especially the 
p.N34S variant (~50%).13-17 Also in our cohort a large percentage of TCP patients 
(31.8%) had a SPINK1 p.N34S mutation, but the most important finding of our study 
was the detection of 8 non-synonymous variants of which 2 were not described 
before. The prevalence of CTRC variations was low in this cohort, except for the 
synonymous c.180 C>T variant that was significantly enriched in patients (29%).  For 
the detected non-synonymous variants, including the newly detected p.G61R 
missense alteration that showed a loss of cellular secretion, detection rates were low 
and differed from 0.7 to 2.7%. 
Further interesting is that TCP patients often conducted a CTRC variant next to a 
SPINK1 variant. The same results were found by others.11, 18 
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In a study of Rosendahl et al. the percentage of affected individuals in a TCP 
population for the individual mutations ranged from 1.4 to 5.6% with a total of 14.1% 
of affected patients. Also they confirmed the finding of SPINK1 variants next to CTRC 
variants.11
  
So it can be concluded that for TCP not only SPINK1 mutations are of influence but 
also CTRC mutations. Notable is that both are often found next to each other in one 
patient, something what is not often seen in other cohorts and other pancreatitis 
related genes. The presence of genetic variants in the SPINK1 and CTRC gene in TCP 
patients, genes that are also associated with other types of CP in the Western world, 
supports the statement by Garg et al. that the term TCP is maybe a misnomer and 
does not differ that much from other forms of CP in other parts of the world.19 For a 
long time it was thought that TCP was caused by nutritional factors like cassava and 
malnutrition. 
The findings of our study and others helped to change that view and shifted it to 
a more genetic-oriented one. 
Also here, the largest limitation of this study is the small study population. In case of 
real causing genetic mutations with a high mutation rate this would be not such a 
problem but in the light of finding smaller, low frequency genetic associations, it is 
needed to analyse large cohorts of patients. 
The small population size could lead to a type II error or more simply said to a higher 
probability that data are missed.  
In order to reduce this risk we combined our data with the data of Rosendahl et al. leading 
to more significant results for the CTRC p.A73T variant. 
Strong points are the detection of a novel CTRC variant, the functional analysis but 
also that our results were comparable to other studies. 
In [Chapter 5], the results of a large European collaborative study on polymorphisms 
at the PRSS1–PRSS2 and CLDN2–MORC4 loci are described. This study was driven 
by the first results of a GWA’s in CP patients that was only recently published.20 
This study not only captured novel risk factors at the PRSS1–PRSS2 and CLDN2–
MORC4 locus ((Claudin2 (CLDN2), ripply transcriptional repressor 1 (RIPPLY1) and 
the MORC family CW-type zinc finger (MORC4)), but also found an association with 
alcoholic chronic pancreatitis. We were able to replicate these findings; for the 
PRSS1–PRSS2 rs10273639 T allele, a protective association was found whereas the 
RIPPLY1 rs7057398 C allele and the MORC4 rs12688220 T allele showed an increased 
risk association for alcoholic chronic pancreatitis. To rule out the association with 
alcohol dependency, the same analysis was done for alcoholic liver cirrhosis and 
alcoholic dependency patients; no relation was found. In non-alcoholic pancreatitis 
patients only an association was found in females for the RIPPLY1 rs7057398 C allele.
Together with the study of Whitcomb et al. these are the first results for the new 
susceptibility locus CLDN2–MORC4. What is not clear yet, is how the genes at this 
locus functionally influence the development of CP. CLDN2 for example encodes for 
a tight-junction protein that forms water and sodium channels in pancreatic ductal 
cells and has no relationship with the important trypsinogen pathway.21  The possible 
normal function of CLDN2 is to react on and interact with the chloride and bicarbonate 
secretion of pancreatic ductal cells through CFTR.22 
Whitcomb et al. further showed that the CLDN2 protein is up-regulated in ductal but 
also acinair cells in chronic pancreatitis patients that are carrier of a CLDN2 variant.20 
For now we can only speculate what this means and how we should translate that to 
our patient with chronic pancreatitis. 
A possible hypothesis is that CLDN2 variants cause functional disturbances in the 
cationic-anionic or pH balance leading to inflammation. Or maybe they interact with 
CFTR mutations? Could it be that CLDN2 variants developed based on evolution and 
as response on CFTR mutations? But how then do we declare the association of the 
CLDN2-MORC4 locus with alcoholic chronic pancreatitis. Some studies found an 
associations of CFTR variants and ACP,23-25 while others did not. 26-28 
Another possibility is that SNPs of the CLDN2–MORC4 locus are part of a haplotype 
and that the described SNPs that associate with pancreatitis simply tag for other 
functional variants of neighbouring genes. 
Therefore it is necessary to also analyse the covering regions and investigate the 
functional consequences of the for now known variants. 
The strength of this study is the large European collaboration in which 3,062 patients 
with ACP/non-ACP and 5,107 controls were included. Never before so many hospitals 
and physicians in Europe collaborated in the field of genetics and CP research. It is 
needed to form these large cohorts; first to increase the power of the results but also 
for comparison with studies from large continents like the United States. 
Another strong point was the absence of an association between the variants and 
alcoholic liver cirrhosis or alcoholic dependency. This strengthened our findings that 
these variants are associated with ACP and not with alcohol abuse. 
The results were new and not yet published by another group.  
Though despite the large population there were some differences in the statistical 
outcomes between some countries. Not every independent country showed a significant 
association although that was the case for the overall group. This can be explained 
by a smaller sample size for a specific country leading to a possible type II error. 
Another limitation is the absence of clinical parameters for a large part of the patients. 
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Partially we were able to analyse the correlation between the genotype and phenotype 
but not for the whole population. It seemed that the RIPPLY1 rs7057398 C allele and 
the MORC4 rs12688220 T allele are more often found in the elderly patient. 
This in line with the earlier mentioned hypothesis that smaller effect variants probably 
do not have an impact on the clinical course and are maybe more associated with an 
older category of patients in combination with environmental factors. 
In [Chapter 6], the association for a new candidate gene in Dutch CP patients was 
investigated. In Interferon regulating factor 2 (IRF2) knock-out mice several interesting 
mechanisms were found causing inflammation of the pancreas; infiltration of inflammatory 
cells, disturbance in protein secretion, up-regulation of trypsinogens and down- 
regulation of CTRC. 29 
This study made IRF2 a highly interesting candidate gene with again the involvement of 
the trypsinogen cascade but now also with influence of the inflammatory system. 
It is not the first time that the inflammatory system is investigated for CP, several 
cytokines were analysed before. For example tumour necrosis factor-alpha 
(TNF-α),30-32  transforming growth factor-beta1 (TGF-ß1),33, 34 and interleukin-8 (IL-8),33 
showed to be associated with CP but not all studies could replicate the same findings. 
In the studies of Sri et al and Chang et al. they found a significant association for a 
TNF-α polymorphism while others could not confirm this.33, 34  The same is the case 
for TGF-ß1.35-37 Also several other cytokines were analysed without showing any 
correlation with the development of CP; monocyte chemotactic protein-1 (MCP-1)38, 39, 
interleukin 1beta (IL-1beta),35 interleukin 1beta (IL-6),35 interleukin 10 (IL-10),34, 37 interferon- 
gamma (IFN-γ)34, 37  and vascular endothelial growth factor (VEGF)35.
In our cohort of CP patients we did not find any association for IRF2 with CP despite 
that it is a suspicious fine candidate gene regarding the involvement of the trypsinogen 
cascade as well as the inflammatory system in the animal model.29 It was the first 
attempt though to find any relationship between this gene and CP patients. Maybe 
another approach in a larger cohort could lead to different results. As is seen in the 
studies mentioned above, sometimes a significant association was found between 
inflammatory cytokines and CP while other could not confirm this. This might be 
caused by factors like the ethnic origin of the population, the population size but also 
by for example the used method. 
In our study we analysed a total of 269 Dutch CP patients with different aetiologies 
but we were unable to find any pathogenic variants in this group. 
Here again the small study population might make it difficult to find small effect 
variants but on the other side we probably would have found some polymorphisms if 
this gene would have any impact on the development of CP.
Melting curve analysis were used to screen for variants. This is an easy and cheap 
method with a high sensitivity and specificity.40, 41 The principle is based on the fact 
that a DNA strand with a high guanine (G) – cytosine (C) content has a higher melting 
point than a DNA strand with a high adenine (A) – thymine (T) content. This is caused 
because a G-C pair has 3 hydrogen bonds while an A-T pair has only 2. Increasing 
the temperature will cause dissociation of the DNA strand and in case of a change in 
the nucleotide arrangement this will lead to a deviating melting curve. Hereafter only 
these deviating samples have to be sequenced for polymorphisms what prevents 
sequencing of all samples and thereby higher costs. The limitation of this method 
though is that you need a good PCR product, good dyes and a good melting curve 
instrument to get reliable results.42
What is new in this study is that we did not analyse a whole cohort of controls but that 
we used a whole genome exome database to predict how this gene acts in the 
general population and which variants can be found. This is a new approach that 
could be used in the future instead of sequencing large amounts of controls for 
candidate genes that turned out be not associated with the disease.
In overall, what is important to learn from these candidate gene studies is that it is 
necessary and important to have a well-defined and large study cohort to decrease 
the risk of missing data. As is seen in [Chapter 5], a significant effect can be found 
in the total cohort but not always in small sub-groups partly because of the small 
sample size. The collaboration with other researchers and hospitals will improve 
future studies and outcomes simply by increasing the power. 
Further it gave us insight in how complex the pathophysiology of CP is. There are so 
many factors involved, from the trypsinogen pathway to the inflammatory system and 
new candidates like the CLDN2 gene. There is not one single mechanisms that 
declares everything but it is a multifactorial interaction of genes and environment. 
And not only is it difficult to identify all these different factors, it is also difficult to 
distinguish it for ethnic groups or for the subgroups of CP. In alcoholic CP other 
factors are of influence than in hereditary CP or idiopathic CP. Maybe it is even 
impossible to ever understand the complete mechanism just because the large 
amount of factors. 
Another point is that with this multifactorial origin it makes it difficult to find therapeutic 
strategies.
There is not one single target to attack but also the small effects of these variants 
make it impossible to use them for therapeutic interventions. 
Even in the case of hereditary CP, where PRSS1 mutations could be a clear therapeutic 
target, there are still no treatment options available. 
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Further it should be luminous that animal models cannot always be translated to the 
human physiology. In [Chapter 6], the small study population might have caused 
missing data but we still did not find any association with CP for the IRF2 gene that 
was so promising in an animal model. 
Animal models are interesting because environmental and genetic conditions can be 
controlled but it is not always possible to translate the findings to physiological 
mechanisms of the human body. The same was for example seen in a study where 
CFTR mutations in the intestine of mice lead to a completely different phenotype than 
was seen in humans.43 Mice are often used to investigate the genetic aspects of a 
disease because their genome is in ways comparable to the human genome. Both 
contain approximately 30.000 protein encoding genes44 and a large percentage of 
the nucleotides (40%) in genomic alignments are identical.45 But important is that 
further evolution also creates differences in both genomes what makes comparison 
or translation difficult.45
What are the functional effects of variants found in CP related 
genes and how do we translate that to the function of  
the human pancreas in situ? 
In [Chapter 4], a new variant in in the CTRC gene in a cohort of TCP patients was 
detected. The p.G61R missense mutation causes a decrease in CTRC activity and 
secretion from human embryonic kidney 293T (HEK 293T) cells. Cell models are 
often used to test the functional aspects of a given mutation because cells are easy 
to grow and transfect. On the other hand should we be careful with comparing cell 
models with the human pancreatic cell in vivo. Differences in for example the 
expression pattern of transcription factors can cause discrepancies. At the moment 
cell models though, are still the best approach to test the functional consequences of 
a genetic mutation. 
In [Chapter 7], not 1 but 3 cell lines were used to test the functional characteristics of 
SPINK1 promoter variants. Next to the already mentioned HEK 293T cells, we 
expanded our assays with the inclusion of the rat pancreatic acinair tumour cell line 
AR42J and the mouse pancreatic acinair tumour cell line 266-6. We started with 
analysing the HEK 293T cells because they are well-known and widely used. We 
tested the possibility of transfecting them with our own constructed SPINK1 promoter 
variants but also set up the Luciferase gene reporter assay to test the functionality. 
Later we tried to replicate these findings in AR42J cell and mouse 266-6 cells. We did 
this to compare the results from a non-pancreatic with a pancreatic cell line and we 
aimed to create a better translation for the in vitro results to the real in vivo functionality. 
In overall it seemed that the SPINK1 promoter variants c.-52G>T, c.-108G>T, 
c.-142T>C, and c.-147A>G all had a loss-of-function and the c.-215G>A variant a 
gain-of-function compared to the wild-type. However, we also found some differences 
between the cell lines making it difficult to draw one conclusion. Our results on the 
other hand confirmed the data of Boulling et al. from 2011 who also tested the 
functionality of these variants in human pancreatic tumour cells; COLO-357 cells.46 
This study further described the possible mechanisms of these mutations by 
declaring that they are located in transcription initiation and positive regulatory sites.46 
The strength of our study was the use of 3 different cell lines and creating different 
cellular growth circumstances (AR42J cells with and without dexamethasone). 
Despite the fact that we did not use a human pancreatic cell line like the group of 
Boulling et al., we were still able to replicate their findings. 
Further we included new variants not tested before and also looked at the protein 
secretion patterns of the used cell lines. 
The used Luciferase gene reporter assays is a highly sensitive assay for gene 
expression studies using the luminescence capabilities of the firefly (Photinus pyralis) 
and the renilla (Renilla reniformis).47, 48 Though the assay is highly sensitive we 
encountered some problems with the reproducibility. As is seen in our data but also 
in the error bars in the results of Boulling et al., the range of activity for one give 
mutation could vary. Next to this, there were also differences between the different 
cell lines. Unclear is what is the exact mechanism of this but we could speculate that 
each cell line has of course his own cellular features and transcription factors that 
might cause differences in expression patterns. 
Functional studies are highly important to predict the effects of mutations in the 
human body. 
Our results underline that we should be careful to directly translate results from cell 
models to in vivo physiology. With testing SPINK1 promoter variants in different cell 
models, we saw that this can lead to different results and that we do not know how 
these variants really act in human pancreatic cells. Although Boulling et al. used a 
human pancreatic tumour cell line, it is still an in vitro tumour cell line that not 
automatically functions as a pancreas cell in vivo.  
General conclusion and future perspectives
This thesis aimed at increasing our knowledge of genetic aspects of chronic 
pancreatitis. We reviewed the already known genes and variants, we set up our own 
database for CP patients, conducted analyses for new candidate genes and tried to 
analyse the functional properties of these risk factors. 
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In overall, we were able to increase our understanding of the genetic aspects of CP 
by finding new genes and variants that are a causing or a modifying risk factor. 
However, still a lot of work has te be done because this multifactorial disease has still 
so many missing parts regarding causative factors or how genetic alterations 
influence the course of the disease. New candidate genes, new approaches, well 
defined cohorts and collaborations are needed to intensify our search for these 
missing factors.  
Future research should focus on the next points;
§	Find new candidate genes and have a new sharp look at the data from the first 
GWAs study done in chronic pancreatitis patients. Maybe other genes than the 
now described CLDN2 locus are of interest for the relation with CP. 
§	Perform functional studies for candidate genes and variants to interpret their effect 
on the human body. As for the recently detected CLDN2 gene, there are no 
functional data available yet and the pathophysiological mechanism still has to be 
defined. 
§	Search for new pathological mechanisms with new techniques like single-cell 
sequencing. With this approach specimens from pancreatic tissue could be 
investigated, hypothesizing that disease causing genetic alterations are not only 
caused by germline mutations but also by acquired genetic mutations during cell 
divisions causing genomic heterogeneity.
§	Establish a better well-organized electronic database that is incorporated in the 
electronic patient files. This makes it easier in the daily clinical practice to use them 
for physicians but in the near future maybe also for patients themselves to add 
extra missing clinical information. It is necessary to gather uniform clinical information 
about patients in order to use them for genotype-phenotype correlations. 
§	Collaboration with others in the field is necessary to increase the power of our 
results. Large cohorts are needed to especially find small effect genetic variants 
that little by little increase our knowledge. The large European collaboration as in 
[Chapter 5] of this thesis should continue and be used for analysing new candidate 
genes and applying new approaches. 
§	Establish new recommendations for genetic testing in chronic pancreatitis patients. 
The last guidelines were published in 2001 and 2007 and since then a lot of new 
discoveries were made in the field of genetics and pancreatitis.49, 50
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SUMMARY
Summary
Chronic pancreatitis (CP) is a long-standing inflammation of the pancreas that 
adversely affects the daily lives of patients. The recurrent inflammation of the pancreas 
destroys the normal architecture of the pancreas leading to replacement of normal 
cells and cellular arrangements by fibrous “scar” tissue. This not only destroys the 
architecture but also the functionality of the pancreas leading to an inability of the 
pancreas to produce and secrete insulin and digestive enzymes. Patients suffer from 
recurrent intractable pain attacks, have a risk for developing diabetes mellitus and/or 
digestion problems or eventually even pancreatic cancer.
Causes of CP are very diverse and range from toxic factors such as alcohol abuse to 
anatomical obstructive factors or to underlying genetic variations. It is important to 
understand that it is a highly complex disease where multiple factors often interact. 
Since the last 20 years the focus was largely set on gene discovery in CP patients. In 
1996 it became clear that mutations in the cationic trypsinogen (PRSS1) gene are 
responsible for the development of autosomal dominant  hereditary pancreatitis, an 
entity where patients at very young ages may suffer from recurrent pancreatitis 
attacks. This spurred the search for finding other candidate genes and mutations, 
first of all in this trypsinogen pathway but later also in other cellular and inflammatory 
pathways. Genes such as CFTR in cystic fibrosis and genes in the trypsinogen 
pathway for example SPINK1, CTRC and CTSB were all associated with CP although 
in a much less strong frequency and association as the PRSS1 gene and hereditary 
pancreatitis. 
The difficult part of interpreting and translating all these results, is that human 
diseases most often cannot be explained by one single pathological mechanism. For 
example, in alcoholic chronic pancreatitis the causal factor seems obvious but how 
then is it possible that not all people that drink the same amount of alcohol, develop 
pancreatitis?  Why do fewer than 10% of chronic heavy alcohol users ever develop 
pancreatitis? While others develop alcoholic liver disease, other alcohol-associated 
problems or sometimes even no problems at all?
The answer must lie in the genetic make-up of each single person. Variations in 
genes must make someone more prone to develop pancreatitis when also alcohol 
abuse or other toxic or inflammatory factors play a role. These highly complex 
mechanisms and interactions make chronic pancreatitis an interesting research 
model that still needs to be further investigated.
The aim of this thesis was to extend our knowledge of genetic factors in CP and 
find new genes, new mutations and new mechanisms of action that lead to the 
development of CP. 
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In [Chapter 1], the introduction, we give a general overview of the clinical, epidemio-
logical and diagnostic aspects of chronic pancreatitis. We discuss and outline how 
chronic pancreatitis is an interesting research model and how this led to the research 
questions that are the foundation for this thesis. 
[Chapter 2] is an extensive review article about the genetic factors in CP. In this 
review, as much as possible genes and genetic variations are described in order to 
give a complete as possible overview of all the hundreds of studies that are performed 
during the last years. Not only the pathological mechanisms of the trypsinogen 
pathway and the alcoholic detoxifying enzymes for example are described but also 
the individual genes and the most important mutations are discussed. Genes like 
PRSS1, PRSS2, PRSS3, CTRC, SPINK1, CTSB, CASR CFTR, CPA and CLDN2 will be 
discussed in this up-dated review. 
In [Chapter 3] we concentrated on the presence of PRSS1 gene mutations and the 
correlation with the clinical presentation in a Dutch cohort of hereditary CP patients. 
In case of a PRSS1 mutation, the median age of onset was 10 years which is substantially 
younger than when no mutation is present.
Further, a significant amount of patients suffer from pain and require analgesics next 
to the fact that patients have a higher risk of developing complications of CP like 
diabetes and/or exocrine insufficiency. 
In overall, we found a high proportion of PRSS1 mutations in this cohort of hereditary 
pancreatitis patients although the small number of patients included in this study 
made it difficult to really draw conclusions on mutation-phenotype correlations.
In [Chapter 4], we attempted to find new genetic associations in tropical chronic 
pancreatitis patients, an entity of chronic pancreatitis seen in tropical countries like 
Asia and Africa. Likewise as in hereditary pancreatitis, a familial segregation is seen 
in around 8% of the cases suggesting a possible underlying genetic basis. Because 
of this familial aspect and the often young age of presentation, we tried to find new 
factors that have a role in the pathogenesis. 
Other studies already had shown the importance of SPINK1 mutations but we tried to 
analyse a new cohort and a new candidate gene; CTRC. 
In our cohort a substantial amount of TCP patients (31.8%) had a SPINK1 p.N34S 
mutation but the most important finding of our study was the detection of 8 CTRC 
variants of which 2 were not described before. 
Further, we detected a new CTRC variant, p.G61R, that was predicted as probably 
damaging by in-silico analysis and showed to be highly conserved in several 
mammalian sequences indicating that this mutation might affect structurally and/or 
mechanistically important residues. At last, functional analysis showed there was a 
complete absence of secretion compared to the wild-type. This would lead to an 
insufficient intracellular inhibition of trypsin and thereby causing a disturbed tryp-
sin-trypsinogen balance with the risk of developing pancreatitis. 
Another patient-control association study is described in [Chapter 5] were we looked 
for an association between the PRSS1–PRSS2 locus (rs10273639; near the gene 
encoding PRSS1) and the CLDN2–MORC4 locus (rs7057398 in RIPPLY1 and 
rs12688220 in MORC4) in a large European cohort of alcoholic chronic pancreatitis 
patients. This study comes after a large GWA study were the new locus CLDN2–
MORC4 was identified and associated with ACP. In our cohort we found that the T 
allele of the PRSS1 rs10273639 variant protects against the development of CP even 
after comparison of ACP patients with alcoholic liver cirrhosis patients or alcohol 
dependency patients. This association is therefore independent from alcohol 
dependency or alcohol use on its own. 
The rs7057398 variant in RIPPLY1 and the rs12688220 variant in MORC4 though were 
in a negative matter associated with ACP leading to a higher risk for developing 
pancreatitis. Our results refine the results from the large GWA study and are an extra 
motivation to further investigate the functionality of these mutations because at the 
moment we are unable to explain the functional effects of mutations in this CLDN2–
MORC4 locus. It also might be interesting to investigate if the CLDN2–MORC4 locus 
is only a part of a haplotype were the associated SNP’s just simply tag for other 
variants of neighbouring genes. 
In the line of new candidate genes we analysed the IRF2 gene in our Dutch cohort of 
CP patients and described this in [Chapter 6]. The IRF2 was seen as a highly 
interesting candidate gene because a mouse knock out model (-/-) showed clear 
disturbances in the trypsinogen but also the inflammatory pathway. Unfortunately we 
could not detect any association between this gene and our cohort with melting 
curve analysis. What was new though in this study was the use of whole exome 
database as “control” population. 
Instead of screening a whole group without finding any associations in the patients group, 
we used these data to predict how much variability is tolerated by the gene.
A functional study with cell lines is described in [Chapter 7]. With the use of 3 different 
cell lines; 2 pancreatic (mouse and rat) and 1 human kidney cell line we studied the 
effect of SPINK1 promoter variants. We speculated that loss-of-function mutations 
might have an effect on SPINK1 expression and thereby on the inhibitory effect of 
SPINK1. Four loss-of-function variants were identified; variants c.-52G>T, c.-108G>T, 
c.-142T>C, and c.-147A>G and only one gain-of-function variant; c.-215G>A. 
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In overall, we found that SPINK1 promoter variants typically have only a relatively 
small effects on promoter activity. The difficulty though of this study is the in vitro - in 
vivo extrapolation and the different results that were found between the different cell 
lines. Our results on the other hand confirmed data from a study done before who 
tested the functionality of these variants in human pancreatic tumour cells; COLO-357 
cells.
In [chapter 8], a general discussion of this thesis and the future perspectives can be 
found. 
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Chronische pancreatitis (CP), oftewel chronische alvleesklierontsteking, komt niet 
zeer frequent voor in de Westerse wereld maar heeft een duidelijke negatieve invloed 
op de dagelijkse levens van patiënten. 
De terugkerende ontsteking van de pancreas vernietigd de normale opbouw waarbij 
het normale weefsel wordt vervangen door littekenweefsel. Dit heeft niet alleen effect 
op de opbouw van de pancreas maar ook op de functionaliteit waardoor de pancreas 
geen insuline en verteringsenzymen meer kan produceren of afvoeren. Patiënten 
hebben frequent last van hevige terugkerende pijnaanvallen, hebben een risico op 
het ontwikkelen van suikerziekte (diabetes mellitus) en/of verteringsproblemen 
(maldigestie) naast ook een bestaand verhoogd risico op het ontwikkelen van een 
alvleesklier kwaadaardigheid (carcinoom).
De oorzaken van chronische pancreatitis zijn zeer divers en uiteenlopend van alcohol 
misbruik, de meest voorkomende risicofactor, tot anatomische afwijkingen, metabole 
stoornissen, auto-immuunziekten en onderliggende genetische risicofactoren.  
Van belang echter is om te begrijpen dat het om een zeer complexe ziekte gaat 
waarbij meerdere factoren vaak met elkaar interacteren en waarbij er dus niet altijd 
één oorzaak aan te wijzen is.
De laatste 20 jaar is er een sterke focus geweest om de onderliggende genetische 
oorzaken van CP te ontdekken. De eerste stap hiertoe werd gezet in 1996 toen de 
eerste DNA afwijkingen, oftewel mutaties, werden gevonden in het cationic trypsinogen 
(PRSS1) gen.
Trypsinogen is de inactieve voorloper van trypsine, een verteringsenzym uit de 
pancreas, en wordt normaal pas in de dunne darm geactiveerd om daar te zorgen 
voor de vertering van eiwitten die we via de voeding tot ons genomen hebben. Indien 
er een mutatie aanwezig is in het trypsinogen gen wordt trypsine al actief in de 
pancreas en leidt dit tot een vertering van de eigen pancreas en een hierbij horende 
ontsteking.
Mutaties in dit PRSS1 gen zijn verantwoordelijk voor de ontwikkeling van erfelijke 
pancreatitis, een ziektebeeld waarbij patiënten al op zeer jonge leeftijd geconfronteerd 
worden met terugkerende aanvallen van pancreatitis. 
Deze bevindingen leidde tot een grote zoektocht naar nieuwe mutaties en nieuwe 
kandidaat genen waarbij in het begin vooral gezocht werd in de trypsinogen cascade 
maar later ook in andere cellulaire en inflammatoire pathways.
Genen zoals CFTR in cystic fibrosis (taaislijmziekte) en andere genen in de 
trypsinogeen cascade zoals SPINK1 (serine protease inhibitor Kazal-type 1), CTRC 
(chymotrypsine C) en CTSB (cathepsin B) bleken allen geassocieerd met CP echter 
in vele lagere frequenties dan er werd gezien bij erfelijke pancreatitis en het PRSS1 gen. 
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Al deze studies gaven ons nieuwe inzichten in de onderliggende ontstaanswijzen van 
deze ziekte maar desondanks missen we nog steeds delen van de puzzel en wordt 
er nog steeds actief gezocht naar nieuwe oorzakelijke genetische factoren die alleen 
of in interactie met andere factoren CP kunnen veroorzaken. Een volgende vraag die 
hierbij echter ook opkomt is hoe we al deze bevindingen kunnen vertalen naar de 
klinische praktijk. Het moeilijke van vele menselijke ziektes is namelijk dat je ze niet 
kan verklaren met één enkel pathofysiologisch mechanisme. Bij patiënten met 
alcoholische pancreatitis bijvoorbeeld lijkt de oorzaak voor de hand liggend, maar 
hoe komt het dan dat niet alle mensen die in dezelfde mate alcohol drinken een 
pancreatitis ontwikkelen? Waarom ontwikkelen sommige mensen een leveront-
steking (hepatitis), anderen een pancreatitis terwijl een andere groep helemaal geen 
problematiek ondervind?  Het antwoord hierop moet gelegen zijn in de genetische 
opbouw van elk individu. Genetische variaties zullen waarschijnlijk de oorzaak zijn 
van een bepaalde gevoeligheid om bijvoorbeeld een pancreatitis te ontwikkelen 
ondanks dat bijvoorbeeld toxische of inflammatoire invloeden ook een rol hebben. 
Deze complexe interactie van verschillende factoren maakt chronische pancreatitis 
een interessant onderzoeksmodel. 
Het doel van dit proefschrift was dan ook om onze kennis van de onderliggende 
genetische factoren in chronische pancreatitis te vergroten door nieuwe mutaties en 
nieuwe genen te vinden maar ook door functionele studies te verrichten om uiteindelijk 
meer inzicht te krijgen in de pathofysiologie van chronische pancreatitis.
In [Hoofdstuk 1], de introductie, geven we een algeheel overzicht van de klinische, 
epidemiologische en diagnostische aspecten van chronische pancreatitis. Verder 
beschrijven we waarom chronische pancreatitis een interessant onderzoeksmodel is 
en hoe dit heeft geleid tot de onderzoeksvragen van dit proefschrift.
[Hoofdstuk 2] is een uitgebreid review artikel over de genetische risicofactoren van 
CP. Gedurende de laatste jaren zijn er vele onderzoeken verricht die we in dit hoofdstuk 
zo compleet mogelijk proberen samen te vatten. Hierbij beschrijven we niet alleen 
de meest gevonden mutaties maar ook de pathofysiologische mechanismen uit 
onder andere de trypsinogeen pathway. Mutaties in genen als PRSS1, PRSS2, 
PRSS3, CTRC, SPINK1, CTSB, CASR, CFTR, CPA en CLDN2 worden in dit hoofdstuk 
beschreven. 
In [Hoofdstuk 3] onderzoeken we de aanwezigheid van PRSS1 gen mutaties in een 
Nederlands cohort van erfelijke CP patiënten. In deze studie werd duidelijk dat de 
aanwezigheid van zo’n mutaties een grote impact heeft op de klinische presentatie 
doordat bijvoorbeeld de gemiddelde leeftijd waarbij klachten optreden substantieel 
lager is, gemiddeld op een leeftijd van 10 jaar, dan wanneer er geen mutatie aanwezig 
is. Hiernaast lijkt een significant deel van de patiënten pijnklachten te ondervinden 
waarvoor pijnmedicatie vaak noodzakelijk is en hebben ze een groter risico op het 
ontwikkelen van complicaties ten gevolge van de pancreatitis zoals diabetes mellitus 
en/of exocriene insufficiëntie (maldigestie). Al met al vonden we een hoog percentage 
PRSS1 mutaties in dit cohort van erfelijke pancreatitis patiënten maar is het ook lastig 
om echt goede conclusies te trekken over genotype-fenotype correlaties gezien de 
kleine studiepopulatie. 
In [Hoofdstuk 4], proberen we nieuwe genetische risicofactoren te vinden in een 
andere populatie, namelijk in een groep met tropische chronische pancreatitis 
patiënten, een entiteit die wordt gezien in tropische regionen zoals Azië en Afrika. Net 
als bij erfelijke pancreatitis wordt ook hier een familiaire clustering gezien echter in 
een veel lagere frequentie van ongeveer 8%. Eerdere studies lieten reeds zien dat 
mutaties in het SPINK1 gen hierin een rol hebben. In ons eigen onderzoek keken we 
zowel naar mutaties in dit SPINK1 gen als ook naar een nieuw kandidaat gen, namelijk 
het CTRC gen. We vonden een hoog percentage SPINK1 p.N34S mutaties in patiënten 
(31.8%) maar ook 8 nieuwe varianten in het CTRC gen waarvan er 2 nog nooit eerder 
beschreven waren. 
Verder ontdekten we een nieuwe genetische variant in het CTRC gen, de p.G61R 
mutatie, die middels een computer analyse beschouwd word als “waarschijnlijk” 
schadelijk en waarbij wordt gezien dat dit gebied in meerdere zoogdieren dezelfde 
DNA sequentie laat zien wat impliceert dat deze mutatie een mogelijk belangrijke 
invloed heeft op structurele en/of mechanistische eigenschappen. 
Ter ondersteuning liet ook de functionele analyse zien dat er geen CTRC eiwit 
geproduceerd werd in geval van aanwezigheid van deze mutatie. Zoals eerder al 
beschreven in dit proefschrift, zou hierdoor een verstoring in de trypsine-trypsino-
geen balans kunnen ontstaan met als gevolg het ontwikkelen van een pancreatitis. 
Een grote Europese case-control associatie studie wordt beschreven in [Hoofdstuk 5] 
waar we keken naar de associatie van een locus in het PRSS1–PRSS2 gen (rs10273639; 
dichtbij het PRSS1 gen) en een locus in het CLDN2–MORC4 gen (rs7057398 in RIPPLY1 
en rs12688220 in MORC4). Deze studie volgt op een Genome Wide Association 
(GWA) studie waar deze nieuwe genetische risicofactoren geassocieerd werden 
met alcoholische chronische pancreatitis. Wij vonden dat het T allel van de PRSS1 
rs10273639 variant beschermend was voor de ontwikkeling van chronische pancreatitis, 
ook na vergelijking met patiënten alcoholische levercirrose of alcohol afhankelijkheid. 
Dit wijst erop dat deze associatie los staat van alcohol  afhankelijkheid of alcohol 
gebruik op zich zelf. 
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De rs7057398 variant in RIPPLY1 en de rs12688220 variant in MORC4 waren echter 
wel in een negatieve manier geassocieerd met ACP gezien en leidden tot een hoger 
risico. Wat echter de functionele gevolgen zijn van deze mutaties en hoe ze leiden tot 
een pancreatitis is nog onduidelijk. Misschien is het zelfs wel zo dat dit locus niet de 
echte onderliggende oorzaak is, maar dat het een onderdeel is van een haplotype en 
dat de echte geassocieerde genetische veranderingen liggen in andere aangrenzende 
genen.
Een ander nieuw kandidaat gen werd onderzocht in [Hoofdstuk 6]. Het IRF2 gen leek 
een interessant kandidaat gen omdat IRF2 knock-out muizen duidelijke veranderingen 
lieten zien in zowel de trypsinogeen als de ontstekings-pathway. Helaas konden wij 
middels smeltcurve analyse geen duidelijke associatie vinden in ons cohort van CP 
patiënten. Een nieuwe aanpak in deze studie was het gebruik van een whole exome 
database als “controle” populatie. Data uit deze database werden gebruikt om te 
voorspellen hoeveel variabiliteit getolereerd wordt in dit gen in een “normale” populatie. 
Ten slotte beschrijven we een functionele analyse naar SPINK1 promoter varianten 
middels het gebruik van verschillende cellijnen in [Hoofdstuk 7]. 
Onze hypothese was dat mutaties in de promoter van het SPINK1 gen, leidend tot 
een verlies van functie, mogelijk een effect hebben op SPINK1 gen expressie en 
daarmee een effect hebben op het remmende effect van SPINK1 op trypsinogeen.
We vonden 4 mutaties met een verlies van de normale functie; varianten c.-52G>T, 
c.-108G>T, c.-142T>C, en c.-147A>G maar ook een variant leidend tot een toename 
van de functie namelijk de c.-215G>A variant. 
Samenvattend lijkt het echter dat mutaties in de SPINK1 promoter maar een klein 
effect hebben op de echte activiteit en is het ook lastig om goede conclusies te 
trekken over een in-vivo studie en de resultaten uit verschillende cellijnen. Van de 
andere kant ondersteunen onze resultaten de data van een andere studie die gebruik 
maakten van weer een andere cellijn.
[Hoofdstuk 8], beschrijft de algehele discussie van dit proefschrift en worden toe-
komstplannen geschetst voor verder onderzoek ten aanzien van genetica en klinisch 
onderzoek in chronische pancreatitis.
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Dankwoord
Eindelijk aangekomen bij het laatste onderdeel van dit proefschrift; het schrijven van 
het dankwoord! Het was een lange reis, niet altijd even makkelijk, maar zeker erg 
leerzaam. Het is mooi om terug te kijken naar deze periode en te realiseren wat ik heb 
mogen leren; Ik heb mee mogen kijken in de keuken van het wetenschappelijk 
onderzoek, ik heb wat kennis mogen oppikken van een aantal uitermate slimme, 
vooruitstrevende en enthousiaste mensen, ik heb wat meer van de wereld mogen 
zien, geleerd efficiënt te werken (want hoe moet je anders een proefschrift afronden 
naast je opleiding), maar bovenal heb ik door dit hele proces en wat er allemaal bij 
komt kijken ook meer inzicht gekregen in mezelf. Ik wil dan ook iedereen bedanken 
die direct of indirect heeft bijgedragen aan dit proefschrift en/of dit leerproces. 
Prof. Dr. J.P.H. Drenth, beste Joost, bedankt voor alle begeleiding, ondersteuning en 
mogelijkheden die je me hebt gegeven. Het is indrukwekkend om te zien wat je 
allemaal doet en hoe je het voor elkaar krijgt. We kunnen er altijd op rekenen dat onze 
opgestuurde manuscripten snel worden nagekeken en van het nodige commentaar 
worden voorzien om ons weer op het goede pad te zetten. Hiernaast is de onder-
zoeksgroep die je leidt en opgezet hebt de laatste jaren sterk gegroeid. Ondanks dat 
de weg lang was is het je toch gelukt om me zover te krijgen. Bedankt. 
Leden van de manuscriptcommissie; Prof. dr. Marco Bruno, Prof. dr. Harry van Goor 
en Prof. dr. ir. Joris Veltman, hartelijk dank voor jullie beoordeling van het manuscript 
en de bereidheid deel te nemen in mijn promotiecommissie. 
Daarnaast wil ik dr. Marc Besselink, dr. Aura van Esch en dr. Marcel Spanier bedanken 
dat zij op willen treden als opponent.
Beste Aura, jou wil ik hierbij echter nog apart bedanken. Vanaf het moment dat ik als 
student-assistent bij de MDL onderzoek ging doen was jij voor mij een voorbeeld 
waarvan ik hoopte over een heel aantal jaren te staan; bijna klaar als MDL arts en 
bijna klaar met dat proefschrift. Bedankt voor je interesse en je enthousiasme.
Ing. R.H. te Morsche, beste René, bedankt voor je steun en alle hulp die je gegeven 
hebt tijdens de korte periodes, vaak tussen de bedrijven door, wanneer ik op het lab 
vertoefde of je hulp nodig had. Alles was altijd mogelijk en ondanks dat ik niet tot de 
vaste club behoorde kon ik altijd met mijn vragen bij je terecht. 
Dr. J. Rosendahl, dear Jonas, I would like to thank you in special. I’m really thankful 
for all your efforts, your help and the nice meetings we had. You organized the 
PRSS1-CLDN2 study so well and I’m grateful that I could be a part of it. Thanks!
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Prof. Dr. M. Sahin-Tóth, dear Miklos, thanks for the opportunity that I could work at 
your lab for six months. I had a great time in Boston and I learned a lot at your 
laboratory. 
Dear Andrea, Andras, Balazs and Laura, thanks for all your help and the nice time at 
the lab.
Dear Sara, Claudia, Gary, Chantal, Matti, Sheryl and all the other great people that I 
met over there, thanks for our awesome time together in Boston. We had so many 
nice trips and spent so much great time together! You guys made it unforgettable!
Further, I would like to thank all the members of the PanEuropean Working group for 
the international collaboration and all the efforts that went into the PRSS1-CLDN2 study.
Mijn dank gaat tevens uit naar Tramedico B.V. voor het verstrekken van een subsidie 
die een deel van de onderzoeken uit dit proefschrift mogelijk heeft gemaakt. Daarnaast 
gaat mijn dank uit naar de sponsoren voor hun financiële bijdrage voor het drukken 
van dit proefschrift.
Beste oud-collega’s en stafleden van de Interne Geneeskunde in het Rijnstate ziekenhuis. 
Bedankt voor de gezellige tijd en de ontzettend fijne werk- en leeromgeving. Het was 
geweldig en een voorrecht om bij jullie de vooropleiding te mogen afronden.
Beste collega AIOS en stafleden van de Maag-, Darm- en Leverziekten in het Rijnstate 
ziekenhuis. Bedankt voor de fijne sfeer waarin we in het Rijnstate met elkaar samen 
mogen werken. Het is mooi om in zo’n groep als die van jullie te mogen werken; het 
enthousiasme, de passie, de fijne en stimulerende leeromgeving maar ook zeker de 
flauwe grappen zijn een dagelijks plezier om in te werken. Vanaf het moment dat ik 
als co-assistent Interne Geneeskunde voor het eerst bij jullie op de afdeling kwam 
wist ik dat ik graag zou willen werken op een afdeling zoals die van jullie. Ik ben dan 
ook erg blij dat ik voor mijn senior co-schap maar ook voor mijn opleiding tot MDL 
arts bij jullie terug mocht komen. 
Lieve Marieke en Armine, ik ben ontzettend blij dat jullie naast mij staan tijdens de 
verdediging van dit proefschrift. 
Marieke, onze vriendschap begon met een schoenenspel tijdens de introductieweek 
waarbij we door onze schoenen naar elkaar toe getrokken werden. Heel vrouwelijk 
zou je zeggen maar destijds waren onze schoenen nog niet zo vrouwelijk als nu maar 
vooral zwart, stevig en stoer. In al die jaren hebben we samen gestudeerd, gesport, 
theetjes maar ook zeker biertjes gedronken, zijn we naar concerten gegaan en zijn 
we uiteindelijk beiden terecht gekomen waar we al die jaren samen voor gewerkt 
hebben. Ontzettend bedankt voor de geweldig mooie tijd. 
Armine, wij zijn sterk naar elkaar toe gegroeid tijdens onze vooropleiding Interne 
Geneeskunde en misschien nog wel meer nadien. Onze afspraken leiden ons altijd 
naar het sushi restaurant waar we de hele avond vol kletsen over van alles en nog 
wat. Het is geweldig om te zien hoe je geniet van de kleine man die nu in jullie leven 
erbij is gekomen en ik bewonder hoe jij alle ballen in de lucht houdt met je werk, je 
proefschrift en je privéleven. 
Lieve Maartje, Yvette, Sander, Bonny en Maaike, Arjan, Laura, Chiel en Judith maar 
ook zeker niet te vergeten de ontzettend leuke vriendenclub die ik via Sven heb 
mogen erven; Roel en Jessica, Leonie en Stijn, Dieuwertje en Rob, Leo en Gonda, 
Bram en Lisanne, Jeroen en Susan, Loes en Ferry, Pauline en Charles, Laura en Paul, 
Bram en Marrit; Bedankt voor alle leuke en gezellige momenten! 
Lieve Christine en Henk, wat ben ik blij dat ik zulke leuke en lieve schoonouders heb 
mogen treffen. Bedankt voor jullie ongelofelijke steun en alle fijne momenten samen.
Lieve Wilmie, grote zus van me. Ondanks dat voor jou niet alles even gemakkelijk is 
en er vaker behoorlijke zorgen op je pad komen en heuvels genomen moeten worden 
ben je er altijd voor me. We zullen samen vast nog vele heuvels nemen maar ik zal er 
altijd voor je zijn. 
Lieve pap en mam, ik weet niet eens waar ik moet beginnen om uit te drukken hoe 
dankbaar ik ben voor wat jullie voor me gedaan hebben en doen, en wat jullie voor 
me betekenen. Altijd waren en zijn jullie er; van wekelijks mee naar de manege of op 
wedstrijd, tot me midden in de nacht op komen halen na een avondje stappen, en 
niet te vergeten alle koppen cappuccino die voor me gemaakt werden als ik thuis zat 
te studeren. 
Ik kan altijd bij jullie terecht met mijn vragen en mijn zorgen. Graag zouden jullie me 
wat dichterbij willen hebben maar ik zal mijn best doen om zo vaak mogelijk naar huis 
te komen.
Lieve Sven, wat ben ik blij dat jij aan mijn zijde staat, dat je mijn maatje en mijn partner 
bent. Ik ben zo dankbaar voor alle momenten waarop we leuke dingen samen doen 
maar ook voor alle momenten dat je me steunt, relativeert en me op de goede weg 
brengt. Ik hoop dat ik op mijn tachtigste een beetje van jou relativerend vermogen en 
rust over heb genomen en dat we dan samen kunnen lachen om al de momenten dat 
ik liep te stressen en jij me met één opmerking weer met beide benen op de grond en 
aan het lachen kreeg. Ik hoop dat we nog lang samen mogen zijn en mogen genieten 
van alle leuke dingen in het leven. 
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Mocht ik toch nog iemand zijn vergeten dan bied ik bij deze alvast mijn excuses aan! 
Ter afsluiting van mijn dankwoord zeg ik nogmaals; Bedankt iedereen!
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